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ABSTRACT  
 
The South African National Antiretroviral Treatment Guidelines recommend the use of 
HIV-1 viral load assays for routine monitoring of HIV-1 positive patients receiving highly 
active antiretroviral therapy (HAART). This thesis describes the innovative approaches to 
developing more affordable HIV-1 diagnostics and monitoring assays for South Africa, 
which take into account the tiered laboratory infrastructure of this country.  
An in-house HIV-1 viral load assay – the LUX assay, was developed and evaluated with a 
view of implementing this more affordable option in high tier laboratories. The LUX assay 
represents quantitative real-time RT-PCR that utilizes the LightCycler® technology 
(Roche) in a novel combination with a LUX™ primer. The assay showed good analytical 
sensitivity, specificity and reproducibility of its linear dynamic range of 4x102 to 4x106 
RNA copies/ml. Preliminary clinical evaluation (n = 458) of the LUX assay showed good 
agreement with the COBAS Amplicor assay, and demonstrated its usefulness for long term 
monitoring of HAART patients.  
ELISA based viral load testing approaches were investigated as low cost and less 
technically complex alternatives for medium tier laboratories. The HiSens HIV-1 p24 Ag 
Ultra (Perkin Elmer) and the ExaVir™ Load Quantitative HIV-RT kits (CAVIDI) were 
compared with the Roche Amplicor assay. Both assays showed strong association with the 
Roche Amplicor assay, with R2 = 0.686 and R2 = 0.810, respectively (n = 117). These 
alternative assays seemed most useful in the serial monitoring of patients on HAART. 
Major drawbacks included the wide variability of both assays, insufficient sensitivity of the 
p24 antigen assay and low throughput of the RT assay.  
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Development of a point-of-care HIV-1 RNA assay could address issues related to early and 
cost effective diagnosis of acute HIV infection. A novel isothermal amplification technique 
termed the Reverse Transcription Loop Dependant Amplification (RT-LDA) was 
developed as one component for a potential point-of-care HIV-1 RNA assay. The RT-LDA 
converted RNA into partially looped ssDNA amplicons, over a wide RNA concentration 
range (4x103 to 4x108 copies/ml) using a 1 hour incubation at 53ºC. The RT-LDA 
technology is fully compatible with a lateral flow detection system using dipsticks and 
highly suitable for point-of-care testing.  
Overall, this study demonstrates the feasibility of developing novel, more affordable HIV-
1 testing options that would be appropriate for the tiered laboratory infrastructure present 
in South Africa. Evaluation of commercially available, less expensive alternative HIV viral 
load assays in local settings facilitates their implementation.  
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CHAPTER 1  
 
BACKGROUND  
1.1 Rationale for the development and evaluation of affordable Human 
Immunodeficiency Virus Type 1 (HIV-1) diagnostic and monitoring assays 
in South Africa  
The World Health Organization (WHO) and the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) estimated that an average of 39.5 million (34.1 - 47.1 million) 
individuals worldwide were infected with HIV by the end of 2006. This staggering number 
includes ~ 4.3 million (3.6 - 6.6 million) adults and children newly infected in 2006 and 
2.9 million (2.5 - 3.5 million) people that died of AIDS related illnesses in the same year 
(UNAIDS). South Africa has one of the worst AIDS epidemics in the world currently 
showing no evidence of a decline. An estimated 5.5 million (4.9 - 6.1 million) people were 
living with HIV in South Africa in 2005 (UNAIDS).  
 
According to the South African government’s announcement made in April 2004, all HIV 
positive individuals classified as having stage 4 AIDS (WHO, 2005), or CD4 counts <200 
cells/µl become eligible for anti-retroviral treatment (ARV). Currently, approximately 140 
000 people in South Africa are enrolled on highly active anti-retroviral treatment 
(HAART) in the public health sector and 80 000 people in the private sector (MacFarlane, 
2006). More than R3.4 billion has been allocated for procurement of antiretroviral drugs 
for the current period ending 2007 (Implementation of the comprehensive plan on 
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prevention treatment and care of HIV and AIDS; www.info.gov.za). Recent statistics 
reflected an increase in people tested at public health care facilities for HIV infection from 
511 843 in 2003/4 to 1 019 476 during 2004/5 (Implementation of the comprehensive plan 
on prevention treatment and care of HIV and AIDS; www.info.gov.za). Implementation of 
Highly Active Antiretroviral Therapy (HAART) under the national roll-out program in 
South Africa raised a need for increased access to affordable laboratory tests for diagnosis 
and monitoring of therapy. Despite recent substantial decreases in the cost of ARV drugs, 
expensive laboratory tests still add significantly to the overall cost of an individual 
patient’s treatment (Glencross et al., 2003). In the context of the incredibly large number of 
individuals requiring therapy in South Africa, scaling up laboratory investigations for 
monitoring treatment efficacy represents a significant challenge for the country. According 
to the South African National Antiretroviral Treatment Guidelines (National Department of 
Health, SA, 2004) routine monitoring of patients on HAART has to include determination 
of CD4+ counts, HIV-1 viral load and alanine transaminase (ALT) testing. The recent 
development and implementation of a cost effective PanLeucogating (PLG) strategy for 
CD4+ T-cell enumeration (Glencross et al., 2002) allowed for approximately 30% cost 
savings for the public sector ARV program in South Africa. Similar approaches have been 
investigated internationally and nationally in an attempt to reduce the cost of HIV viral 
load testing in resource constrained settings. Commercial tests that are currently used in 
South Africa for HIV-1 viral load determination remain expensive: the COBAS Amplicor 
HIV-1 Monitor™ 1.5 test (Roche Molecular Systems) and the NucliSens™ EasyQ 
(Biomérieux) cost ~ 45$ and ~75$ per test, respectively. Development of a more affordable 
in-house HIV-1 viral load assay will ease the financial burden of treatment and monitoring 
of AIDS patients in our country.  
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The realistic picture of South Africa’s HIV/AIDS problem would not be complete without 
mentioning the difficulties of diagnosing incident cases that are HIV antibody negative by 
rapid or ELISA assay (Stevens et al., submitted). The importance of diagnosing HIV-1 
infection in the acute phase is discussed in section 1.3 of this chapter. An overview of 
diagnostic tests (section 1.3) shows that currently not many technical approaches for the 
diagnosis of acute HIV-1 infection are available. In particular, HIV-1 p24 antigen detection 
and HIV-1 RNA quantitation (viral load) assays are the options for diagnosis of the acute 
phase of the infection. Both types of assays require a specialized laboratory set-up. To our 
knowledge, a rapid, RNA based “near patient” type of assay for diagnosis of acute HIV-1 
phase is not commercially available. Figure 1.5 shows that viral RNA can be detected in 
plasma from week 1 post-infection, which makes nucleic acid testing (NAT) the 
methodology of choice for developing such a diagnostic test. In the South African context 
another difficulty of diagnosing acute infection is related to the loss to follow-up when 
patients do not return at a later date to receive their results. Therefore, the most desirable 
approach for our country would be a NAT based point-of-care (POC) test ensuring 
immediate post-test counseling at the voluntary counseling and testing (VCT) centers or 
primary health care clinics in the remote areas.  
 
Public sector laboratory services in South Africa are provided by the National Health 
Laboratory Service (NHLS). The laboratory infrastructure of the NHLS is comprised of 
three laboratory tiers differing in their size, staffing resources, and the scope and 
complexity of the work undertaken. These are classified as follows: a) 
tertiary/reference/high tier laboratories located at the teaching hospitals; b) medium tier 
laboratories at district hospitals and c) primary health care laboratories (low tier) at 
subdistrict hospitals or clinic facilities (Bates and Mendelow, 2006). Generally, tertiary 
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care laboratories are capable of implementing “high tech” assays and handling large 
volumes of work. These facilities have the appropriate technical resources including 
constant electricity and water supply, freezer capacity and dedicated laboratory space for 
different procedures. Skilled personnel, receiving offices with trained phlebotomists, 
training programs and basic quality control (QC) procedures are also in place. Medium tier 
laboratories do not have these specialized facilities (except for water and electricity supply) 
and thus suitable assays for these environments are generally less complex techniques that 
provide medium or low throughput. Primary health care laboratories or clinic facilities can 
cope with conducting technically non-demanding assays such are rapid and POC tests. 
Laboratory facilities in South Africa are unevenly distributed throughout the country. High 
volume, reference laboratories constitute approximately 21% of all the laboratories in the 
public sector and they are located mainly at the large industrial, urban centers. Medium tier 
laboratories are affiliated to the secondary, district hospitals that are found in the urban and 
peri-urban areas and form ~10.2% of the total network. Primary health care laboratories are 
affiliated to primary health care clinics that are mostly located in the rural areas and they 
constitute ~ 68.8% of the total NHLS laboratory facilities in South Africa. Figure 1.1 
shows the NHLS laboratory network in South Africa.  
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Figure 1.1: Distribution of NHLS laboratories in South Africa. The locations of NHLS 
laboratories on the map are indicated by the dots.  
 
The overall aim of this study is to address South Africa’s current problem related to the 
prohibitive cost of current HIV viral load assays for monitoring HIV infected patients on 
HAART, and absence of POC testing for diagnosing acute/primary HIV-1 infection. The 
study was designed taking into account different needs of different laboratory tiers in 
South Africa. The primary objectives of this study are:  
 To develop and evaluate a more affordable, NAT based in-house HIV-1 viral load 
assay for implementation in high tier laboratories;  
 To evaluate commercially available non-NAT based, cost effective alternative 
HIV-1 viral load tests suitable for medium tier laboratories in South Africa;  
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 To develop a novel isothermal amplification technique that can be used as part of 
an automated POC assay for detection of viral RNA during acute HIV-1 infection 
suitable for low tier laboratories in South Africa.  
 
The structure of this thesis reflects the three primary objectives of this study. Chapter 2 is 
dedicated to the development and preliminary clinical evaluation of a new, more affordable 
HIV-1 viral load assay for monitoring the efficacy of HAART. The assay utilizes RNA 
quantitation based on real-time RT-PCR technology using the LightCycler® platform 
(Roche Applied Science, Mannheim, Germany) and was developed and evaluated using 
plasma samples from South African patients on HAART, with a view to implement testing 
in a reference, high volume laboratory. The main challenge of this project was to develop 
an HIV-1 viral load assay with performance characteristics compatible to those of current 
“gold standard” commercial assays, yet making it more affordable.  
 
Chapter 3 describes an evaluation of two commercially available alternative assays for 
HIV-1 viral load monitoring - the Perkin-Elmer HD HiSens p24 assay and the Cavidi 
ExaVir® Load Quantitative HIV-RT assay. These assays are less technically demanding, 
require minimal capital outlay for the initial implementation and low maintenance and thus 
represent a potential viral load testing alternative for the medium tier laboratory level. The 
HiSens p24 Ag and the ExaVir™ HIV-RT assays were evaluated using plasma samples 
obtained from South African patients currently receiving ARV therapy.  
 
Chapter 4 is related to the development of a novel isothermal RNA amplification technique 
for use in a NAT based POC assay for early diagnosis of acute HIV-1 infection. An 
amplification reaction (Reverse transcription Loop Dependent Amplification, RT-LDA) 
that could quickly and efficiently convert isolated viral RNA molecules into the single 
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stranded DNA (ssDNA) amplicons was developed. The proof-of-concept study for the 
development of RT-LDA was performed using a synthetic RNA target. Amplicons 
(ssDNA) were detected (in the visual range) by nucleic acid lateral flow (NALF) 
technology that makes use of nitrocellulose dipsticks. The use of a more sensitive detection 
format using a magnetic assay reader (MAR, Quantum Design, San-Diego, CA, USA) as 
well as future automation of the assay for POC testing is discussed.  
 
The concluding chapter (chapter 5) summarizes the most important findings and 
conclusions of this study. This chapter also discusses future directions of research and 
development in the field of HIV-1 diagnostics and monitoring in resource poor settings.  
 
1.2 Commercial assays available for HIV-1 viral load quantification  
 Plasma viremia during the course of HIV-1 infection is commonly referred to as plasma 
viral load. HIV-1 viral load is measured by quantifying the number of viral RNA copies 
per milliliter (ml) of plasma. Before seroconversion extremely high levels of plasma 
viremia are maintained by rapid viral replication, which in turn causes continuous re-
infection and destruction of CD4+ T cells. Due to the onset of host immune responses the 
HIV-1 viral load decreases and reaches the so called steady-state level (“set-point”) that 
lasts for years (asymptomatic phase; Figure 1.2).  
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Figure 1.2: Kinetics of HIV disease (Adapted from Alimonty et al., 2003). Schematic 
representation of the typical course of HIV/AIDS disease progression, in the absence of 
anti-retroviral therapy. The initial spike in HIV load in the acute phase is accompanied by 
an increase in HIV-specific CTLs (cytotoxic T lymphocytes) and a decrease in the number 
of CD4+ T cells. Within 1 to 2 months the viral load is reduced and maintained at a new 
lower threshold by the immune response. The lower viral load is concomitant with an 
increase in CD4+ T cells, and at 2 to 3 months seroconversion occurs as HIV-specific 
antibodies appear. This new asymptomatic state is generally maintained for a number of 
years. Gradually the CD4+ T cell counts decrease to below 200mm3 in the blood signaling 
the onset of AIDS and increased susceptibility to opportunistic infections. This is followed 
by an increase in the virus load, along with a decrease in the HIV-specific CTL, and 
neutralizing antibodies.  
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The “set-point” levels of viral load differ significantly between individuals. Identification 
of HIV-1 steady-state viral load prior to treatment initiation (base line measurement) 
represents a strong clinical marker of disease progression. A higher set-point is associated 
with faster disease progression to development of Acquired Immune Deficiency Syndrome 
(AIDS) and death, while lower set-points indicate slower disease progression to AIDS 
(Mellors et al., 1996; Wei et al., 1995). Serial measurements of HIV-1 viral load in 
combination with CD4+ T cell counts are used routinely to monitor the disease phase of the 
patient, as well as the efficacy of antiviral therapy (Mellors et al., 1997; O'Brien et al., 
1997).  
 
There are a wide variety of commercially available assays for quantifying HIV-1 RNA. 
The majority of these assays are NAT that involve viral RNA isolation, subsequent target 
or signal amplification and detection of the amplification product. Three main 
methodologies have been FDA approved (Galli et al., 2005; Swanson et al., 2005) and are 
considered “gold standard’ assays for HIV-1 viral load quantitation: the COBAS Amplicor 
HIV-1 Monitor™ 1.5 test (Roche Molecular Systems, Branchburg, N.J., USA), the 
NucliSens™ HIV-1 QT test (BioMérieux, Inc., Durham, NC) and the Versant HIV-1 RNA 
3.0 test (Bayer Diagnostics, Tarrytown, NY). For over a decade these methodologies have 
undergone numerous modifications and evaluations aimed to improve their specificity for 
different HIV-1 subtypes (Antunes et al., 2003; Parekh et al., 1999; Respess et al., 1997; 
Swanson et al., 2005; Swanson et al., 2001). The current versions of the “gold standard” 
assays, listed above, and their new, recently developed modifications are reviewed below. 
The Amplicor ™ HIV-1 Monitor 1.5 assay (Roche Molecular Systems, Branchburg, N.J.) 
represents competitive quantitative reverse transcription polymerase chain reaction (CQ 
RT-PCR). The assay has two versions: a standard and ultrasensitive assay. The two 
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versions differ in their sensitivity and linear dynamic range. A standard version of the 
assay requires 0.35 ml of patient plasma for viral RNA extraction. Specimen preparation 
for an ultrasensitive version of the assay involves ultracentrifugation of 0.5 ml of plasma 
prior to extraction (Sun et al., 1998). HIV-1 RNA is reverse transcribed to produce single 
stranded complementary DNA (cDNA; RT step), which is subsequently amplified by PCR. 
The entire target amplification process (RT-PCR) is driven by rTth polymerase, which 
under certain buffer conditions combines the properties of both reverse transcriptase and 
DNA polymerase enzymes (Mulder et al., 1994; Respess et al., 1997). Primers and probes 
for the Roche Amplicor assay version 1.5 are specific for the p24 gag region of HIV-1. 
Quantitation of virus is based on the use of an internal quantitation standard (QS). The 
standard is an in vitro transcribed RNA molecule with a scrambled HIV-1 sequence. The 
QS RNA molecule has the same primer binding sites as HIV-1 RNA, but a different probe 
binding sequence to differentiate between the amplicons (Michael et al., 1999; Triques et 
al., 1999). A new, automated modification of the Roche Amplicor version 1.5 uses an 
automated Cobas AmpliPrep specimen preparation system and a COBAS Amplicor robotic 
Analyzer for RT-PCR and post-PCR detection (Berger et al., 2005; Berger et al., 2002). In 
brief, detection is performed by the probe-based capture of PCR product on magnetic 
particles and subsequent colorimetric detection of the captured molecules. The overall 
dynamic range of the COBAS Amplicor assay covers 5 logs of magnitude, with a lower 
limit of quantitation (LLQ) at 50 RNA copies/ml and the upper limit of quantitation (ULQ) 
at 750 000 RNA copies/ml (Erali and Hillyard, 1999; Swanson et al., 2005). In South 
Africa this assay is the “gold standard” test for HIV-1 viral load quantitation. The most 
recent development from Roche Molecular Systems is the COBAS TaqMan HIV-1 test. It 
makes use of real-time PCR technology and similarly to the Amplicor test version 1.5 
involves viral RNA extraction, RT-PCR and real-time detection of amplification product. 
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Real-time RT-PCR and on-line detection are performed on the COBAS TaqMan 48 
Analyzer using a fluorescently labeled TaqMan probe. The assay uses the highly conserved 
region of the HIV-1 gag gene in order to ensure equal detection specificity for various 
HIV-1 group M subtypes. Quantitation of viral copies is based on the use of an internal 
standard. The dynamic range of the COBAS TaqMan HIV-1 assay is 40 – 10,000,000 
RNA copies/ml (Katsoulidou et al., 2006).  
 
The NucliSens™ HIV-1 QT test (BioMérieux, Inc., Durham, NC) employs an isothermal 
target amplification system named nucleic acid sequence-based amplification (NASBA). 
Unlike PCR technology that requires temperature cycling, an isothermal amplification is 
performed at a single temperature, i.e., 41ºC for NASBA. NASBA is driven by 
simultaneous activity of three different enzymes: AMV (Avian Myeloblastosis Virus) 
reverse transcriptase, T7 RNA polymerase and RNase H. One of the two primers used for 
NASBA is usually modified by the addition of a T7 promoter sequence recognized by T7 
RNA polymerase (Campton, 1991). Figure 1.3 illustrates the mechanism of amplification 
using NASBA. Quantitation of viral load with the NucliSens™ QT assay is based on the 
co-amplification of viral RNA with the three internal calibrators of a known concentration. 
Detection of the anti-sense RNA amplicons from both viral target and the calibrators 
utilizes ruthenium-labeled probes and a magnetic bead capture format. The signal from the 
probes is read and quantified by an electrochemiluminescence (ECL) reader (van Gemen et 
al., 1993; van Gemen et al., 1994). The primers used for the NucliSens™ QT assay are 
specific for a highly conserved region of the HIV-1 gag gene (Yen-Lieberman et al., 
1996). HIV-1 RNA is extracted from 0.2ml of patient plasma, and the dynamic range of 
the NucliSens™ QT assay is from 80 to 5 000 000 RNA copies/ml (Swanson et al., 2005). 
Good performance characteristics of NucliSens™ QT test, in particular high sensitivity and 
 12
specificity have been demonstrated not only using plasma samples (Lujan-Zilbermann et 
al., 2003), but also on seminal plasma (Fiscus et al., 2000) and dried blood spots 
(Brambilla et al., 2003).  
 
A new HIV-1 viral load assay - NucliSens™ EasyQ (version 1.1) has recently been 
developed by BioMérieux. The EasyQ test uses a single internal calibrator for quantitation 
of viral copies and a fluorescently labeled molecular beacon probe for detection of RNA 
amplicons (Figure 1.3). The NASBA reaction and real-time detection of amplicons is 
performed using the real-time EasyQ analyzer. This assay has a wider dynamic range than 
the NucliSens QT test (Weusten et al., 2002). Evaluation of the EasyQ test on HIV-1 
subtype C samples in our laboratory showed good correlation with the COBAS Amplicor 
version 1.5 assay (Stevens et al., 2005b). The EasyQ assay has recently been implemented 
in South Africa for HIV-1 viral load monitoring in patients enrolled in the national ARV 
treatment program.  
 13
 
Figure 1.3: Schematic representation of the NASBA reaction and molecular beacon 
detection (diagram adapted from Polstra et al., 2002). The P1 (anti-sense) primer with the 
T7 promoter overhang binds viral RNA. AMV RT converts sense RNA into cDNA. The 
resulting viral RNA/cDNA hybrid is converted to the single stranded (ss) DNA by RNase 
H activity of the AMV enzyme that digests sense RNA. Anti-sense ssDNA is converted to 
the double stranded (ds) DNA by P2 (sense) primer and AMV. This dsDNA represents a 
template with a functional T7 promoter that can be used by T7 RNA polymerase to 
produce multiple copies of anti-sense RNA (linear phase of amplification). Each copy of 
anti-sense RNA binds P2 primer and serves as a target for the next round of amplification – 
the process described above gets repeated (cycling phase). The molecular beacon is a dual 
labeled fluorogenic probe for detection of the anti-sense RNA amplicons. In the presence 
of the target molecules the stem-loop structure of the probe opens and it hybridizes to the 
target. Upon hybridization, the fluorescent and quencher dye get separated and 
fluorescence levels significantly increase.  
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The Versant HIV-1 RNA 3.0 test (Bayer Diagnostics, Tarrytown, NY), also referred to as 
the Quantiplex HIV-1 RNA test is based on an isothermal (45ºC), branched DNA (bDNA) 
amplification of signal . At the initial step of the assay, virus particles are concentrated by 
centrifugation of plasma and the pellet lyzed by proteinase K and detergent to release 
RNA. Subsequent, linear signal enhancement by bDNA technology utilizes a combination 
of five types of oligonucleotide probes (Figure 1.4). Microtiter plates prepared for the 
assay have capture probes attached to the sides of the wells. Another set of capture probes 
– the capture extenders (CEs) have sequences complementary to the capture probes and to 
viral RNA. Isolated HIV-1 RNA is captured by hybridizing to CE probes. Next, the large 
number (>30) of viral RNA-specific probes – label extenders (LEs) also bind to the 
captured target. Each of the numerous LE probes are then hybridized to the longer probe 
called the pre-amplifier. The pre-amplifier probes in turn bind many amplifiers labeled 
with alkaline phosphatase (AP). The current version of the bDNA test also makes use of 
modified, novel nucleotides – isoG and isoC. These modified dNTPs are incorporated into 
the sequences of pre-amplifier, amplifier and AP-labeled probes. This minimizes 
background signal by reducing non-specific binding between different probes since isoC 
and isoG won’t hybridize to the natural dCTP and dGTP. Detection is achieved by 
incubating the probe-target complex with the chemiluminescent substrate and measuring 
emitted light with a luminometer. The strength of luminescent signal is directly 
proportional to the amount of initial RNA target in the reaction. HIV-1 RNA is quantified 
using an external standard curve run in the same assay (Collings et al., 1997). The Versant 
HIV-1 RNA 3.0 test targets the highly conserved regions of the HIV-1 pol gene and 
requires 1ml of plasma for RNA isolation. The LLQ of the bDNA assay is set at <100 
RNA copies/ml (according to exUSA and USA package inserts <50 RNA copies/ml and 
<75 RNA copies/ml, respectively) and the UQL of the assay is 500 000 RNA copes/ml 
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(Swanson et al., 2005). Several studies demonstrated highly significant correlation between 
the bDNA assay and the Ultra sensitive Roche Amplicor version 1.5 assays. The Versant 
version 3.0 assay also showed good sensitivity, dynamic range and excellent 
reproducibility (Berndt et al., 2000; Elbeik et al., 2000; Erice et al., 2000; Galli et al., 
2005).  
 
 
 
 
Figure 1.4: Basic bDNA assay components (Figure and legend adapted directly from 
Collings et al., 1997). (A) First generation assay; (B) second and third generation assays. 
The preamplifier (heavy lines) is unique to the second and third generation assays.  
 
Overall, all three “gold” standard assays are highly correlated and demonstrate excellent 
performance characteristics: good reproducibility, high sensitivity (50-100 RNA 
copies/ml), 100% specificity and are capable of quantifying group M subtypes (A-G) of 
HIV-1.  
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There are also other NAT based commercial assays available for monitoring HIV-1 viral 
load that are in wide spread use but do not have FDA approval. The LCx® HIV-1 RNA 
quantitative assay (Abbott Laboratories, North Chicago, IL) utilizes competitive RT-PCR 
followed by microparticle enzyme immunoassay detection on the LCx Analyzer. HIV-1 
RNA is purified from 1 ml of plasma using the Qiagen sample preparation kit (QIAGEN® 
GmbH, Germany). The assay makes use of an internal control and an externally run 
calibration curve for quantitation of HIV-1 RNA copies. The dynamic range of the assay is 
50 - 1000000 RNA copies/ml. Primers and probes are specific to a highly conserved pol IN 
region of the HIV-1 genome (Johanson et al., 2001). The LCx® HIV-1 RNA quantitative 
assay shows good specificity, good correlation of quantitation results with the “gold” 
standard tests for all subtypes of group M and more efficient quantitation of group O 
samples than the “gold” standard tests (Berger et al., 2001; Katsoulidou et al., 2004; 
Swanson et al., 2005; Swanson et al., 2001).  
 
A recent development from Abbott (Abbott Molecular Inc., Des Plaines, IL) is the 
automated, high throughput (96 samples) RealTime™ HIV-1 assay. For this assay viral 
RNA is extracted from 1ml of plasma using the Abbott m2000sp™ automated sample 
preparation system and quantitative real-time RT-PCR is performed on the m2000rt™ 
instrument (Abbott Molecular Inc.). The RealTime™ HIV-1 assay provides wide linear 
dynamic range from 40 to 10 000 000 RNA copies/ml in the presence of an internal 
control. Primers and probes used in the assay are specific to the pol IN region of HIV-1. 
Evaluation of the RealTime™ HIV-1 assay using a panel of 91 plasma specimens from 
Brazil demonstrated equivalent quantitative performance with LCx HIV assay on subtypes 
B, C, F and recombinant B/F strains. Good agreement between the new assay and the LCx 
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HIV assay was demonstrated for this panel using the Bland-Altman model (Swanson et al., 
2006).  
 
The Gen-Probe HIV-1 viral load assay (Gen-Probe Inc., San Diego, CA) uses 
transcription-mediated amplification (TMA) and detection by chemiluminescence. TMA 
technology is almost identical to NASBA (Figure 1.3) with a single difference: TMA 
makes use of the AMV enzyme which possesses RNase H activity. The dynamic range of 
the assay is from 25 to 100 000 RNA copies/ml. The Gen-Probe viral load targets the 
conserved region of the pol gene of HIV-1 which allows good detection and quantitation of 
all subtypes from group M of HIV-1 and even rarer group O strains. The assay has shown 
to be a good alternative for monitoring HIV-1 viral load in plasma and other types of 
biological specimens, in particular breast milk and genital swabs (De Vange Panteleeff et 
al., 2002; Emery et al., 2000; Neilson et al., 1999).  
The Retina HIV-1 viral load assay (Primagen Holding B.V., Amsterdam, The Netherlands) 
uses NASBA technology for target amplification and molecular beacon probes for real-
time detection of amplicons. Reproducible sensitivity of the assay is 500 RNA copies/ml. 
Primers and probe are specific for a highly conserved region of the HIV-1 genome, the 
long terminal repeat (LTR) region. The assay can reliably detect and quantitate viral RNA 
in group M, N and O subtypes of HIV-1 (de Baar et al., 2000; de Baar et al., 2001).  
 
As described above, NAT based HIV-1 RNA quantitation tests reveal high performance 
characteristics and are most useful for monitoring patient viral load in response to ARV 
therapy. They provide reasonably high throughput and are semi- or fully automated. 
However, these “high tech” assays remain largely unaffordable for the developing world. 
Implementation of NAT requires a laboratory set-up with preferably unidirectional work 
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flow with dedicated areas for sample preparation, amplification and detection. Moreover, a 
set of specialized equipment and costly reagents make these assays quite expensive for the 
resource constrained settings.  An overview of the main technical characteristics of FDA 
approved and some recently developed NAT based viral load assay are summarized in 
Appendix A.  
 
In an attempt to provide more affordable, simpler options for developing world scenarios 
certain commercial companies have designed non-NAT based approaches to develop less 
complex, affordable alternatives to HIV-1 viral load monitoring. The Perkin-Elmer heat-
denatured (HD), signal-boosted HiSens HIV-1 p24 assay and the Cavidi ExaVir® Load 
Quantitative HIV-RT assay are examples of such approaches that do not use viral RNA as 
a target. Indirect measurement of HIV-1 viral load is performed by quantitation of p24 
antigen in the Perkin-Elmer HiSens p24 assay and by estimation of HIV-1 reverse 
transcriptase (RT) activity in the Cavidi RT assay (Award, et al., 1997; Garcia, et al., 1998; 
Ledergerber, et al., 2000; Schüpbach, et al., 1996). Both assays utilize less expensive 
enzyme-linked immunosorbent assay (ELISA) detection formats and can be performed in 
the less sophisticated laboratory set-up. Evaluation of these more affordable alternative 
HIV-1 viral load tests in a South African setting represents one of the primary objectives of 
this study. A more detailed description of methodologies used for these non-NAT based 
alternative viral loads are reviewed in chapter 3.  
 
1.3 Identification of Acute HIV-1 infection (AHI)  
The typical course of HIV-1 infection is characterized by an acute/primary phase that 
usually lasts for a few weeks, followed by an asymptomatic phase that usually lasts 3- 10 
years, which eventually leads to immune collapse termed the Acquired Immune Deficiency 
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Syndrome (AIDS) (Figure 1.2). The acute phase of HIV infection is also described as the 
HIV antibody-negative stage of the disease. During the acute phase the absence of host 
immune responses favors uncontrolled viral replication. Consequently, very high levels of 
viremia occur, and there is increased shedding of virus from mucosal sites. A reduction in 
viremia approximately 30 days post infection occurs when immune responses to the virus 
emerge and anti-HIV antibodies become detectable (seroconversion). A gradual reduction 
in viremia follows and the establishment of a so called “set-point” (Figure 1.2) indicates 
the start of a clinically asymptomatic phase (Alimonty, et al., 2003; Pilcher, et al., 2004). 
Between 1-4 weeks post-infection some individuals in the acute phase develop influenza-
like symptoms that are characteristic of most febrile illnesses (Coco, 2005; Schacker et al., 
1996). This combination of non-specific symptoms observed during the acute phase of 
HIV-1 infection has been termed the acute retroviral syndrome (Kahn and Walker, 
1998).Thus, AHI remains largely undiagnosed (>90%) due to the absence of specific 
clinical manifestations (Pilcher, et al., 2004; Coco, 2005). 
 
From a public health point of view early diagnosis of AHI in a high prevalence population 
could potentially decrease transmission of the infection and the epidemic spread of the 
disease. Several studies of acute HIV-1 show that viral load in semen (Vernazza et al., 
1994; Vernazza et al., 1997) and female genital fluids (Hart, 1999) can be higher than the 
extremely high viral load detected in plasma. High viremia is also associated with 
strikingly elevated genital and rectal shedding of virus during acute HIV-1 infection (Dyer 
et al., 1997; Pilcher et al., 2004b). The characteristic high plasma viral load and elevated 
shedding from mucosal and genital areas identify the period of “hyper infectiousness”, 
which accounts for up to a 20-fold increase in sexual transmission rates (Pilcher et al., 
2004b). Hyper infectiousness in the acute phase in combination with unawareness of ones 
 20
HIV-1 status has largely contributed to the rapid global spread of HIV-1 infection (Coco, 
2005; Leynaert et al., 1998). Diagnosis of acute HIV-1 infection is also critical for 
prevention of mother-to-child transmission (MTCT) relying on early administration of 
treatment both in neonates and mothers. In addition, identification of HIV-1 during the first 
few weeks of infection can substantially increase the safety of donated blood and blood 
products from acutely infected HIV infected individuals, and helps to prevent this route of 
viral transmission (Fiebig et al., 2003). Some studies demonstrated that initiation of 
treatment during the acute phase of HIV-1 infection may dramatically improve the 
outcome of ARV therapy by directly targeting latent reservoirs of virus (Lafeuillade et al., 
2003) and facilitating maximum anti-HIV immune responses that also help to clear viral 
reservoirs (Oxenius et al., 2000; Rosenberg et al., 2000).  
 
In general, the diagnosis of HIV infection is based on the identification of viral markers 
that appear in an individual’s blood or other body fluids in the following chronological 
order: viral RNA, DNA, p24 antigen, and antibody to HIV antigens. In the context of HIV 
detection, the time interval before antibodies appear is known as the serological “window 
period”. This period is characterized by seronegativity, high levels of viremia detectable by 
the presence of viral RNA and p24 antigen, and variable CD4+ T lymphocyte levels. In the 
majority of individuals, antibodies to HIV are usually detected within 1-2 months post 
infection regardless of the method used (Constantine et al., 1992). Commercial HIV-1 
diagnostic tests can be classified depending on the type of viral marker used as a detection 
target to identify the infection. Additionally, irrespective of the viral markers used HIV 
diagnostic assays fall into two major categories: (i) screening (diagnostic) assays, which 
are designed to identify all infected individuals; and (ii) confirmatory (supplemental) 
assays, which are designed to differentiate between false positive and truly positive results 
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obtained using the screening assays. Correspondingly, screening assays are characterized 
by a high degree of sensitivity (low false negative rate) and confirmatory assays are 
designed to provide high specificity (low false positive rate). In most cases both categories 
of assays are used consecutively to ensure highly accurate and reliable diagnosis of HIV 
infection. Often, for cost saving purposes a combination of different screening assays is 
used in a specially designed confirmatory algorithm (e.g. rapid assays are usually 
confirmed using either third or fourth generation enzyme-linked immunosorbent assays 
(ELISA) assays) (Constantine and Zink, 2005).  
 
Rapid HIV-1 serologic tests have been designed to detect anti-HIV antibodies in oral 
mucosal transudate, whole blood, serum and plasma. These tests are most useful for 
diagnosing HIV infection after seroconversion. These assays are suitable for POC testing 
as they are quick (~20- 45 minutes), generally easy to perform (in 1-2 steps) and do not 
require a laboratory setting, specialized equipment or skilled personnel. Rapid assays 
employ different technologies: (i) flow-through; (ii) lateral flow; or (iii) agglutination 
assays (Aaron et al., 2006; Gupta and Chaudhary, 2003; Sudha et al., 2005). A wide 
variety of rapid tests are commercially available (Respess et al., 2001). OraQuick and 
OraQuick ADVANCE rapid HIV-1/2 antibody tests (OraSure Technologies, Inc., 
Bethlehem, PA, USA) for oral transudate received the US Food and Drug Administration 
(FDA) approval based on their performance characteristics (Aaron et al., 2006; Cohen et 
al., 2003; Liang et al., 2005; Reynolds and Muwonga, 2004). According to the WHO 
recommendations (WHO/UNAIDS, 1999) rationalized testing strategies (algorithms) based 
on employing a combination of 2-3 consecutive rapid tests (rapid screening test followed 
by other rapid, confirmatory tests) are often used. These confirmatory testing algorithms 
reduce the number of indeterminate and incorrect results, but increase the cost of testing 
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(Menard et al., 2005; Respess et al., 2001; Wright et al., 2004). The use of rapid tests is 
standard of care in resource limited settings where laboratory infrastructure, stable supply 
of electricity and trained personnel are omnipresent. In South Africa the most widely used 
HIV rapid tests are the Determine HIV-1/2 (Abbott Laboratories, USA), Uni-Gold HIV 
(Trinity Biotech plc, Ireland) and Capillus HIV-1/2 (Cambridge Diagnostics, Galloway, 
Ireland). Determine HIV-1/2 and Uni-Gold HIV represent lateral flow based anti-HIV 
antibody rapid tests, and the Capillus is a particle agglutination test. These rapid tests show 
high sensitivity and specificity and are often used in alternative screening as well as in 
confirmatory HIV testing algorithms to provide more accurate HIV diagnostics (De Baets 
et al., 2005; Ferreira Junior et al., 2005; McKenna et al., 1997; Menard et al., 2005; 
Phillips et al., 2000; Ramalingam et al., 2002; Soroka et al., 2003).  
 
ELISAs or enzyme immunosorbent assays (EIA, term is used interchangeably) for 
detection of anti-HIV IgG and IgM antibodies are often referred to as third generation 
assays. Detection of IgM which appears prior to IgG allows the early diagnosis of HIV. 
Antibody (Ab) ELISA assays can be performed on oral fluid, urine and blood samples. 
ELISA configuration of the third generation assays makes use of so called antigen 
sandwich detection where the bivalent anti-HIV antibody binds to both the capture antigen 
attached to the solid support and the detector antigen labeled with an enzyme. Generally, 
third generation assays have slightly higher sensitivity and specificity of antibody detection 
than rapid tests. During seroconversion, the third generation assays can detect anti-HIV 
antibody 2-8 days earlier than the rapid tests (Makuwa et al., 2002). These assays provide 
cost-effective and high throughput diagnostics for HIV. The third generation Vironostika 
Uni-Form II plus O assay (BioMérieux, The Netherlands) is a widely used assay in South 
Africa for HIV-1diagnosis. This anti-HIV Ab ELISA assay is highly sensitive and shows 
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good specificity across different HIV-1 groups M and O subtypes (Aboud et al., 2006; 
Murphy et al., 2003; van Binsbergen et al., 1996; van Binsbergen et al., 1997; van 
Binsbergen et al., 1999). The Vironostika Ab ELISA assay in combination with the 
Orasure HIV-1 oral specimen collection device was used to estimate the HIV-1 prevalence 
in the South African population (Connolly et al., 2004).  
Another type of laboratory based diagnostic assay allows combined detection of HIV 
antigen (Ag) and antibody (Ab). These assays are also known as fourth generation assays 
(Weber et al., 1998). There are a variety of commercially available fourth generation 
assays including AxSym HIV Ag/Ab Combo (Abbott Laboratories, IL, USA), Enzygnost 
HIV Integral (Dabe Behring, Penzberg, Germany), Genscreen Plus HIV Ag/Ab (Bio-Rad, 
Marnes La Coquette, France) and Murex HIV Ag/Ab Combo (Abbott, Dartford Kent, 
England), amongst others. Due to the detection of HIV p24 antigen in seroconversion 
samples, combined Ab/Ag tests reduce the detection window by approximately 6 days, to 
approximately 14-15 days post infection, when compared to the third generation assays 
(Aghokeng et al., 2004; Ly et al., 2004). In South Africa one of the most widely used 
fourth generation ELISA assays is the Murex HIV antigen/antibody assay (Abbott Murex, 
UK). The assay was shown to be one of the most sensitive among the Ab/Ag combined 
assays allowing detection of early seroconversion samples (Aboud et al., 2006; Ly et al., 
2004; Ly et al., 2001).  
 
Verification of the results obtained with Ab and Ab/Ag ELISA assays is performed using 
the most common serologic confirmatory assays like HIV Western blots (WB) and Line 
Immuno Assays (LIA). Generally, in the developed countries the Western blot is the most 
widely accepted confirmatory assay and may be considered as the “gold standard” assay 
for detection of anti-HIV antibodies and validation of HIV results (Constantine and Zink, 
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2005). Western blots detect reactivity of the human antibodies against at least 10 different 
viral antigens. Criteria for interpretation of Western blot results may differ in different 
laboratories and in different kit formats.Generaly, reactivity to at least two of the following 
antigens: gp160/120, gp41, or p24, is required to identify a reaction as positive. Criteria for 
interpretation of WB results suggested by the Centre for Disease Control (CDC, USA) 
differ from those recommended by WHO (US Department of Health and Human Services, 
Centers for Disease Control. Interpretation and use of the Western blot assay for 
serodiagnosis of human immunodeficiency virus type 1 infection; WHO, proposed criteria 
for interpreting results from Western blot assays for HIV-1, HIV-2 and HTLV-I/HTLV-
II.). The absence of any reactivity in WB indicates negative HIV results. Although, WB 
and LIA confirmatory assays are commercially available in a kit form they are costly, and 
require expensive and sophisticated equipment (Cohen et al., 2003; Ferreira Junior et al., 
2005; Makuwa et al., 2002), which also makes them unaffordable for developing countries. 
WHO and CDC recommendations for HIV testing strategies, HIV screening and 
confirmatory algorithms differ for the developing and developed countries 
(http://www.cdc.gov/mmwr/pdf/rr/rr/1519.pdf). 
 
The rapid and third generation EIA assays detect anti-HIV antibody, which makes them 
inappropriate for the diagnosis of the acute, antibody-negative phase of HIV infection 
(Figure 1.5). Even though the fourth generation assays detect p24 antigen, their sensitivity 
of detection is significantly lower when compared to p24 Ag ELISA assays (Ly et al., 
2004). Therefore, diagnosis of acute HIV-1 infection relies on detection of p24 antigen 
(p24 Ag EIA) and/or HIV-1 RNA or proviral DNA. Both p24 antigen and HIV RNA 
increase in parallel during viral replication. However, due to higher sensitivity of RNA 
amplification tests this marker is detected earlier than p24 antigen. A number of 
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commercial p24 Ag EIA assays are available including the FDA approved Abbott HIV-1 
Ag monoclonal and Coulter HIV-1 p24 antigen assay. On average, limits of sensitivity of 
p24 Ag ELISA assays are 3- 10pg of p24 antigen per ml (Fransen et al., 2001; Weber et al., 
1999). Viral RNA can be detected during the first 2 weeks after infection, before p24 
antigen is detectable (Figure 1.5).  
 
 
 
 
Figure 1.5: Kinetics of viral markers during primary HIV-1 infection (adapted from Cohen 
and Powderly, 2003). Keys: Pink = plasma HIV RNA; Purple = p24; Blue = anti-HIV 
antibody. Serologic window period is ~ 3 weeks post-infection; after this period anti-HIV 
Ab(s) become detectable. Detection of HIV-1 RNA can reduce the detection window to 
day 11-12 post-infection and provide means for earliest diagnosis of AHI.  
 
NAT for determination of viral RNA are mainly used for monitoring HIV-1 viral load. 
Specimen pooling strategies combined with reverse transcription polymerase chain 
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reaction (RT-PCR) have been used to reduce costs of screening of acute HIV-1 infection in 
low and high prevalence populations (Pilcher et al., 2002; Stevens et al., submitted). 
Approved commercial assays for HIV-1 RNA quantitation were discussed previously 
(section 1.2). Studies conducted by different groups come to the mutual conclusion that 
p24 Ag ELISA assays are less sensitive, but more specific for detection of acute HIV-1 
infection when compared to viral RNA tests (Daar et al., 2000; Hecht et al., 2002). 
Reduced specificity of NAT is due to false positive results. Ideally, NAT for HIV-1 RNA 
could provide the earliest diagnosis of the acute phase by further reducing the detection 
window when compared to the p24 Ag ELISA (Figure 1.5).  
 
However, irrespective of the high (100%) sensitivity (Daar et al., 2000; Hecht et al., 2002) 
of current HIV-1 RNA assays, specialized laboratory set-up, expensive equipment and cost 
of testing makes them less appropriate for routine screening of acute/primary HIV-1 
infection in resource constrained settings. The most appropriate assay for diagnosing 
incidence of AHI in South Africa would be a POC assay based on nucleic acid 
amplification technique(s) (NAAT). To our knowledge, such an assay that will allow 
detection of HIV-1 RNA in a POC testing format is not commercially available at present.  
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CHAPTER 2  
 
DEVELOPMENT AND EVALUATION OF AN HIV-1 
QUANTITATIVE REAL-TIME RT-PCR ASSAY USING 
THE LIGHTCYCLER® PLATFORM  
This chapter is dedicated to the development and preliminary evaluation of a new, in-house 
quantitative real-time RT-PCR assay for monitoring HIV-1 viral load in plasma. The initial 
development of the assay, including basic optimisation of RT-PCR conditions and other 
technical parameters, was performed using the LightCycler® platform version 1.2 (Roche 
Applied Science, Mannheim, Germany) and the FRET probes for detection of amplicons. 
Recombinant plasmids with a cloned external standard (ES) for quantitation and an internal 
control (IC) were produced for the assay. Evaluation of assay performance was done using 
an RNA transcript of the ES and the BBI panel for HIV-1 subtype C infected plasma. The 
developed viral load assay was subsequently transferred to the new, more advanced 
version of the LightCycler® instrument (version 2) as this became available in South 
Africa. Following the technology platform transfer two main modifications were applied to 
the original “FRET assay”: (i) RT-PCR was performed in a larger reaction volume (50 µl 
instead of 20 µl) and (ii) the FRET probe detection format was replaced with the LUX™ 
(Light upon Extension) primer. For simplicity the initial version of the developed viral load 
assay that uses FRET hybridization probes and the final version of the assay that uses a 
LUX™ primer detection format is referred to as the FRET assay and the LUX assay, 
respectively. Initial evaluation of the LUX assay was performed using ES RNA transcript 
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and VQA copy controls. Preliminary clinical evaluation was performed using plasma 
samples obtained from known HIV-1 seronegative patients (n = 50), and clinical 
specimens from a random group of HIV-1 positive patients (n = 142) and a cohort of 55 
HIV-1 positive patients on HAART followed-up longitudinally (n = 266; 458 plasma 
specimens in total). 
2.1 Introduction  
A comprehensive review of all aspects and variations of real-time polymerase chain 
reaction (PCR) technology is beyond the scope of this thesis and therefore this introductory 
section will focus only on the aspects of this technology that are related to the current 
investigation. Real-time PCR is the greatest innovation that has been recently applied to 
PCR technology. Analyzing PCR product on-line, during the amplification process is 
termed “real-time” PCR. Real-time PCR is made feasible by a new approach to amplicon 
detection and modifications made to the conventional thermal cycler (Wittwer et al., 
1997a). Non-sequence-specific detection of amplicons in real-time PCR is performed using 
fluorescent DNA dyes. The most widely used fluorophore is SYBR Green I dye that 
intercalates into double stranded DNA molecules and emits much higher levels of 
fluorescence than the unbound dye (Morrison et al., 1998; Pfaffl and Hageleit, 2001). 
Sequence-specific detection of PCR product is achieved by using oligonucleotide probes or 
modified primers that carry a fluorescent label. Although, numerous probes and primers 
differ in their design, there are two ways of generating a fluorescent signal: the separation 
of a fluorophore from a quencher or the association of a donor and acceptor dye to generate 
a fluorescent signal by energy transfer. Among probes labeled with a fluorescent and a 
quencher dye are TaqMan™ probes (Desire et al., 2001; Holland et al., 1991; Klein et al., 
2003) and TaqMan™ probes with a 3’ minor groove binding (MGB) group added  (de Kok 
et al., 2002), Scorpion™ primers (Saha et al., 2001), Light upon Extension (LUX™) 
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primers (Nazarenko et al., 2002b; Nazarenko et al., 2002a), MGB Eclipse™ (Afonina et 
al., 2002) and double stranded “Yin-Yang” probes (Li et al., 2002). Fluorescent resonance 
energy transfer (FRET) hybridization probes (Figure 2.1) are labeled with a donor and an 
acceptor dye and represent the detection format most commonly used on the LightCycler® 
platform (Farcas et al., 2006; Lay and Wittwer, 1997; Makinen et al., 2002). LUX™ 
primers represent a recent advance in real-time detection technology. This detection format 
includes one single-labelled, self-quenched primer and an unlabelled counterpart. Figure 
2.2 demonstrates the mechanism by which structural changes of the LUX primer during the 
steps of each PCR cycle allows for controlling the intensity of fluorescence. Although 
DNA-binding dyes are less expensive, the use of fluorescently labelled probes allows 
better specificity of detection and multiplex, simultaneous detection of multiple targets 
(Elenitova-Johnson et al., 2001).  
 
Real-time PCR instruments combine features of a conventional thermocycler and a 
fluorimeter. Currently, there are a wide variety of real-time PCR instruments on the market 
(Bustin, 2002; Gibson, 2006). Among the first commercially available technologies were 
the ABI Prism instruments from Applied Biosystems, iCycler from BioRad and the Roche 
LightCycler® system. The LightCycler® (Roche Applied Science, Mannheim, Germany) is 
one of the fastest real-time PCR instruments. PCR reactions using the LightCycler® system 
are performed in glass capillaries placed in a rotating carousel (Wittwer et al., 1997b). The 
system uses pumped air for rapid heating and cooling of the reaction chamber that holds 
the carousel with 32 capillaries. A PCR cycle can be completed in 15-20 seconds. The 
LightCycler® system has blue LED light source for fluorescence excitation.  
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Figure 2.1: FRET Probes (Diagram adapted from Mocellin et al., 2003). (a) FRET 
detection format uses a pair of oligonucleotide probes: one probe labeled at the 3’ end with 
a donor dye (R1) and another probe carrying an acceptor dye at the 5’ end (R2). (b). during 
the annealing step of the PCR cycle both probes hybridize to the target sequence in a head-
to-tail orientation bringing the donor and the acceptor dyes in close proximity of each 
other. The donor dye (usually FAM or Fluorescein) is excited by the light source (LED) of 
the real-time instrument, the energy from the excited donor fluorophore gets transferred to 
the acceptor dye and it in turn emits fluorescence recorded as a signal by the instrument.  
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Figure 2.2: Schematic representation of the LUX™ Primer (Diagram adapted from: 
http://www.wzw.tum.de/gene-quantification/qpcr2004/pub/Nickson.pdf). Changes in 
emission of fluorescence are affected by the primary and secondary structure of a LUX™ 
primer. The labelled 3’-end of a LUX primer requires guanosine bases near the conjugated 
fluorescent tag. The 5’-end of this fluorogenic primer is modified by the addition of a short 
sequence that is complementary to the labelled 3’-end of the primer. This 5’ tail allows a 
LUX™ primer to assume a hairpin configuration, which causes a fluorescence quenching 
effect. During PCR, when a fluorogenic LUX™ primer binds to the complementary 
sequence and becomes linear, the fluorophore is de-quenched and the levels of 
fluorescence increase by 10-fold.  
 
Earlier versions of the LightCycler® instrument had three detection channels and could 
only accommodate small volume (20 µl) capillaries. The latest LightCycler® instrument, 
version 2.0, allows the use of 20 µl and 100 µl capillaries and has six detection channels: 
530 nm (FAM, Fluorescein, SYBR Green), 560 nm (HEX, VIC), 610 nm (LightCycler 
(LC) Red 610), 640 nm (LC Red 640) and 710 nm (LC Red710). Similarly to other real-
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time PCR instruments, the LightCycler® is operated through a computer system and 
specially designed software. Data analysis (qualitative or quantitative) is performed after 
completion of PCR using the LightCycler® software (Roche Applied Science, Mannheim, 
Germany) (Gibson, 2006).  
 
Real-time detection systems have simplified and improved quantitative PCR. Conventional 
competitive quantitative PCR employs time consuming gel electrophoresis followed by 
less accurate densitometry analysis or probe based color detection for an end-point 
quantitation of product (Schutten et al., 2000). Real-time PCR platforms monitor 
fluorescent signals during each PCR cycle and the integrated software identifies the 
threshold cycle (CT) within the exponential increase phase of PCR. The (CT) value is the 
cycle at which the fluorescence acquired during the log-linear phase of amplification is 
significantly higher than the baseline (background) level. Theoretically, the threshold cycle 
is inversely correlated to the initial (input) amount of template molecules and represents a 
unique signature of template concentration. There are two “methods” of quantitation using 
real-time PCR – relative and absolute and both methods are based on identification of the 
CT value. Relative quantitation is mostly used to study gene dosage or gene expression 
levels in comparison to the various housekeeping genes. The quantitation values are 
normally expressed as a ratio of the CT of a housekeeping gene and the target gene. 
Absolute quantitation, or recently referred to as the standard curve quantitation method, is 
based on the use of an external quantitation standard. An external standard (ES) is defined 
as a sample of known concentration. Serially diluted ES samples (at least three different 
concentrations) are included in each run to determine the concentration of unknown 
samples. The integrated software of a real-time PCR system constructs a standard curve 
plotting the known concentration values of ES on the X-axis and the extrapolated, 
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corresponding CT values on the Y-axis. Therefore, the resulting standard curve reflects the 
linear relation between the template input and the CT value. The concentration of template 
in an unknown sample is deduced by plugging its CT value into the standard curve (Bustin 
and Nolan, 2004; Higuchi et al., 1993; Schmittgen et al., 2000; Wittwer). The 
concentrations obtained using an absolute quantitation method are usually expressed in 
weigh units or copy numbers of molecules per unit of volume, e.g. 400 pg/ml or 50 RNA 
copies/µl. In comparison to the end-point quantitative analysis of a conventional PCR, 
real-time quantitation is performed in a log-linear phase of exponential product 
accumulation and hence it is more accurate, sensitive and has a wide dynamic range.  
 
Nucleic acid extraction (manual or automated) represents an important and certainly the 
most time consuming step of real-time PCR based assays. Several automated and manual 
extraction technologies are available in South Africa. The QIAamp® Viral RNA mini kit 
(Qiagen) which makes use of Boom’s extraction method (Boom et al., 1998) and silica 
columns is widely used since it provides high sensitivity and reproducibility (Fischer et al., 
1999; Fransen et al., 1998; Niubo et al., 2000). Automated extraction systems are ideally 
suited for the high volume requirements occurring in the routine diagnostic laboratories in 
South Africa. The MagNA Pure LC instrument (Roche) offers efficiency of extraction that 
is equivalent to the BioRobot 9604 system (Qiagen, Inc., Chatsworth, CA) (Espy et al., 
2001), and was available for the purposes of this study. Nucleic acid extraction kits used 
with the MagNA Pure system utilize magnetic glass particles for capture and purification 
of nucleic acid molecules. The MagNA Pure method when compared to the NucliSens 
manual extraction kit (BioMérieux) requires 10 –fold smaller volumes of plasma to yield 
equivalent amounts of nucleic acid as the NucliSens kit (Mohammadi et al., 2003).  
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Real-time PCR is a relatively new technology that has been widely implemented in 
research and diagnostics fields. The entire process of amplification and detection occurs in 
one closed system with no need for post-PCR manipulations. This significantly decreases 
the risk of carry-over contamination with the PCR product and reduces hands-on time. 
Real-time PCR instruments offer high throughput, up to 384 samples per run, and the more 
recent developments of this technology are directed towards full automation. All of the 
above in combination with dramatically improved detection and quantitation of product 
makes real-time PCR a very attractive technology for application in the diagnostics field. 
In particular, a number of real-time PCR assays, both commercial and in-house, have been 
developed recently for detection and quantitation of viral pathogens (Candotti et al., 2004; 
Katsoulidou et al., 2006; Keyaerts et al., 2006; Sum et al., 2005; Swanson et al., 2006). 
Quantitative real-time RT-PCR using the LightCycler® technology in combination with 
FRET probes, LUX ™ primers and manual and automated extraction methods have been 
explored in this study as potential alternatives for more affordable HIV-1 viral load testing 
in South Africa.  
 
2.2 Materials and Methods  
An overview of methodologies for the development of an in-house HIV-1 viral load assay 
is depicted below.  
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This diagram provides a comprehensive overview of a multi-step process involved in 
production of ES and IC. Viral RNA was extracted using manual and automated (MagNA 
Pure, Roche) methods. Initially, the FRET probe based assay was developed, followed by 
the final version of an in-house assay using the LUX™ primer detection format. 
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2.2.1 HIV-1 specific primers  
A previously well characterized conserved sequence within the p24 region of the HIV-1 
gag gene (Figure 2.5) was selected as an amplification target (Bogh et al., 2001; Grankvist 
et al., 1996; Triques et al., 1999). Forward primer SKT145 and reverse primer SKT150 
(Olfert Landt, personal communication, TIB MOLBIOL, Berlin, Germany) were 
manufactured by TIB MOLBIOL (Berlin, Germany) and define 128 bases region within 
the HIV-1 gag gene. The primer SKT145 represents a 9 nucleotides truncated version of a 
previously described primer SK145 (Bogh et al., 2001; Grankvist et al., 1996; Triques et 
al., 1999). The primer SKT150 partially overlaps with the primer SKCC1B (Grankvist et 
al., 1996; Triques et al., 1999) and is located internally to this primer.  
The sequences of the primers are as follows:  
SKT145 - 5’ -ACA TCA AGC AGC CAT GCA AAT -3'  
SKT150 - 5’ -TGT CAC TTC CCC TTG GTT CTC TC - 3'  
Sequences of the primers were checked for the degree of homology using the BLAST 
program (http://www.ncbi.nlm.nih.gov/BLAST). No homology was found with sequences 
other than HIV-1.  
 
2.2.2 Preparation of an External Standard (ES) for quantitation of HIV-1 RNA  
2.2.2.1 Preparation of the RNA template for cloning  
A plasma sample from a South African patient with a high (5 log10) HIV-1 viral load as 
estimated by the Roche Amplicor assay was used to manually extract viral RNA for 
template preparation (see section 2.2.4.1). Extracted HIV-1 RNA was used as a template 
for conventional one-step RT-PCR performed on the MyCycler™ thermal cycler (BIO-
RAD Laboratories, Inc., USA). A total reaction volume of 50 µl was used containing 25.5 
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µl of a master mix assembled using the QuantiTect™ RT-PCR kit (Qiagen GmbH, Hilden, 
Germany), SKT145 and SKT150 primers at a final concentration of 0.5 µM and 20 µl of 
RNA. The thermal cycling conditions included an initial reverse transcriptase (RT) step 
performed at 50ºC for 45 minutes (min) and a hot start at 95ºC for 15 min followed by 40 
cycles of amplification with a denaturation step at 95ºC for 1min, annealing at 58ºC for 30 
seconds (s), and extension at 72ºC for 45 s; and a final elongation for 7 min.  
 
The amplicons of HIV-1 generated with primers SKT145/150 were verified using 
conventional 2% agarose gel electrophoresis (Appendix B; see below). The RT-PCR 
product was diluted 1:100 in molecular grade water (MGW) provided in the QuantiTect™ 
RT-PCR kit. The diluted PCR product served as the template in a second round PCR 
performed using PCR Master Mix (Promega, Madison, WI, USA) to ensure amplification 
of DNA fragments possessing 3’-A overhangs for subsequent cloning. Fifty µl of PCR mix 
consisted of 25 µl of the reaction mix from the kit, primers SKT145 and SKT150 at the 
final concentration of 0.5 µM, 15 µl of PCR grade water from the kit and 5 µl of the 
diluted first round PCR product. Thirty cycles of PCR were performed according to the 
following amplification profile: initial denaturation step at 95ºC for 2 min followed by 40 
cycles of amplification  with a denaturation step at 95ºC for 1min, annealing at 58ºC for 30 
s, and extension at 72ºC for 45 s; final elongation for 7 min. Ten microliters of 
amplification product was mixed with 5 µl of the gel loading dye (Fermentas UAB, 
Lithuania) and loaded onto a 2% agarose gel (Agarose MP, Roche Applied Science, 
Mannheim, Germany) prepared with 1xTAE buffer (see Appendix B) and 3 µl of ethidium 
bromide stock solution (10 mg/ml; Sigma-Aldrich., St. Louis, Missouri, USA) per 100 ml 
of gel. Agarose gel electrophoresis was performed at 100V for 1-2 hours. Size verification 
of the product was performed by running 10 µl of the O’GeneRuler™ 50bp DNA ladder 
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(Fermentas, UAB, Lithuania) along side the sample. The gel was viewed under the UV 
light. After product verification, the remaining PCR amplification mix was loaded onto a 
1% agarose gel (~20 µl per well) and electrophoresis was performed as described above. 
The gel band was excised and purified using the MinElute™ Gel Extraction kit (Qiagen, 
GmbH Hilden, Germany) according to the manufacturer’s instructions. DNA was eluted in 
10µl of the elution buffer supplied in the kit.  
 
Quantitation of the purified PCR product was performed using a PicoGreen® dsDNA 
quantitation kit (Molecular Probes, Eugene, USA) and the FLX 800 microplate 
fluorescence reader (BIO-TEK Instruments, Inc., Vermont, USA). The kit contains 
PicoGreen® dsDNA quantitation reagent, which is an ultrasensitive fluorescent nucleic 
acid stain used for quantitation of double-stranded DNA (dsDNA) in solution. The 
quantitation standard (λ DNA) from the kit and the PCR sample were diluted according to 
the protocol supplied with the kit. The high-range standard curve included the following 
concentrations of the λ DNA standard: 1 µg/ml, 500 ng/ml, 100 ng/ml, 20 ng/ml and the no 
λ DNA (blank) sample. Two dilutions of PCR product - 1:50 and 1:100 were used for 
quantitation.  Total reaction volume (200 µl) of the diluted standards and the diluted 
amplification product were loaded onto the microtiter plate and fluorescence was recorded 
on the FLX 800 fluorimeter. The KC Junior™ microplate data analysis software (BIO-
TEK Instruments, Inc., Vermont, USA) was used to generate a standard curve for 
quantitation of DNA. Final concentrations of the PCR product were calculated as a mean 
of the two values calculated by the software for both dilutions; the dilution factor was 
taken into account.  
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2.2.2.2 Cloning the external standard  
The purified PCR product (section 2.2.2.1) was used as an insert for cloning into the 
pGEM®-T Easy Vector System (Promega, Madison, WI, USA). The high copy number 
pGEM®-T Easy Vector represents a convenient system for efficient cloning of PCR 
product. The vector is linear and possesses 3’ terminal thymidine (T) at both ends. The 
pGEM®-T Easy Vector contains T7 and SP6 RNA polymerase promoters flanking a 
multiple cloning region within the α-peptide coding region of the enzyme β-galactosidase. 
Insertional inactivation of the α-peptide allows identification of recombinant clones by 
blue/white screening on indicator plates. The multiple cloning site also contains restriction 
sites for isolation of the desired, cloned fragment by enzymatic restriction. The process of 
cloning included the following steps:  
 Ligation of  the DNA insert (PCR product) into the vector;  
 Transformation of competent cells with the recombinant vector;  
 Plating out the transformed competent cells on the indicator plates for blue/white 
screening of colonies.  
 
All these steps were performed strictly following the protocol included in the pGEM®-T 
Easy Vector System (Promega, Madison, WI, USA) kit. According to the manufacturer’s 
recommendations different “insert: vector” molar ratios were used (in particular 3:1 and 
6:1). A positive control (provided in the kit) and background control (no insert DNA) was 
also included in the ligation experiment. Ligation reactions were left overnight at 4ºC to 
achieve maximum number of recombinant plasmids. Transformation of the competent E-
coli XL1-Blue stains (Stratagene, USA) using the pGEM®-T Easy Vector ligation reactions 
were also performed according to the manufacturer’s instructions (Promega, Madison, 
USA). The SOC medium required for transformation was prepared according to the recipe 
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provided in the kit insert (see Appendix C). One hundred µl of each transformation culture 
was plated onto duplicate Luria Bertani (LB)/ampicillin/IPTG/X-Gal agar plates 
(Appendix C). Plates were incubated overnight at 37ºC. After incubation, several white 
colonies from the plate with insert: vector 6:1 ratio were selected and inoculated into 10 ml 
of LB/Amp broth (see Appendix C) using sterile 50 ml falcon tubes and incubated 
overnight at 37 ºC in the Labotec (Labotec, Midrand, SA) orbital shaker (~145 rpm).  
 
Potential clones grown in the LB/Amp broth were centrifuged (2000 rpm) on the bench top 
Eppendorf centrifuge 5810R (Eppendorf AG, Hamburg, Germany) for 30 min. 
Recombinant plasmid DNA (i.e. pGEM®-T vector with the DNA insert) was extracted 
using the High Pure Plasmid Isolation mini kit (Roche Molecular Biochemicals, 
Mannheim, Germany) according to the manufacturer’s instructions. Recombinant plasmid 
DNA was eluted in 100 µl of elution buffer supplied in the kit. The DNA yield from the 
plasmid preparation was estimated by performing conventional spectrophotometry using a 
1:100 dilution of DNA sample. Purified recombinant plasmid DNA was also assessed by 
conventional agarose gel electrophoresis – 2 µl of DNA was loaded onto an ethidium 
bromide stained 1% agarose gel and electrophoresis performed at 80 V for an hour.  
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2.2.2.3 Sequencing the plasmids  
Three out of several different clones were selected and used for sequencing in order to 
determine the integrity of the insert. Two µl of purified plasmid DNA (see 2.2.2.2) from 
the selected three clones were used in each sequencing reaction. Two primers (Inqaba 
Biotech, Pretoria, SA) specific for the T7 and SP6 promoter regions of the pGEM®-T 
vector, were used to sequence the region in both directions. Primer sequences were as 
follows: T7 – 5’-TAA TAC GAC TCA CTA TAG GGC -3’; SP6 – 5’-ATT TAG GTG 
ACACTA TAG AAT-3’. The sequencing reaction was undertaken with the Big Dye® 
Terminator version 3.1 cycle sequencing kit from Applied Biosystems (Foster City CA, 
USA) according to the manufacturer’s instructions, on the ABI Prism 3100-Avant Genetic 
Analyzer (Applied Biosystems). Sequence data analysis was performed using the 
Sequencing Analysis V3.3 programs (Applied Biosystems) and assembled using the 
Sequencher program version 4.1.4 (Genecodes, Ann Arbor, MI). The edited gene fragment 
from the cloned insert was aligned and compared with reference sequences from the HIV-1 
subtype B HXB2 isolate (http://hiv-web.lanl.gov) using the Clustal X program 
(Jeanmougin et al., 1998; Thompson et al., 1997); http://bips.u-
strasbg.fr/fr/Documentation/ClustalX).  
 
2.2.2.4 Synthesis of the external standard RNA  
After the sequence verification, clone A5 was selected, based on the high DNA 
concentration, as a template for in vitro RNA transcription. Template preparation for ES 
RNA synthesis included enzymatic digestion of the plasmid and purification of the 
linearized template.  
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Plasmid DNA of A5 clone was digested using SpeI restriction endonuclease (Roche, 
Applied Science, Mannheim, Germany). Fifty µl of the digestion reaction contained 
approximately 5 µg of plasmid DNA, 1 x SureCut buffer H (supplied with the enzyme), 2 
units of SpeI and molecular grade water (Sigma-Aldrich, St. Louis, Missouri, USA). The 
reaction was incubated at 37ºC for 2 hours. The digestion product was verified by gel 
electrophoresis: 10 µl of the digestion reaction and 2 µl of uncut recombinant plasmid were 
each mixed with 5 µl of the gel loading dye and loaded onto an ethidium bromide stained 
1% agarose gel, prepared with 1xTAE buffer (Appendix B). A one kilo base (kb) 
molecular weigh marker (Fermentas, UAB, Lithuania) was used to confirm the size of the 
digested plasmid. Electrophoresis was performed at 90 V for 1-2 hour. After confirmation 
of complete digestion the remaining reaction was incubated at 65ºC for 15 min for heat-
inactivation of the SpeI enzyme. Electrophoresis using the remaining reaction was 
performed using a 1% agarose gel as described above. The gel band containing the product 
was excised from the gel and purified using the MinElute™ Gel Extraction kit (Qiagen, 
GmbH Hilden, Germany) as per manufacturer’s protocol. The initial 20 µl of reaction was 
eluted into 10µl of elution buffer provided in the kit.  
 
Synthesis of the ES RNA was performed by in vitro transcription using the RT-PCR 
Competitor Construction kit (Ambion, Austin, Texas, USA) and linearized, purified 
plasmid of the A5 clone (see section 2.2.2.4). The transcription reaction was assembled 
according to the manufacturer’s instructions and incubated at 37ºC overnight. After 
completion of synthesis, template DNA was removed by DNase I treatment, supplied in 
the kit.  
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The RNeasy® Mini kit (Qiagen, GmbH Hilden, Germany) was used to terminate the 
transcription reaction and purify newly synthesized RNA. The procedure was performed 
according to the protocol supplied with the kit. RNA was eluted with 50 µl of RNase-free 
water from the RNeasy® Mini kit.  
 
The quality of RNA transcript was verified using a denaturing 15% Acrylamide/8M Urea 
gel (Appendix B) and 5 µl of the RNA Ladder, low range (Fermentas UAB, Lithuania). 
Different quantities of RNA transcript: 5 µl, 10 µl and 20 µl were mixed with the 
equivalent volumes of the dye supplied with the RNA ladder, and loaded onto the 0.75 mm 
gel. Polyacrylamide gel electrophoresis (PAGE) was performed at a constant voltage of 
150 V until the faster migrating dye reached the bottom of the gel (approximately 2 hours). 
Following electrophoresis the gel was placed on a glass plate coated with fluorescent silica, 
and the RNA was visualized by exposing the gel to long-wavelength UV light using a 
hand-held UV lamp. The full-length product was excised from the gel with a razor blade. 
The gel slices were transferred to a microfuge tube and submerged by brief vortexing and 
centrifuging in 400 µl of Probe Elution Buffer (RT-PCR Competitor Construction kit, 
Ambion). The tubes were incubated overnight at 37°C. Next, the acrylamide gel slice was 
removed from the tube and 800 µl of 100% ethanol (Merck Chemicals, Germiston, SA) 
was added to the Probe Elution buffer with RNA. The tubes were incubated at - 70°C for 
20 min and centrifuged at 13000 x g at 4°C for 20 min using a bench top Eppendorf 5415R 
centrifuge (Eppendorf AG, Hamburg, Germany). The pellet was washed once with 70% 
ethanol. The pellets were dried at room temperature and then dissolved in 30 µl of 
RNase/DNase free water (Sigma-Aldrich, St. Louis, Missouri, USA). Purified ES RNA 
transcript was verified again using PAGE analysis.  
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2.2.2.5 Quantitation of in vitro transcribed ES RNA yield  
The gel purified in vitro ES RNA transcript was quantified using a RiboGreen™ 
quantitation reagent (Molecular Probes, Eugene, USA), which is an ultrasensitive 
fluorescent nucleic acid stain for quantitating RNA in solution and includes a ribosomal 
RNA quantitation standard. The procedure was performed according to the manufacturer’s 
instructions. The high-range standard curve for quantitation included ribosomal RNA 
standard at the following concentrations: 1 µg/ml, 500 ng/ml, 100 ng/ml, 20 ng/ml and no 
RNA (blank) sample. Two ES RNA dilutions were used: 1:50 and 1:100. The full reaction 
volume of 200µl of each sample was loaded into a microtiter plate and fluorescence was 
recorded using an FLX 800 fluorimeter. Contraction of a standard curve and quantitation 
of ES RNA concentration was performed using KC Junior™ data analysis software. ES 
RNA concentration values in ng/ml calculated by the software were multiplied by the 
dilution factor. The final concentration of ES RNA transcript was calculated as a mean of 
the two concentrations obtained using both 1:50 and1:100 dilutions.  
 
The concentration of ES RNA transcript obtained from the RiboGreen quantitation assay in 
“ng/ml’ (i.e. weight/volume units) was converted into a concentration expressed in RNA 
“copy per µl”. Conversion was performed according to the following calculations: 
(Obtained from the Roche Molecular Biochemicals Technical Note, LC, 11/2000).  
  
 MW= Molecular Weight (g/mol)  
 General formula for average MW of single stranded (ss) RNA is:  
  (Number of base) x (340 daltons/base)  
 1 mol = 6 x 1023 molecules (= copies)  
 Concentration of nucleic acid should be converted from ng/ml into g/µl.  
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 The formula below was used to calculate concentration of ES RNA transcript in 
copies per µl:  
6 x 1023 (copies/mol) x concentration (g/ µl)        = amount (copies/µl)  
                            MW (g/mol)  
In order to demonstrate this type of calculation, see an example using 5 µl of ES RNA 
transcript loaded onto the denaturing gel and purified from the excised gel band (see 
2.2.2.4):  
 Concentration ES RNA transcript (“10 µl sample”) estimated by RiboGreen 
quantitative assay was 2.7 x 10-9 g/µl  
 Size of ES RNA transcript (this includes T7 promoter and a part of restriction site 
of pGEM -T® vector and 128 bases of cloned HIV-1 specific insert) was 192 bases.  
 MW (ES RNA) = 192bases x 340daltons/base =  65280 g/mol  
 
6 x 1023 (copies/mol) x 2.7 x 10-9 (g/ µl)         = 2.5 x 1010 copies/µl  
                            65280 (g/mol)  
Serially diluted ES RNA transcript was then used as a quantitation standard in quantitative 
real-time RT-PCR. After serial dilution of ES RNA in RNase/DNase free water each 
standard was spiked with MS2 phage RNA to obtain a final concentration of 8 ng/µl of the 
background RNA. On average, 4 to 6 external standards at different concentrations were 
used to construct a standard curve.  
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 2.2.3 Preparation of an Internal Control (IC)  
2.2.3.1 Construction of a template for cloning  
A competitive internal control (IC) was designed to have SKT145 and SKT150 primer 
binding sites and an artificial sequence (scrambled HIV-1 subtype C gag sequence) in the 
region internal to these primers. Therefore, the competitive IC has the same primer binding 
sites, length (128 bases), and base composition as the ES. A double stranded DNA 
template for preparing an IC was assembled using four oligonucleotides. Sequences of 
these oligonucleotides were sent to MWG-Biotech AG (Germany) for synthesis.  
The sequences of the oligonucleotides are as follows:  
HIV (IC) S1: 5’ – CTA GAA CAT CAA GCA GCC ATG CAA ATG TAG GAC ATG 
ACG AGA ATA CAT GAT AAG TAT GTG AGA GGA – 3’  
HIV (IC) A1: p 5’ – GAA TGC TCC TCT CAC ATA CTT ATC ATG TAT TCT CGT 
CAT GTC CTA CAT TTG CAT GGC TGC TTG ATG TT – 3’  
HIV (IC) S2: p 5’ – GCA TTC ATA CTC GAG ACA GCT CAC GTA GAG CAG GCT 
CGT CGC ACG AGA GAA CCA AGG GGA AGT GAC AC – 3’  
HIV (IC) A2: 5’ – TCG AGT GTC ACT TCC CCT TGG TTC TCT CGT GCG ACG 
AGC CTG CTC TAC GTG AGC TGT CTC GAG TAT – 3’  
 
The 5’ ends of the oligonucleotides A1 and S2 were phosphorylated in order to facilitate 
ligation. The 5’ ends of oligos S1 and A2 have short overhangs – 5 nucleotides each 
(shown in italics). Oligos A1 and A2 correspond to the anti-sense strand, and S1 and S2 - 
to the sense strand. Each of the lyophilised oligonucleotides was reconstituted with 
RNase/DNase free water (Sigma, St Louis, Missouri, USA) to obtain the final 
concentration of 100 pmol/µl stock solution. Oligonucleotides S1 and S2 were initially 
annealed with the complementary oligonucleotides A1 and A2 respectively to form two 
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short, double stranded (ds) DNA fragments – S1A1 and S2A2 (Figure 2.3). Two annealing 
reactions were set up with oligos S1/A1 and S2/A2 diluted in RNase/DNase free water to 
the final concentration of 10 pmol/µl. The reactions were kept at 95ºC for 5 min and were 
allowed to cool down to room temperature. Next, the annealed fragments (S1A1 and 
S2A2) were ligated to each other using their 5’ phosphorylated ends and T4 ligase (Roche 
Applied Science, Mannheim, Germany). The ligation reaction contained: S1A1 and S2A2 
dsDNA fragments at the final concentration of 2 pmol/µl, 1Unit of T4 ligase and 1 x 
ligation buffer (supplied with T4 ligase kit). Ligation (Figure 2.3) was performed at 16ºC 
overnight.  
 
The ligation product (138 bp DNA fragment) was used directly as a template for 
conventional PCR to generate amplicons suitable for cloning. Fifty µl of PCR mix 
consisted of 2 5 µl of ready-to use PCR Master Mix (Promega, Madison, WI, USA), 
primers SKT145 and SKT150 at a final concentration of 0.5 µM, 10 µl of PCR grade water 
from the kit and 10 µl of the ligation product. PCR was performed using the MyCycler™ 
instrument according to the following run profile: initial denaturation at 95ºC for 2 min, 
followed by 40 cycles with a denaturation step at 95ºC for 1min, annealing at 58ºC for 30 
s, and extension at 72ºC for 45 s; final elongation for 7 min. Agarose gel electrophoresis 
for verification of amplification product, purification of the PCR product from the gel and 
the PicoGreen quantitative assay were performed according to the protocols described in 
section 2.2.2.1.  
 
2.2.3.2 Preparation of a competitive IC RNA in vitro transcript  
The PCR product (section 2.2.3.1) was used as a template for cloning into the pGEM®-T 
Easy Vector System (Promega, Madison, WI, USA). Cloning of the competitive IC, 
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isolation of recombinant plasmid DNA and estimation of DNA yield was performed 
according to procedures described in section 2.2.2.2. Three clones were selected for 
sequencing to verify the integrity of the DNA insert (see section 2.2.2.3). Edited sequences 
were compared to the sequence designed for a competitive IC. Clone M1 was selected as a 
template for further in vitro RNA transcription. M1 plasmid digestion with SpeI and 
purification of linearized template for RNA synthesis, in vitro RNA transcription using 
RT-PCR Competitor Construction kit (Ambion, Austin, Texas, USA), purification of IC 
RNA transcript and quantitation using the RiboGreen™ quantitation reagent (Molecular 
Probes, Eugene, USA) were performed according to the procedures described previously in 
sections 2.2.2.4 and 2.2.2.5.  
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Figure 2.3: Preparation of dsDNA fragment of a competitive IC. Initial annealing step 
produced two dsDNA fragments: S1A1 and S2A2. Next, ligation of these fragments 
formed one dsDNA fragment of a competitive IC (128 bp) that contains mostly an artificial 
sequence (excluding the primer binding sites for SKT145/150).  
 
2.2.3.3 Preparation of a competitive IC DNA product  
M1 linearized plasmid was diluted 1:100 and 5 µl of this dilution was used as a template 
for conventional PCR. The reaction was performed in a 50 µl volume containing 25 µl of 
ReadyMix™ Taq PCR Reaction Mix with MgCl2 (Sigma, St Louis, Missouri, USA), 0.5 
µM final concentration of each primer SKT145 and SKT150, 5 µl of the diluted M1 
plasmid and 15 µl of MGW from the kit. PCR was performed using the MyCycler™ 
instrument according  
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to the following profile: initial denaturation at 95ºC for 3min and 40 amplification cycles 
of 95ºC for 1 min, 58ºC for 30 s and 72ºC for 45 s, with a final elongation at  72ºC for 7 
min. The amplification product was verified by agarose gel electrophoresis, purified from 
the gel and concentration of the product was estimated using the PicoGreen quantitative 
assay (section 2.2.2.1). The amplification product described above represents a DNA 
equivalent of a competitive IC. The concentration of dsDNA competitive IC estimated 
using the PicoGreen quantitative assay was converted from ng/ml into copies of dsDNA 
per µl. Molecular weight for the dsDNA molecule was calculated as follows:  
MW (dsDNA IC) = 128 bases x 660 daltons/base = 84480 g/mol  
 
The remaining calculations of dsDNA copies/ µl were performed using the formula given 
in section 2.2.2.5 (Roche). This dsDNA product was used as a competitive IC in real-time 
RT-PCR experiments for optimization of the FRET assay.  
 
2.2.3.4 Preparation of a non-competitive IC  
The M1 linearized recombinant plasmid containing the sequence of the competitive IC (see 
section 2.2.3.1 and 2.2.3.2) was used as a template for generating a non-competitive IC 
with different primer binding sites to the ES and viral RNA. The purified PCR product of 
the competitive IC (section 2.2.3.1) was modified by PCR engineering to produce a non-
competitive IC (Figure 2.4). This involved the replacement of SKT145 and SKT150 primer 
binding sites with new, different sequences, derived from the scrambled sequences of 
primers SKT145 and SKT150. PCR engineering was performed in two experiments using 
the following two sets of primers, respectively:  
SK IPC 145(A): 5’- AAC CTA TCC GGA CAA TAA CGA GTA GGA CAT GAC GAG 
AAT-3’  
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SK IPC 150(A): 5’-TCC CGT CCG ATC TTT TTC TCG CTG CGA CGA GCC TGC 
TCT ACG-3’  
SK IPC145: 5’- AAC CTA TCC GGA CAA TAA CGA-3’  
SK IPC150: 5’-CTC CCG TCC GAT CTT TTT CTC GCT-3’  
 
The designed sequence of the non-competitive IC (128 bp) amplified with primers SK 
IPC145 and SK IPC150 is given below:  
5’- AAC CTA TCC GGA CAA TAA CGA GTA GGA CAT GAC GAG AAT ACA TGA 
TAA GTA TGT GAG AGG AGC ATT CAT ACT CGA GAC AGC TCA CGT AGA 
GCA GGC TCG TCG CAA GCG AGA AAA AGA TCG GAC GGG AG - 3’  
 
The first set of primers (A) contains a sequence that is internal to the primers SKT145 and 
SKT150 with overhangs that represent new, scrambled primer sequences. The second set 
of primers, SK IPC145 and SK IPC150 (Inqaba Biotec, Pretoria, SA), correspond to the 
new, scrambled sequences that replaced the SKT145/150 primer binding sites. Two PCR 
experiments were performed to produce a non-competitive IC. The initial PCR was 
performed in a 50 µl reaction volume containing 25 µl of the ReadyMix™ reaction mix 
(Sigma, St Louis, Missouri, USA), 0.5 µM primers SK IPC145 (A) and SK IPC150 (A), 15 
µl of MWG from the PCR kit and 5 µl of the  amplification product (section 2.2.3.1). The 
PCR product amplified with primers SK IPC145 (A)/150(A) was verified on a 2% agarose 
gel.  
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Figure 2.4: Replacement of primer binding sites in competitive IC. Primer binding sites for 
SKT145/150 are indicated in blue. For simplicity the process of replacing these sites is 
shown only for an anti-sense strand; the same process occurs simultaneously on the sense 
strand of dsDNA IC. The forward (F) and the reverse primers (R), internal to the primers 
SKT 145/150 have overhangs that correspond to the “new” primer binding sites (shown in 
red). Theoretically, already in PCR cycle 3, the product (S1A1) represents the first dsDNA 
product of a non-competitive IC with primer binding sites for SK IPC 145/150. Further 
PCR amplification of (S1A1) product results in accumulation of a non-competitive IC 
(dsDNA).  
 
A second round PCR was then performed using 5 µl of the first amplification product, 
diluted 1:100 in MGW, as a template and primers SK IPC145 and SK IPC150. The 
amplification reaction was assembled as described above for the first round PCR. Both 
PCR experiments were performed on the MyCycler™ PCR instrument according to the 
amplification profile described in section 2.2.3.3. Verification of the amplification product 
by agarose gel electrophoresis, purification of the PCR product and quantitation of the non-
competitive IC DNA yield using the PicoGreen quantitation reagent was performed 
according to the protocols described in section 2.2.2.1.  
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2.2.4 Isolation of HIV-1 RNA template for quantitative real-time RT-PCR  
2.2.4.1 Manual extraction of viral RNA using column purification  
Manual extraction of HIV-1 RNA was performed using 0.5 ml of plasma. Virus in the 
plasma samples was concentrated by centrifugation in a bench top Eppendorf 5415R 
centrifuge (Eppendorf AG, Hamburg, Germany) at 16 000 x g for 1.5 hours at 4°C. After 
centrifugation 360 µl of sample supernatant was discarded and the remaining 140 µl of 
plasma and viral pellet were used for RNA extraction using the QIAamp® Viral RNA mini 
kit (Qiagen, GmbH, Hilden, Germany) as per manufacturers instructions in a bench top 
Eppendorf 5415D mini centrifuge (Eppendorf AG, Hamburg, Germany). Column purified 
HIV-1 RNA was eluted in 60 µl of the elution buffer supplied with a kit.  
 
The QIAamp® Viral RNA extraction method combines the selective binding properties of a 
silica-gel-based membrane/column with micro-centrifugation. According to the 
manufacturer’s claims, this method provides high-quality and good yields of viral RNA 
that is free of protein, nucleases, and other contaminants and inhibitors (see QIAamp® 
Viral RNA Mini Kit Handbook, p.7). A maximum of twenty four plasma samples were 
processed simultaneously using the full sample capacity of the Eppendorf mini centrifuge.  
 
2.2.4.2 Automated extraction of viral RNA using MagNA Pure LC instrument  
Automated HIV-1 RNA extractions were performed using the MagNA Pure LC instrument 
(Roche Applied Systems, Mannheim, Germany) and the MagNA Pure LC Total nucleic 
acid isolation kit and consumables (Roche Applied Systems, Mannheim, Germany) Viral 
RNA was isolated from 200 µl of plasma as per manufacturer’s instructions. Purified RNA 
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was eluted in 60 µl of elution buffer from the kit. Viral RNA samples obtained with both 
methods (2.2.4.1 and 2.2.4.2) were used for real-time RT-PCR immediately after isolation 
or stored at - 70ºC until analyzed.  
 
2.2.4.3 Sample material  
Control samples  
HIV-1 RNA copy controls from the VQA laboratory (Virology Quality Assurance 
Laboratory, Rush-Presbyterian-St. Luke’s Medical Centre, Chicago, Ill.) were used 
throughout assay development and evaluation. This laboratory is currently the NIH 
reference laboratory for viral RNA quantitation standards and protocols. The VQA RNA 
copy controls panel consist of five plasma samples with known concentration of virus at: 
1.5x105, 1.5x104, 1.5x103, 1.5x102 RNA copies/ml and 0 copies, respectively. The VQA 
RNA copy controls represent cultured HIV-1 (subtype B) that has been subsequently 
diluted in negative human plasma. The concentration of virus in the stocks represents a 
mean value, which is determined using the Ultrasensitive Roche Amplicor HIV-1 
Monitor™ v1.5 test and the Ultrasensitive COBAS Amplicor HIV-1 Monitor™ v1.5 test 
(more information is available at http://aactg.s-3.com/vqa.htm).  
 
Another plasma sample from the HIV-1 RNA Clade performance panel (PRD201, sample 
ID # BBI BV-5007, clade C, Boston Biochemica Inc (BBI)) was included in this 
evaluation. The stock sample of this BBI panel represents a dilution of cultured HIV-1 to 
approximately 5x104 virus particles per ml in defibrinated human plasma negative for 
HIV-1 RNA. The concentration of virus in the stocks was determined using Electron 
microscopy (EM) particle counts and the genotype was assigned by sequencing. The 
purchased BBI panel (www.bbii.com) was provided with a range of HIV-1 antigen and 
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nucleic acid test results, obtained using several commercially available HIV-1 viral load 
assays like Chiron HIV-1/HCV TMA Assay (GenProbe Inc., San-Diego, CA, USA), 
NucliSens™ HIV-1 QT (Organon Technika, Boxtel, The Netherlands) and COBAS 
Amplicor HIV-1 Monitor™ version 1.5 (Roche Diagnostic Systems, Branchburg, NJ, 
USA) amongst others.  
 
Clinical specimens  
Evaluation of the LUX assay using stored specimens (tested retrospectively) was 
conducted in full conformance with local ethics committee approval (Appendix D). A 
group of 50 known HIV-1 negative patients was used to test the specificity of the LUX 
assay. For these HIV seronegative plasma samples nucleic acids were extracted using the 
MagNA Pure LC instrument (Roche Applied Systems, Mannheim, Germany) and the 
MagNA Pure LC Total nucleic acid isolation kit (Roche Applied Systems, Mannheim, 
Germany). The extraction procedure was performed using 0.2 ml of plasma and the 
MagNA Pure system as described in section 2.2.4.2.  
 
Plasma specimens were obtained from 142 randomly selected HIV-1 positive individuals 
from Johannesburg (South Africa) and the surrounding region. These patients were treated 
under the South African national roll-out program and monitored at the Johannesburg 
Hospital outpatient HIV clinic. The random selection of these samples was performed 
retrospectively, based on their HIV-1 viral load results and independent of the clinical 
information attached to the patient’s antiretroviral (ARV) treatment status. HIV-1 viral 
load in these patients was routinely monitored using the standard COBAS Amplicor HIV-1 
Monitor™, version 1.5 assay (Roche Molecular Diagnostics, Branchburg, NJ, USA). Viral 
RNA from these samples was extracted from 0.5 ml of plasma according to the manual 
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extraction method described in section 2.2.4.1.  
 
The cohort of 55 patients (266 plasma samples) was obtained from the patients enrolled in 
the ARV treatment program supported by the Comprehensive International Program of 
Research on AIDS (CIPRA) and followed-up longitudinally. The CIPRA grant was 
provided by the National Institute of Health’s Division of AIDS, funds coming from the 
National Institute of Allergy and Infectious Diseases. HIV–1 viral load was monitored on 
the CIPRA Program using both the standard and ultra-sensitive version of the Roche 
COBAS Amplicor assay. Samples obtained at the baseline visit (week 0) and than at the 
follow-up visits on weeks 4, 8, 12 and 24 were processed. All 266 plasma samples used in 
this study were stored at -70°C for several months before being batch processed with the 
LUX assay. Samples from the week 24 visit were not yet available for analysis of 9 out of 
the 55 patients. In this cohort HIV-1 RNA was extracted using 0.2 ml of plasma and the 
MagNA Pure system as described in section 2.2.4.2. In addition, negative human plasma 
(NHP) samples obtained from the COBAS Amplicor kits were used as controls for both the 
manual and automated RNA extraction methods and included in every RT-PCR run as a 
negative control.  
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2.2.5 Quantitative real-time RT-PCR using FRET probes and the LightCycler® 
platform (version 1.2)  
Primers SKT145 and SKT150, described in section 2.2.1, were used to amplify HIV-1 
RNA and the ES RNA transcript and competitive IC. The non-competitive IC was 
amplified using primers SK IPC145/150 (see section 2.2.3.4). Two sets of FRET 
hybridization probes (TIB MOLBIOL, Berlin, Germany) were used for discrimination and 
detection of the HIV, ES and the IC amplicons, respectively. The HIV-1 and ES 
amplification products were viewed in channel F2 and the IC - in channel F3 of the 
LightCycler®, version 1.2 instrument (Roche Applied Science, Mannheim, Germany). The 
sequences of primers and probes used for the FRET assay are given in Table 2.1. 
Sequences of the FRET probes for detection of HIV-1 RNA were analyzed using the 
BLAST program (http://www.ncbi.nlm.nih.gov/BLAST) and no significant homology was 
found with sequences other than HIV-1.  
 
Real-time quantitative RT-PCR was performed in a one step assay format. A total reaction 
volume of 31 µl contained 13 μl of master mix assembled using a QuantiTect™ Probe RT-
PCR kit (Qiagen GmbH, Hilden, Germany), 13 μl of RNA template and 2 μl of IC cDNA 
(1056 copies per reaction). Primers SKT145/150 were used at final concentrations of 0.5 
μM and primers SK IPC145/150 were used at 0.1 μM final concentrations. Probes for 
detection of HIV/ES were used at final concentrations of 0.3 μM and IC probes were used 
at 0.1 μM. The thermal cycling profile on the LightCycler® platform comprised an RT step 
at 55oC for 45 min, initial activation at 95oC for 15 min, 10 cycles of 95oC for 5 s, 52oC for 
30 s, 72oC for 20 s followed by 40 cycles of 95oC for 5 s, 55oC for 30 s, 72oC for 20 s. 
Ramping rates were 20oC/s for denaturation, 4oC/s for the annealing step and 20oC/s for 
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the extension.  
Table 2.1: Sequences of primers and probes used in the FRET assay.  
 
Amplification 
target 
Primers FRET Hybridisation Probes 
Primer SKT145 (Forward):   
5' -ACA TCA AGC AGC CAT 
GCA  AAT -3' 
Probe labelled with a donor dye – 
Fluorescein*  
5’- GCA TGN ACT GGA TGT 
AWT CTA TCC CA-Fluorescein 
HIV/ES 
Primer SKT150 (Reverse):   
5' -TGT CAC TTC CCC TTG GTT 
CTC TC - 3' 
Probe labelled with an acceptor 
dye - LightCycler (LC) Red 640*  
5’- LC Red640 – CTG CAG CCT 
CYT CAT TGA TNG TRT CTT 
TTA - Phosphate 
Primer SK IPC145 (Forward):  
5' -AAC CTA TCC GGA CAA 
TAA CGA - 3' 
Probe labelled with a donor dye – 
Fluorescein  
5’ – TGT GAG AGG AGC ATT 
CAT ACT CGA GAC A – 
Fluorescein 
IC 
(non- 
competitive) 
Primer SK IPC150 (Reverse):  
5' -TCC CGT CCG ATC TTT TTC 
TCG CT - 3' 
Probe labelled with an acceptor 
dye - LightCycler (LC) Red 705  
5’ – LC Red705 – CTC ACG 
TAG AGC AGG CTC GTC GC - 
Phosphate 
*Code for degenerate base positions: N = A/C/G/T; W = A/T; R = A/G; Y = C/T  
 
Fluorescent signals were acquired during the annealing step. Melting curve analysis 
included 95oC for 0 s, 55oC for 1 min and heating up to 90oC with continuous fluorescence 
measurement. The HIV-1 and ES amplification products were viewed using a combination 
of channels F2/F1 and the IC products were viewed in channels  F3/F1 on the 
LightCycler™, instrument version 1.2 (Roche Applied Science, Mannheim, Germany). 
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Quantitative analysis that included construction of the standard curves was performed 
using the LightCycler Software version 3.5.3 (Roche Applied Science, Mannheim, 
Germany). This software allows for the performing of two quantitation methods – the 
Second Derivative Maximum and the Fit Points method. During the assay development 
and optimization both methods were investigated. For the preliminary evaluation of FRET 
assay performance only the Fit Points method was employed. Detailed description of these 
methods and the instructions for use are provided in the LightCycler Software version 
3.5.3 manual, pages 39 to 50.  
 
2.2.6 Quantitative real-time RT-PCR using the LUX™ primer detection 
format and the LightCycler® platform (version 2)  
Primers SKT145, described in section 2.2.1, and the LUX™ primer SKT150 (FAM) were 
used in the LUX assay for amplification of HIV-1 RNA and ES RNA transcript. 
Modifications were made to the reverse primer SKT150 (see section 2.2.1) in order to 
transform it into the LUX™ detection format. According to the manufacturer’s 
recommendations a 7 nucleotide long tail was added to the 5’-end of the primer SKT150 
and a fluorescent dye FAM to the T base at the 3’ end (http://www.invitrogen.com/lux; 
Invitrogen Corporation, Carlsbad CA, USA).  
 
The sequences of the primers are as follows: SKT145: 5’-ACA TCA AGC AGC CAT 
GCA AAT -3'; SKT150 (FAM): 5’- GAG AGA ATG TCA CTT CCC CTT GGT TCT 
CT(FAM)C -3’. RT-PCR product amplified with primers SKT145 and SKT150 (FAM) 
was viewed in channel 530 nm of the LightCycler® instrument, version 2 (Roche Applied 
Science, Mannheim, Germany). The LUX™ primer SKT150 (FAM) was analyzed for 
sequence homology using the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST).  
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The non-competitive IC was amplified using the forward primer SK IPC145 (see section 
2.2.3.4) and the reverse LUX™ primer SK IPC150. Primer SK IPC150 has a 7 nucleotide 
long tail and a fluorescent tag JOE (Invitrogen Corporation, Carlsbad CA, USA) at the T 
base of the 3’ end. The sequences of primers are as follows: SK IPC145: 5' -AAC CTA 
TCC GGA CAA TAA CGA - 3'; SK IPC150 (JOE): 5’- AGC GAG ATC CCG TCC GAT 
CTT TTT C (JOE) TC GCT-3’. The amplicons of the non-competitive IC generated with 
primers SK IPC145 and SK IPC150 (JOE) were viewed in channel 560 nm of the 
LightCycler® instrument, version 2. Inhibition of PCR is determined by the complete 
absence of amplification of the IC above the background levels of fluorescence or by a 
significant shift in the amplification curve of at least 5 threshold cycles (CT) or more. 
 
One step RT-PCR was performed in a 50 µl reaction volume containing 25 µl of master 
mix provided in the QuantiTect™ Probe RT-PCR kit (Qiagen GmbH, Hilden, Germany), 
0.5 µM of each primer, 2 U of heat labile uracil – DNA – glycosylase (HL-UNG; Roche 
Applied Science, Mannheim, Germany) and 22 µl of RNA template. The duplicate 
reactions containing IC were assembled using 25 µl of the reaction mix from a 
QuantiTect™ Probe RT-PCR kit, 0.5 µM primers SK IPC145 and SK IPC150, 2 U of HL-
UNG, 2.5 µl of IC  DNA (2x105 to 2x106 copies/reaction) and 20 µl of RNA template.  
 
The thermal cycling profile on the LightCycler® version 2 (Roche Applied Science, 
Mannheim, Germany) platform comprised an RT (reverse transcription) step at 55oC for 50 
min, initial activation at 95oC for 15 min, 10 cycles of 95oC for 5 s, 52oC for 15 s, 72oC for 
20 s, 77ºC for 3 s followed by 50 cycles of 95oC for 5 s, 55oC for 15 s, 72oC for 20 s and 
77ºC. Ramping rates were 20oC/s for all the steps of the PCR cycle. Fluorescent signals 
were acquired during the additional heating step (77ºC for 3 s) in order to denature non-
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specific product, i.e. primer dimers. Melting curve analysis included 95oC for 0 s, 50oC for 
1 min and heating up to 90oC with continuous fluorescence measurement. This RT-PCR 
profile was used for a preliminary evaluation of the LUX assay (Rekhviashvili et al., 
2006).  
 
A slightly modified protocol to increase the stringency of amplification was used for 
further evaluation with clinical specimens. The modified real-time RT-PCR profile 
includes: RT step at 50oC for 50 min, initial activation at 95oC for 15 min, 10 cycles of 
95oC for 5 s, 58oC for 25 s, 72oC for 20 s, 78ºC for 4 s followed by 50 cycles of 95oC for 5 
s, 60oC for 30 s, 72oC for 20 s and 78ºC for 4 s. Ramping rates were 20oC/s and the 
fluorescent signal was acquired during the fourth heating step at the end of each PCR cycle 
- at 78oC for 4 s. Melting curve analysis was: 95oC for 0 s, 50oC for 1 min and heating up 
to 90oC with continuous fluorescence measurement (Rekhviashvili et al., submitted).  
 
For the optimization of the LUX assay, quantitation was performed using a Fit points 
method and an Automated method provided by the LightCycler® (version 2) Software 
version 4 (Roche Applied Science, Mannheim, Germany). Evaluation of the LUX assay 
was performed using an Automated (user non-influenced) method for quantitative analysis. 
Characterizations of both quantitation methods and the recommendations for use are 
available in the LightCycler® (version 2) Operator’s Manual (version 1.2), pages 95-110. 
For the preliminary evaluation of the LUX assay using ES RNA transcripts, the 
concentration of standards were entered into the software (version 4) in copies/ml. ES 
values in copies/ml were calculated based on the known input concentration of each 
standard and only the “real-time” standard curves were used (i.e. non-imported). For 
evaluation of the LUX assay using clinical specimens two to three external standards were 
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included in each RT-PCR run in order to import the best suitable standard curve into the 
run. Concentrations of standards were entered into the software in copies/µl and thus HIV-
1 viral load values for the plasma samples were obtained in the same units.  Since different 
extraction methods were used for patient samples, final viral load values were re-calculated 
taking into account starting volume of plasma and RNA elution volume, and the 
corresponding values in copies/ml were obtained. For example: 5000 copies/µl x 60 µl/ 0.2 
ml = 150 000 copies/ml. In this example, 5000 copies/µl is the viral load value obtained 
with the LUX assay (an arbitrary value), 60 µl is the elution volume and 0.2 ml is the 
starting volume of plasma.  
 
2.2.7 Viral load quantitation using COBAS Amplicor HIV-1 Monitor™, 
version 1.5 assay  
The Roche AmpliPrep/Amplicor system was used as the reference methodology for all 
comparative evaluations conducted in this study (see section 1.2 for description of the 
assay). HIV-1 RNA extraction was conducted using the AmpliPrep automated specimen 
preparation system followed by amplification and detection using the Roche COBAS 
Amplicor HIV-1 Monitor™ 1.5 assay (Roche Molecular Systems, Branchburg, N.J.) All 
assays were performed strictly according to the manufacturer’s instructions. For the 
standard procedure 0.35 ml of plasma sample, and for the ultra sensitive version of the 
assay - ,0.7 ml of plasma was used.  
 
2.2.8 Statistical analysis  
Statistical analysis for the FRET assay, in particular determination of the linearity of the 
dynamic range, was performed using the Stata™ 7 (StataCorp, 4905 Lakeway Drive, 
College Station, Texas 77845 USA). Both versions (1.2 and 2.0) of the LightCycler® 
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system evaluated in this study provide standard deviation (SD) and mean concentration 
values for the replicate testing of the samples. SD and log10 transformed mean 
concentration values obtained for both the FRET and the LUX assays were entered into the 
Microsoft Excel program and used to calculate the coefficient of variation (CV) for each 
assay, respectively.  
 
The main statistical analysis for clinical evaluation of the LUX assay was performed in 
Stata™ 9.1 (StataCorp, 4905 Lakeway Drive, College Station, Texas 77845 USA) using 
log (base 10) transformed viral load values. Histograms and box plots were used to assess 
distributions of log10 viral loads observed for both LUX and COBAS Amplicor assays. 
Agreement between the two assays was assessed by means of the intra-class correlation 
coefficient (ICC) estimated via a one-way analysis of variance (Snedecor and Cochran, 
1989) as implemented in Stata™ 9.1. In addition a Bland-Altman plot (Bland and Altman, 
1986), a well recognized method for measuring agreement between two assays measured 
on a continuous scale, was generated. Differences between the log 10 values of the data 
pairs are graphically represented on the vertical axis against the mean of the log 10 values 
of the data pairs (mean log10 copies/ml) on the horizontal axis. The mean log 10 paired 
difference (the bias) and the limits of agreement (mean ± 2SD, standard deviation) are 
indicated on the plots. To assess for changes in viral load obtained with the LUX assay and 
the COBAS Amplicor test over patient’s visits, schematic (box and whisker) plots were 
used. A mixed-effects model could not be used to analyze trends over visits because once 
treatment commenced, viral load values on both assays dropped to undetectable levels, 
thus showing little variability over subsequent visits.  
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2.3 Results  
2.3.1 Optimisation and preliminary evaluation of quantitative real-time RT-
PCR using FRET hybridization probes and the LightCycler® platform (version 
1.2)  
DNA template for in vitro synthesis of an ES RNA was successfully cloned, sequenced 
and analyzed. The nucleotide sequence was aligned with a reference gag sequence of HIV-
1 subtype B HXB2 isolate (Figure 2.5), confirming the correct region had been cloned. 
Therefore, the ES RNA in vitro transcript (192 bases) contains a sequence of 128 bases 
that corresponds to the fragment within the p24 region of HIV-1 gag. Phylogenetic 
analysis revealed that the cloned fragment was subtype C specific in this region of p24 
(results not shown). Good quality and highly concentrated ES RNA (Figure 2.6) stock 
solution was diluted to 109 and 108 copies/µl working stocks and kept at -70ºC. Serial 1:10 
dilutions of ES RNA covering the concentration range of 103 – 107copies/ml were used for 
optimization of a new quantitative real-time RT-PCR for HIV-1 viral load quantitation. ES 
RNA samples of each concentration (103, 104, 105, 106 and 107 copies/ml) were run in 
replicates in every RT-PCR experiment. One or two sets of ES RNA replicate samples (103 
– 107 copies/ml) were entered into the LightCycler® software version 3.5 as quantitation 
standards to generate a standard curve, and the remaining replicate ES RNA samples were 
entered as “unknown” samples.  
 
Initial assay development was performed on the LightCycler® platform (version 1.2) using 
FRET hybridization probes as a detection format. Several parameters of the quantitative 
real-time RT-PCR had to be optimized. Optimization of the RT-PCR profile showed that a 
longer incubation time (50 min) for the RT step and ten cycles of initial amplification with 
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a lower annealing temperature increased the sensitivity of quantitation. Different 
concentrations of SKT 145/150 primers (0.25 µM, 0.5 µM and 0.75 µM) and FRET 
hybridization probes (0.2 µM, 0.3 µM, and 0.4 µM) were titrated for the ES RNA range of 
103 – 107 copies/ml. The experiments showed that a final concentration of primers at 0.5 
µM and final concentration of each of the hybridization probes at 0.3 µM were found to be 
optimal for the wide range of ES RNA concentrations used. The addition of MS2 phage 
RNA as a stabilizing background nucleic acid to each of the ES RNA dilutions (103 – 107 
copies/ml) significantly improved sensitivity, accuracy and reproducibility of a standard 
curve based quantitation (data not shown). Numerous RT-PCR runs were performed to 
identify the most optimal concentration of an RNA transcript of the competitive IC. These 
experiments revealed that approximately a 1000 copies/ml of IC RNA can be co-amplified 
with a range of ES RNA from 104 -106 copies/ml. The addition of IC RNA to RT-PCR 
reactions reduced sensitivity and accuracy of quantitation (data not shown).  
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                      *        20         *        40         *        60         *        80         *        
B.HXB2  : ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAA :   90 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                       
                    100         *       120         *       140         *       160         *       180        
B.HXB2  : TTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATA :  180 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                      *       200         *       220         *       240         *       260         *        
B.HXB2  : CTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAA :  270 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                    280         *       300         *       320         *       340         *       360        
B.HXB2  : AGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCT :  360 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                      *       380         *       400         *       420         *       440         *        
B.HXB2  : GACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCAAATGGTACATCAGGCCATATCACCTAGA :  450 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                    460         *       480         *       500         *       520         *       540        
B.HXB2  : ACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGGAGCCACC :  540 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                              
                      *       560         *       580         *       600         *       620         *        
B.HXB2  : CCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCA :  630 
ES RNA     : --------------------------------------ACATCAAGCAGCCATGCAAATGTTAAAAGATACAATCAATGAGGAGGCTGCA :   52 
                                                                                                               
                    640         *       660         *       680         *       700         *       720        
B.HXB2  : GAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACT :  720 
ES RNA     : GAATGGGATAGAATACATCCAGTACATGCGGGGCCTATTGCACCAGGCCAAATGAGAGAACCAAGGGGAAGTGACA-------------- :  128 
                                                                                                               
                      *       740         *       760         *       780         *       800         *        
B.HXB2  : AGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCCCAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTA :  810 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                    820         *       840         *       860         *       880         *       900        
B.HXB2  : AATAAAATAGTAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTC :  900 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                      *       920         *       940         *       960         *       980         *        
B.HXB2  : TATAAAACTCTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGAACCCAGATTGT :  990 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                   1000         *      1020         *      1040         *      1060         *      1080        
B.HXB2  : AAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATGTCAGGGAGTAGGAGGACCCGGCCATAAGGCA : 1080 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                      *      1100         *      1120         *      1140         *      1160         *        
B.HXB2  : AGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCAGCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTT : 1170 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                   1180         *      1200         *      1220         *      1240         *      1260        
B.HXB2  : AAGTGTTTCAATTGTGGCAAAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGGA : 1260 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                      *      1280         *      1300         *      1320         *      1340         *        
B.HXB2  : CACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGAATTTTCTTCAG : 1350 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                                               
                   1360         *      1380         *      1400         *      1420         *      1440        
B.HXB2  : AGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGGTAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGAC : 1440 
ES RNA     : ------------------------------------------------------------------------------------------ :    - 
                                                                                    
                      *      1460         *      1480         *      1500           
B.HXB2  : AAGGAACTGTATCCTTTAACTTCCCTCAGGTCACTCTTTGGCAACGACCCCTCGTCACAATAA : 1503 
ES RNA     : --------------------------------------------------------------- :    - 
                                                                                    
 
 
Figure 2.5: Nucleotide sequence alignment of gag (p55) from the HIV-1 subtype B HXB2 
isolate with the ES RNA synthetic fragment. The p24 region is highlighted in yellow, and 
the ES RNA synthetic fragment is shown in green.  
 
The attempts to use DNA IC were even less successful. Next, multiple experiments were 
performed using DNA of a non-competitive IC, where concentrations of a non-competitive 
IC  
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DNA and primers SK IPC145/150 were titrated simultaneously. The most optimal 
combination was represented by 1056 copies of a non-competitive IC DNA per reaction 
amplified using 0.1 µM primers (Figure 2.7).  
 
 
 
 
Figure 2.6: Denaturing polyacrylamide gel electrophoresis for verification of purified ES 
RNA transcript. Lane 1 - RNA molecular weight marker (100 bases); lanes 2, 3, 4 - show 
5, 10 and 20 µl of ES RNA transcript (~ 192 bases) loaded onto the gel, respectively.  
 
Preliminary evaluation of the developed quantitative real-time RT-PCR (FRET assay) was 
performed using ES RNA transcript, VQA copy controls and the BBI proficiency panel. In 
order to assess reproducibility of the FRET assay ten - fold serial dilutions of ES RNA 
covering the range from 1.5x103 to 1.5x107 copies/ml were used in five RT-PCR 
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experiments performed on different days. Each of five standards was spiked with non-
competitive IC (1056 copies/reaction) and tested in six replicates within each run.  
 
 
 
 
Figure 2.7: Post-PCR melting curve analyses for titration of a non-competitive IC.  
Melting curve profiles show amplification of a non- competitive internal control (IC) DNA 
spiked into ES RNA samples. Key: sample containing IC only (- -); ES RNA dilutions 
from 1.5 x 103 - 1.5 x 105 copies/ml (x), ES RNA dilutions at the concentration of 1.5 x 106 
and 1.5 x 107 copies/ml (ο); no IC sample (-) shows the absence of a melting peak.  
 
The coefficient of variation (CV) for reproducibility of the FRET assay was calculated 
based on the mean of the calculated concentration values and the corresponding standard 
deviation (SD). Intra-assay variability CV for the FRET assay was determined for the 
replicated standards on each particular day, and found to range from 23% CV to 43, 3% 
CV for 1.5x107 and 1.5x104 copies/ml of ES RNA, respectively. Inter-assay variability of 
the FRET assay was 23, 1% CV and 7, 4% CV for 1.5x107 and 1.5x104 copies/ml of ES 
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RNA, respectively. Analytical sensitivity of the FRET assay was estimated based on the 
repeated runs (5 experiments with 6 replicates of each standard). The standard of 
1.5x103copies/ml could not be quantified reproducibly within each run (Figure 2.8).  
Reproducible quantitation (100%) was observed at the standard of 1.5x104copies/ml that 
defined the lower limit of quantitation (LLQ) of the FRET assay.  
 
 
 
 
Figure 2.8: Standard curve generated using serial dilutions of ES RNA transcript.  
Quantitation range covers 1.5x103 to 1.5x107 copies/ml of ES RNA transcript. The 
standard curve was generated using the “fit points” analysis (software version 3.5) on the 
LightCycler® instrument (version 1.2).  
 
Linearity of the dynamic range for the FRET assay was established using between-run 
mean values of calculated ES RNA copy numbers obtained from the repeated runs (Figure 
2.9). The coefficient of linear regression R2 = 0.98 was obtained for the quantitation range 
of 1.5x104 to 1.5x107 copies/ml of ES RNA.  
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Figure 2.9: Linear regression analyses for the dynamic range of the FRET assay.  
Log10 transformed mean values of experimentally established ES RNA copy numbers 
obtained from the repeated FRET assays (5 repeat runs with six replicates of each standard 
from 1.5x104 to 1.5x107 copies/ml of ES RNA) are plotted on the Y-axis. Log transformed 
values of the expected (input) concentrations for the same standards are plotted on the X-
axis.  
 
In order to verify the in-house external quantitation standard (ES RNA), viral RNA 
extracted from the VQA copy controls was used. No quantitation of HIV-1 RNA was 
obtained in all four VQA samples using the FRET assay. However, conventional gel 
electrophoresis revealed the presence of HIV specific amplification product in the VQA 
samples with viral load values of 1.5 x104 and 1.5 x105 copies/ml (data not shown). 
Therefore, the unsuccessful quantitation observed with the VQA copy controls was 
attributed to the insufficient detection of amplicons with the FRET hybridization probes.  
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Verification of the external quantitation standard (ES RNA) and preliminary evaluation of 
the FRET assay were performed using the BBI proficiency panel. Viral RNA extracted 
from the stock sample was tested in triplicate using the FRET assay. The quantitative 
analysis of this experiment was performed using a standard curve (1.5x103 to 1.5x107 
copies/ml of ES RNA) generated in the same run as well as a standard curve imported from 
a previous run. Real-time quantitation of the triplicate sample showed a mean of 38 403 
copies/ml. Quantitation using an imported standard curve revealed a mean of 42 267 
copies/ml. An average viral load value obtained using both real-time and an imported 
standard curve was 40 335 copies/ml, corresponding to a 4.6 log10 value. According to the 
package insert for the BBI panel the COBAS Amplicor version 1.5 (Roche) test estimated 
viral load in the BBI sample we used at 20 000 copies/ml (4.3 log10) and the NucliSens™ 
HIV-1 QT (Organon Technika) at 10 000 copies/ml (4 log10). Therefore, the FRET assay 
estimated viral loads of the BBI HIV-1 proficiency panel in the same log10 range of 
concentration as the COBAS Amplicor and NucliSens™ assays. An absolute difference 
between the log10 values obtained with FRET assay and the COBAS Amplicor assay is 
within absolute 0.3 log10 difference. 
 
2.3.2 Optimisation and preliminary evaluation of quantitative real-time RT-
PCR using LUX™ primer and the LightCycler® platform (version 2)  
A quantitative real-time RT-PCR assay for determination of HIV-1 viral load was initially 
developed using FRET hybridization probes as a detection format and version 1.2 of the 
LightCycler® platform. Subsequently, the developed assay was transferred onto a newer, 
more advanced version of the LightCycler® instrument (version 2) once it became 
available. The latest, glass capillary based LightCycler® platform (version 2) allowed 
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modifications and further improvement of the in-house viral load assay. In particular, 
FRET probes were replaced with a LUX™ primer for amplification and simultaneous real-
time detection of amplicons. The real-time RT-PCR profile was adapted to the LUX™ 
primer detection format by the addition of a forth segment at the end of each amplification 
cycle. The additional segment was performed at 77ºC for 3 s and during this time a 
fluorescent signal from the LUX™ primer was acquired. A larger reaction volume (50 µl) 
increased template RNA input volume up to 22 µl. Optimisation of the quantitative real-
time RT-PCR using the LUX™ primer and the LightCycler® platform (version 2) was 
performed using serial dilutions of the ES RNA transcript covering a quantitation range of 
102 – 106 copies/ml. Amplification products of ES RNA and VQA copy controls generated 
with the SKT150 LUX primer and modified reaction conditions were verified using 
agarose gel electrophoresis (Figure 2.10). Numerous experiments were performed in an 
attempt to determine the optimal concentrations of a non-competitive IC DNA and SK IPC 
145/150 primers. These experiments showed that the minimal concentration of IC and the 
primers, which is sufficient for co-amplification with the higher copy numbers of ES RNA, 
inhibits (out competes) the lower concentration standards. Thus, to improve sensitivity of 
the viral load assay and achieve better accuracy of quantitation over a wide dynamic range, 
the non-competitive IC was not added to the external quantitation standards (ES RNA 
transcript) and “unknown” samples. For the LUX assay design it was decided to add IC 
only to a duplicate test of an “unknown” sample that was not used for quantitation of HIV-
1 RNA copies. During evaluation of the LUX assay the duplicate tests were used solely to 
control for PCR inhibition.  
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Figure 2.10: Conventional 3% agarose gel electrophoresis for confirmation of RT-PCR 
product obtained using the LUX assay. Lane 1- 50 bp DNA ladder; lanes 2 and 3 – ES 
RNA samples at the concentrations of 4 x106 and 4 x105 copies/ml respectively; lanes 4 
and 5 – VQA samples at 1500 and 15 000 copies/ml respectively; lanes 6 and 7 - VQA 
samples at 150 000 copies/ml (tested in duplicates); lane 8 – negative human plasma 
(NHP) sample showing no amplification product (negative control).  
 
Preliminary evaluation of the LUX assay was performed using serial dilutions of the ES 
RNA transcript. The following performance characteristics were investigated: analytical 
sensitivity, reproducibility and linearity of the dynamic range. Sensitivity of the LUX assay 
was established using serial dilutions of ES RNA transcript covering a quantitation range 
from 40 to 4x104copies/ml. ES RNA samples at each concentration were tested in five 
replicates within a run. Concentration of each standard in copies/ml was calculated based 
on the input copies of ES RNA transcript (i.e. 22 µl of ES RNA in 50 µl of RT-PCR 
reaction). Sensitivity was 60% at 8 x 101copies/ml and 100% at 4x102copies/ml. Therefore, 
the LLQ of the LUX assay is set at 400 copies/ml.  
 
The reproducibility of the assay was determined as within run (intra-assay) and between 
run (inter-assay) variability. Repeated tests for reproducibility of the LUX assay were 
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performed on four different days and each of the six quantitation standards was repeated 
four times within a run. Similarly to the LLQ study, concentration of ES RNA transcript in 
copies/ml was established based on ES RNA input concentration. For example, 22 µl of 
the quantitation standard (ES RNA) at a starting concentration of 1 x 104 copies/ µl 
correspond to a concentration of 4 x 106 copies /ml when a 50 µl reaction volume is used. 
Concentrations of the LUX assay standards used to establish reproducibility were as 
follows: 4x102, 8x102, 4x103, 4x104, 4x105 and 4x106 copies/ml (Figure 2.11). The mean 
value of the experimentally obtained concentrations for six replicates of each standard was 
used to assess intra-assay (within run) variability. The SD for the corresponding mean 
values of concentrations were calculated by the software (version 4) of the LightCycler® 
instrument (v 2). For inter-assay variability mean concentrations and SD(s) obtained from 
4 repeated runs were used to determine overall mean values for concentrations and SD(s), 
respectively. The CV for intra- and inter-assay variability of the LUX assay was calculated 
based on the log transformed mean concentration values and the corresponding SD values: 
(SD/Log Mean conc.) x 100% = CV(%) . The intra- and inter-assay variability (CV %), 
reflecting the reproducibility of the LUX assay, is shown in Table 2.2.  
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Figure 2.11: Amplification curves and an external standard curve generated using the LUX 
assay (Adapted from Rekhviashvili et al., 2006). The amplification curves reflect the 
differences between serially diluted ES RNA samples, which are used to generate the 
external standard curve for quantitation of HIV-1 RNA copies. Concentrations of the ES1 
to ES6 RNA standards were 4x106, 4x105, 4x104, 4x103, 8x102 and 4x102copies/ml, 
respectively. The negative control (NHP) and no template control (NTC) samples are 
indicated. The standard curve was obtained with the Automated method for quantitation on 
the LightCycler® instrument, version 2.  
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Table 2.2: Intra- and Inter-assay variability of the LUX assay using log10 transformed concentrations (ES RNA copies/ml)  
The four middle columns (replicate tests 1,2,3,4) represent the intra-assay variability for each replicate/day test and include the mean concentration values of 
four replicates of each standard and the intra-variability CV. The last column represents the inter-assay variability (shown by the inter-variability CV) that 
summarizes the results over four replicate experiments. 
Input 
Concentration 
 (log10) 
 
Replicate Test 1* 
 
Replicate Test 2* 
 
Replicate Test 3* 
 
Replicate Test 4* 
 
Replicate Tests 1-4 
  
Mean 
concentration 
(log10) 
 
 
CV% 
 
Mean 
Concentration 
(log10) 
  
 
CV% 
 
Mean 
Concentration 
(log10) 
 
 
CV% 
 
Mean 
concentration 
(log10) 
 
 
CV% 
 
Mean 
Concentration 
(log10) 
 
 
CV% 
 
6.6 
5.6 
4.6 
3.6 
2.9 
2.6 
 
 
6.55 
 
5.74 
 
4.32 
 
3.80 
 
2.72 
 
2.78 
 
 
0.45 
 
1.80 
 
4.70 
 
3.70 
 
4.80 
 
4.60 
 
 
6.62 
 
5.60 
 
4.70 
 
3.57 
 
2.90 
 
2.64 
 
 
0.20 
 
0.13 
 
1.50 
 
0.70 
 
0.20 
 
3.90 
 
 
6.61 
 
5.43 
 
4.86 
 
3.45 
 
2.88 
 
2.60 
 
 
0.06 
 
2.20 
 
4.08 
 
3.20 
 
0.50 
 
0.06 
 
 
6.37 
 
5.84 
 
4.42 
 
3.61 
 
2.91 
 
2.75 
 
 
 
2.50 
 
2.90 
 
2.70 
 
0.20 
 
0.30 
 
3.85 
 
 
6.55 
 
5.68 
 
4.63 
 
3.61 
 
2.91 
 
2.70 
 
 
0.56 
 
0.97 
 
0.43 
 
0.28 
 
0.29 
 
2.60 
*Average of four replicates. (Table adapted from Rekhviashvili et al., 2006).
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Overall variability of the LUX assay was studied in more detail. Log transformed 
concentration values obtained for four replicates of each standard over four different 
experiments were used. A plot is represented in Figure 2.12 to illustrate any data points 
that show a difference >0.5 log10 between the input standard and calculated concentration 
values using the log transformed values. The greatest variability was found at 2.6 log10 and 
less at 5.6 log10 of ES RNA concentrations.  These data reflects the results shown in Table 
1 where three replicate runs out of four have higher intra-assay variability CV for 2.6 log10 
and two out of four replicate runs have an increased intra-assay variability CV for 5.6 
log10.  
 
Linearity of the dynamic range of the LUX assays was established based on the mean 
values of ES RNA concentration range (4x102 – 4x106copies/ml) obtained from four 
repeated experiments performed for reproducibility study. These values were plotted 
against the input copy number of ES RNA in a log-log scale. Coefficients of linear 
regression (R2) of the dynamic range from 4x102 copies/ml to 4x106 copies/ml was R2 = 
0.99. This indicates that the LUX assay is linear over its quantitation range.  
 
Since this viral load assay uses ES RNA for quantitation of the wild type HIV-1 RNA 
copies it is essential that the efficiencies of amplification of the HIV-1 gag region and ES 
RNA are comparable. RT-PCR efficiencies of ES RNA and HIV-1 were compared for the 
LUX assay sing serial dilutions of ES RNA and the VQA RNA copy controls. In the 
experiment all five VQA samples were tested in triplicate. ES RNA samples covering the 
dynamic range of 1.5x102 – 1.5x105copies/ml were also included in the RT-PCR run. In 
order to compare RT-PCR efficiencies VQA samples were first entered into the 
LightCycler® software as standards and a standard curve was generated. The software 
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(version 4) then calculated a PCR efficiency value for every standard curve (see the 
LightCycler® 2.0 Instrument Operator’s Manual, Version 4, page 96). RT-PCR efficiency 
of HIV-1 amplification (VQA copy controls) over 3 log10 of concentration from 1.5x103 to 
1.5x105copies/ml was 1.9. The ES RNA amplification efficiency over the corresponding 
dynamic range was 2.2 (data not shown). Therefore, RT-PCR efficiencies of ES RNA and 
HIV-1 are comparable.  
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Figure 2.12: Differences in log values between input and calculated concentrations of ES 
RNA using the LUX assay. (Adapted from Rekhviashvili et al., 2006). Intra- and inter-
assay variability was studied in four replicate runs and the standards of every concentration  
(4x102 - 4x106copies/ml) were repeated four times within a run (n = 4 x 4). Each point in 
the graph represents the log transformed value for the experimentally calculated ES RNA 
concentrations obtained from these replicate runs. The clinically important cut-offs for the 
log difference between the standard input and calculated values are indicated by the dashed 
lines. The two outliers likely represent technical artifacts.  
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Additionally, different quantitative analysis was applied to the experiment described 
above. In particular, the VQA samples were entered into the LightCycler® software as 
unknown samples and quantified using the standard curve generated with ES RNA. Mean 
concentration values of the triplicate viral load measurements (i.e. each of five VQA 
samples were repeated three times within one RT-PCR run) were obtained for the VQA 
RNA copy controls. Table 2.3 shows the absolute and log10 transformed viral load values 
obtained for the VQA copy controls using the LUX and COBAS Amplicor assays (i.e. 
VQA assigned values). Absolute log10 differences obtained are indicated in the last column 
of the table. The VQA sample of 1.5x102copies/ml was below the quantitation limit of the 
LUX assay.  
 
2.3.3 Evaluation of the LUX assay using clinical specimens obtained from the 
patients in South Africa  
2.3.3.1 Specificity  
Specificity of the primers used for the LUX assay was estimated using the BLAST 
program (http:/www.ncbi.nlm.nih.gov/BLAST) that showed high degree of homology of 
the primer sequences to HIV-1 sequence only. Specificity of the LUX assay was evaluated 
using seronegative plasma samples obtained from 50 HIV-1 seronegative patients. All 
HIV-1 negative samples were tested in duplicate – with and without an IC. No HIV-1 
amplification product was detected in any of the samples using HIV-1 specific primers – 
SKT145/150. IC was amplified in all the duplicate samples showing no PCR inhibition in 
these samples. Therefore, no false positive results were observed for this group of known 
HIV-1 negative patients using the LUX assay (Figure 2.13).  
 80
Table 2.3: HIV-1 viral load for VQA Copy Controls using LUX assay  
  
 
VQA HIV-1 
RNA Copy 
Controls  
(COBAS 
Amplicor viral 
load values in 
copies/ml)  
 
VQA HIV-1 
RNA Copy 
Controls  
(log10 values 
of COBAS 
Amplicor 
viral load) 
 
VQA HIV-1 
RNA Copy 
Controls  
(viral load 
obtained 
using LUX 
assay*, 
copies/ml) 
 
VQA HIV-1 
RNA Copy 
Controls  
(corresponding 
log10 values of 
LUX viral 
load) 
 
Absolute 
log10 
difference  
 
(log10 LUX 
assays minus 
log COBAS  
Amplicor) 
 
1.5x103  
 
3.2 log10 
 
 
1.0x103  
 
3 log10  
 
- 0.2 log10 
 
1.5x104  
 
4.2 log10  
 
3.5x104  
 
4.5 log10  
 
0.3 log10 
 
1.5x105  
 
5.2 log10  
 
1.3x105 
 
5.1 log10  
 
- 0.1 log10 
*Mean of the triplicate viral load readings  
 
2.3.3.2 Comparison of the LUX assay to the COBAS Amplicor assay using a random group 
of 142 HIV-1 positive patients  
A random group of 142 HIV-1 positive patients was used to compare the performance of 
the LUX assay with the COBAS Amplicor assay. All samples obtained from the 142 
patients were tested using a standard procedure for the COBAS Amplicor assay that 
provides a linear dynamic range of <400 - > 750 000 copies/ml. These samples were tested 
with the LUX assay in duplicate – with and without the addition of IC. IC was amplified in 
all samples tested thus showing no PCR inhibition in these samples. Samples from the 
VQA copy control panel were often included in the LUX assay runs to control for accuracy 
of quantitation (Figure 2.14).  
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Figure 2.13: Melting curve analysis performed using HIV-1 seronegative samples.  
Melting curve post-PCR profile is shown for three HIV-1 negative samples and an ES 
RNA standard. ES sample has a melting peak at ~80.5ºC (HIV specific product) when 
using 530 nm filter and the negative samples have a melting peak at ~76ºC (primer 
dimers). Melting curve analysis using filter 560 nm shows amplification product of IC (~ 
82ºC) in the duplicate negative samples thus confirming the absence of RT-PCR inhibition.  
 
 82
 
 
Figure 2.14: Captured image from the LightCycler® showing post-PCR quantitative 
analysis. Viral load values (copies/µl) are quantified by the LightCycler® software for the 
quantitation standards (ES; samples 1-4), the two VQA samples (samples 5 and 6) and 
patient’s samples (7-18), sample 19 – ES RNA used as a positive control. Unselected 
samples represent duplicate patient tests containing IC (samples 20 30).  
 
Statistical analysis of the log10 transformed viral load data was performed for both assays. 
The frequency graph (Fig. 2 A) for this group of patients (n = 142) tested with the COBAS 
Amplicor assay reflected a typical bimodal distribution of viral load values in the 
population receiving ARV therapy, with a mode (peak) at 2.6 log10 (the lower quantitation 
limit) and 5.8 log10 (the higher detection limit) values. The LUX assay distribution is 
trimodal (Fig. 2 B) with modes at 2.6 log10 and 4 – 5 log10 of viral load values. The 
COBAS Amplicor standard assay and the LUX assay have the same lower limit of 
detection (400 copies/ml; 2.6 log10) and hence similar grouping of values at the lower viral 
load range (2.6 log10) is demonstrated by both assays (Fig.2 A and B). Frequency 
distribution analysis (Fig. 2 A, B) shows some difference in the distribution of the results 
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mostly at the higher viral loads obtained with both assays. In particular, the COBAS 
Amplicor has a modal (peak) at 5.8 log log10 and the LUX assay viral load values for these 
samples are more evenly distributed from 4 - 6.6 log10. Figure 1C demonstrates similarity 
in the frequency distribution of HIV-1 viral load values obtained with both the COBAS 
Amplicor and the LUX assays (n = 142). The two assays have similar lower and upper 
quartile values though the COBAS Amplicor has a slightly higher median value then the 
LUX assay.  
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Figure 2.15: Histograms and box plots of the log10 viral load values for the COBAS 
Amplicor and the LUX assays. Graph A shows the frequency distribution (number of log10 
viral load values on the vertical axis) of the log transformed HIV-1 viral load values (log10 
copies/ml on the horizontal axis) obtained for the group of 142 patients using the COBAS 
Amplicor assay. Graph B shows the distribution of log10 values obtained with the LUX 
assay for the same group (n = 142). The combined graph (C) illustrates the distribution for 
both assays in the form of box plots. The distributions for both assays are quite similar (i.e. 
similar upper and lower quartiles). The LUX assay shows more symmetry and slightly 
more variability due to the higher viral load values of the upper quantitation limit 
(4x106copies/ml).  
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Figure 2.16: Bland-Altman model for measuring agreement between the LUX and COBAS 
Amplicor assays. The difference of log10 values between the LUX assay and the COBAS 
Amplicor assay (Y- axis) was plotted against the mean log10 value of the results obtained 
with both assays (X- axis). Mean difference between the log values is 0.03 and the limits of 
agreement for 95% of the data are from – 1.26 to 1.32 (CI 95%).  
 
Agreement between the COBAS Amplicor and the LUX assays was established using the 
intra-class correlation (ICC) analysis. ICC coefficient of 0.85 with the confidence interval 
(CI) of 95% [80; 90] was obtained for this cohort. In addition, agreement between the 
assays was assessed using a Bland - Altman model (Bland and Altman, 1986) as displayed 
in Figure 3. The mean difference between the log10 viral load values of the LUX assay 
minus the COBAS Amplicor log10 values for 142 samples analyzed was 0.03 (limits of – 
1.26 to 1.32). Based on the Bland – Altman analysis ~ 65% of the log10 paired differences 
were ≤ absolute 0.5 log10 (this includes both + 0.5 log10 and – 0.5 log10 intervals) and 
another ~ 22% of the values were within the interval of absolute ≥ 0.5; ≤ 1 log10 difference 
(this includes both plus and minus intervals). The remaining 13% of the values (18 
 86
samples) showed higher variability (≥ absolute 1 log10). Amongst these samples 5 were 
under-quantitated and another 13 samples were over-quantitated by the LUX assay when 
compared to the COBAS Amplicor assay. 
 
2.3.3.3 Evaluation of the LUX assay using a cohort of 55 patients on HAART  
A cohort of 55 patients on HAART, followed up longitudinally over five sequential visits 
(weeks 0, 4, 8, 12 and 24) was analyzed. The samples from the visit on week 24 were 
tested in duplicate using the LUX assay – with and without IC. No inhibition of PCR was 
found in all the duplicate samples. The samples for the baseline viral load measurement 
(visit on week 0) were tested using the standard version of the COBAS Amplicor assay 
with the linear dynamic range of 400 - 750 000 copies/ml. The follow-up samples (week 4, 
8, 12 and 24) were tested using the ultra sensitive version of the Roche Amplicor assay, 
which has the linear dynamic range of 50 - 100 000 copies/ml. Once anti-retroviral (ARV) 
treatment had commenced the viral load values dropped significantly by week 4 in the vast 
majority of patients, from a median 5.44 log10 to 2.40 log10 and log10 5.43 to log10 2.60 for 
the COBAS Amplicor and the LUX assay, respectively (Fig.4). Five patients (n1-n5) out of 
55 showed viral rebound at weeks 4, 8, 12 and 24, respectively. Table 1 shows that the 
increased viral loads detected in these patients by the COBAS Amplicor assay were also 
detected by the LUX assay. For patient n1 (samples from the visit on week 4), the 
ultrasensitive COBAS Amplicor showed a viral load value of 5.0 log10, which corresponds 
to the upper quantitation limit of the test (100 000 copies/ml). Thus the corresponding 
LUX viral load reading of 4 000 000 copies/ml represents a plausible value. In patient n2 
the LUX assay showed consistently lower viral load readings for the baseline sample as 
well as for the sample on the week 12 visit reflecting a “spike” in viral load. In patients n3 
and n5 the LUX assay when compared to the gold standard showed higher viral load values 
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for both baseline and weeks 12 and 24 respectively. For patient n4 the LUX assay detected 
an increase in viral load for the week 24 visit, but the corresponding value obtained with 
the ultra sensitive COBAS Amplicor test was higher.  
 
 
 
 
Figure 2.17: Box plots showing changes in viral load during longitudinal follow-up of 55 
patients on HAART. At the baseline visit (week 0) both assays showed very similar 
median values of 5.44 log10 (COBAS Amplicor) and 5.43 log10 (LUX assay). From the 
next visit (week 4) onwards both methods show the decrease in viral load values to the 
lower quantitation limits – 2.40 log10 (COBAS Amplicor) and to 2.60 log10 (LUX assays). 
Individual patients revealed “spikes” (“blips”) in viral loads detected on different visits.  
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            Table 2.4: Follow-up samples from the patients showing viral rebound. Values      
  indicating viral rebounds are in bold.  
 
Patient  Visit  Amplicor HIV-1 
Monitor™ Viral load 
in log10 (copies/ml) 
LUX assay  
Viral load in log10 
(copies/ml) 
n1 week 0 
week 4 
week 8 
week 12 
week 24 
5.60 log10  
5.00 log 10  
2.21 log10  
1.70 log10  
NA*  
6.60 log10  
6.60 log10  
2.60 log10  
2.60 log10  
NA 
n2 week 0 
week 4 
week 8 
week 12 
week 24 
5.79 log10  
2.62 log10  
1.77 log10  
5.00 log10  
NA 
4.65 log10  
2.60 log10  
2.60 log10  
4.14 log10  
NA 
n3 week 0 
week 4 
week 8 
week 12 
week 24 
5.88 log10  
2.94 log10  
3.20 log10  
3.92 log10  
NA 
6.37 log10  
2.60 log10  
2.60 log10  
4.26 log10  
NA 
n4 week 0 
week 4 
week 8 
week 12 
week 24 
5.88 log10 
3.10 log10 
2.64 log10  
2.64 log10  
3.74 log10  
6.38 log10  
2.60 log10  
2.60 log10  
2.60 log10  
3.02 log10  
n5 week 0 
week 4 
week 8 
week 12 
week 24 
4.98 log10  
2.60 log10  
1.83 log10  
1.70 log10  
3.72 log10  
5.34 log10  
2.60 log10  
2.60 log10  
2.60 log10  
4.35 log10  
  NA* - not available  
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2.4 Discussion  
This chapter describes development and evaluation of a new in-house assay for 
quantitation of HIV-1 RNA in plasma using the LightCycler® platform for real-time PCR. 
Modern real-time PCR technology allows flexibility of developing new, more affordable 
diagnostic assays that show good performance characteristics when compared to gold 
standard assays. A literature review revealed description of two real-time PCR systems 
used most frequently for the development of in- house assays for HIV-1 and HIV- 2 viral 
load quantitation – ABI Prism Sequence Detection System (models 7000, 5700 and 7700) 
from Applied Biosystems (Drosten et al., 2006; Ferns and Garson, 2006; Israel-Ballard et 
al., 2005; Palmer et al., 2003; Rouet et al., 2005; Schutten et al., 2000; Shapshak et al., 
2005) and the LightCycler® real-time PCR system from Roche Applied Science (Demond 
et al., 2002; Gibellini et al., 2006; Gibellini et al., 2004; Gueudin et al., 2003; Gueudin and 
Simon, 2005; Ruelle et al., 2004). Among the two published LightCycler® methods for 
HIV-1 viral load quantitation, one was developed for different subtypes within group O 
(Gueudin et al., 2003; Gueudin and Simon, 2005) and another method for HIV-1 group M, 
subtype B (Gibellini et al., 2004). The assay developed by Gibellini et al (2004) uses a 
conserved region within the HIV-1 gag gene as an amplification target and the non-
sequence specific SYBR Green detection format. However, both reported LightCycler® 
assays for HIV-1 viral load quantitation (Gibellini et al., 2004; Gueudin et al., 2003; 
Gueudin and Simon, 2005) did not use an internal control and were evaluated using limited 
number of clinical specimens.  
 
Initial development of an in-house HIV-1 viral load assay was performed using an early 
version of the LightCycler® platform (version 1.2) and a FRET detection format (FRET 
assay). According to the assay design, quantitation of viral RNA copies is performed using 
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an external standard ES RNA for quantitation and control for RT-PCR inhibition is 
achieved by the addition of an IC to each reaction. Even though viral RNA extracted from 
one of the well characterized HIV-1 panels can be employed for quantitation, the use of a 
small synthetic RNA molecule as ES has certain advantages. Non- infectious in vitro 
transcribed ES RNA can be produced at very high titers (e.g. 1011 copies/μl) for long term 
storage. Since the exact length of the synthetic ES RNA molecule is known, concentrations 
of a stock solution can be precisely established, which is crucial for quantitative RT-PCR. 
Furthermore, synthetic RNA can be chemically modified to dramatically improve its 
stability during storage even at lower temperatures (e.g 4˚C). Both ES and IC were 
designed and produced specifically for this viral load test. ES represents in vitro 
transcribed RNA and includes a conserved sequence from the p24 region of the HIV-1 gag 
gene. To ensure accurate and reliable quantitation using the in-house assay, ES RNA was 
extensively purified and quantified using a fluorescent dye for best sensitivity. 
Optimization of the FRET assay was performed using ES RNA and included RT-PCR 
amplification conditions, reaction volume, concentrations of primers and probes and 
stabilization of ES RNA. Although version 1.2 of the LightCycler® instrument 
recommends performing amplification reactions in 20 µl volume a dramatic improvement 
in sensitivity of the FRET assay was demonstrated using 30 µl reactions. Next, titrations of 
a competitive IC showed that only 3 logs of ES RNA concentrations can be co-amplified 
and reliably quantified in the presence of either in vitro RNA IC or a DNA equivalent of 
IC. In an attempt to improve the dynamic range of an internally controlled FRET assay, the 
competitive IC was modified into a non-competitive IC by replacing the primer binding 
sites in the former. Titrations of a non- competitive IC DNA revealed the most optimal 
concentration of IC primers and IC DNA that can co-amplify with 5 logs of ES RNA 
concentrations (i.e. 1.5x103 to 1.5x107 copies/ml). A DNA IC was evaluated instead of an 
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RNA IC due to its higher stability at lower concentrations and lower costs involved in 
maintaining the stocks. DNA IC similarly to RNA IC would reveal inhibition of PCR. 
However, this approach lacks the advantage of controlling for inhibition during Reverse 
Transcription.  
  
Preliminary evaluation of the FRET assay was performed using ES RNA, VQA copy 
controls and the BBI panel. Preliminary evaluation of specificity of the FRET assay was 
based on a BLAST search, which showed that the sequences of primers and probes used 
for the assay are highly homologous to HIV-1 gag sequence only. Quantitative 
performance of the FRET assay was evaluated in five experiments repeated on different 
days using serially diluted ES RNA. Five RNA standards containing non-competitive IC 
and covering quantitation range from 1.5x103 to 1.5x107 copies/ml were each repeated six 
times within each RT-PCR run. Based on these repeated experiments the sensitivity, 
linearity of the dynamic range and reproducibility of the FRET assay was investigated. 
Quantitation limit of the FRET assay in the presence of IC is 1.5x104copies of ES RNA per 
ml, which indicates rather insufficient sensitivity of the assay. The dynamic range of the 
assay is linear (R2 = 0.98; Figure 2.9) over four orders of magnitude from 1.5x104 to 
1.5x107 copies/ml. The average inter-run variability was 21%, indicating that the assay is 
reproducible. Further evaluation of the FRET assay was performed using the VQA HIV-1 
RNA Copy Controls consisting of subtype B virus. No real-time detection and quantitation 
was observed for all five VQA samples of different concentrations. However, the RT-PCR 
products from VQA samples of 1.5x104 and 1.5x105copies/ml could be visualized on the 
agarose gel, confirming successful amplification. This phenomenon may be explained by 
the presence of sequence mismatches and thus insufficient hybridization of the FRET 
probes to the amplicons generated with primers SKT145/150. FRET hybridization probes 
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usually cover up to 60 bp, and in this particular application probe design was problematic 
due to the high sequence diversity amongst HIV-1 group M isolates. Since HIV-1 subtype 
C is the predominant subtype circulating in South Africa (Papathanasopoulos et al., 2003) 
the FRET probes were designed based on known subtype C polymorphisms within the 
target gag region. In order to accommodate for such polymorphisms and make the 
detection of this subtype more optimal degenerate nucleotides were included in the 
sequence of FRET probes. Next, validation of an in-house quantitation standard (ES RNA) 
was performed using the BBI panel represented by subtype C HIV-1. Minor differences in 
viral load values were obtained for the BBI panel when tested with the FRET assay in 
triplicate using a real-time and an imported standard curve. An average viral load value for 
the panel was log10 transformed and compared to a commercial RT-PCR method – 
COBAS Amplicor assay. An absolute difference between the two methods was 0.3 log10 
indicating that quantitation of HIV-1 RNA provided by the FRET assay compares well to 
the gold standard assay. Overall, the FRET assay showed good reproducibility and good 
accuracy of quantitation using the BBI panel. The assay is also internally controlled to 
prevent false positive results. However, insufficient sensitivity and specificity of detection 
of the FRET assay restricted to subtype C required an improvement.  
 
Further development of the LightCycler® viral load assay was performed using a new, 
more advanced version (version 2) of the platform. The latest capillary based version 
allows the use of a wide variety of real-time detection formats as well as larger reaction 
volumes (e.g. 20 – 100 µl). Therefore, transfer of the originally developed FRET assay 
onto the new version of the instrument was conducted with a view of improving sensitivity 
and specificity of the assay. In order to avoid the effects of possible polymorphisms in the 
HIV-1 gag sequence, the FRET detection format used initially for the in-house viral load 
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assay was replaced with a LUX™ primer format (LUX assay). The use of a LUX™ primer 
format for this purpose is novel and holds a number of advantages. The fluorescently 
labeled self-quenched LUX™ primer does not require a separate quencher (i.e. it is mono-
labeled) and combines the features of a primer and a probe (Chen et al., 2004; Donia et al., 
2005; Lowe et al., 2003; Nazarenko et al., 2002b; Nazarenko et al., 2002a; Sharkey et al., 
2004), which makes it a more cost effective option when compared to other real-time 
detection formats. The LUX™ primer is also more suitable for detection of sequences in 
which polymorphisms are present in abundance, for example HIV-1 sequence. In our 
application, HIV-1 specific primers SKT 145/150 are located within a conserved region of 
the gag gene and thus conversion of one of these primers into a LUX™ format can provide 
better specificity of detection within subtype C as well as across different subtypes of 
virus. As opposed to SYBR Green dyes, TaqMan probes and Molecular Beacons, the 
LUX™ primer offers a combined possibility for multiplexing and performing a melting 
curve analysis (Sharkey et al., 2004). Similarly to SYBR Green dyes a LUX™ primer has 
reduced specificity due to detection of PCR byproducts like primer dimers. Formation of 
primer dimers is often inevitable in quantitative PCR that has a wide quantitation range, 
especially at low concentrations of template. This issue of detecting non-specific PCR 
products with a LUX primer was addressed in previously published studies (Lowe et al., 
2003; Nazarenko et al., 2002b). During optimization of the LUX assay this problem was 
solved by including a fourth segment at the end of each PCR cycle. This additional 
denaturation segment (78˚C for 4 seconds) allowed acquisition of a fluorescent signal at a 
temperature that exceeds the melting point of primer dimers, but is lower than the melting 
point of amplicons. This modification to the real-time RT-PCR profile ensured accurate 
and specific detection and quantitation of HIV-1 amplicons using the LUX SKT 150 
primer. Optimization of the LUX assay also revealed that addition of IC DNA or RNA 
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even at a low copy number reduces the dynamic range of the assay and affects accuracy of 
quantitation at the lower ES RNA concentration range (data not shown). Thus, in order to 
maintain good sensitivity the modified design of the LUX assay includes the use of a DNA 
IC in a duplicate test sample, which is not used for HIV-1 RNA quantitation. A duplicate 
test is used only to control for false negative results. Preliminary evaluation of the LUX 
assay using serial dilutions of ES RNA revealed a LLQ of 400 copies/ml. Significantly 
improved sensitivity of the LUX assay when compared to FRET assay (400 copies/ml 
versus 15 000 copies/ml, respectively) for the most part due to the larger reaction volume 
allowing greater input of RNA template. The sensitivity level of the LUX assay is 
comparable to the West African in-house viral load assay that has a quantitation limit of 
300 copies/ml and makes use of the ABI Prism technology (Rouet, et al., 2005). The 
LightCycler in-house viral load assay developed by Gibellini and colleagues provides a 
sensitivity of 50 copies/ml. using an older version of the platform, and 20 µl of a total 
reaction volume. High sensitivity of this assay may be attributed to the larger volumes of 
patient plasma (1 ml) used for HIV-1 RNA extraction (Gibellini, et al., 2004). In general, 
sensitivity and reproducibility of RT-PCR at low copy numbers is affected by a number of 
factors. Low copy number of the initial template molecules is influenced by statistical 
distribution effects, as described by Poisson’s distribution law, and therefore only some 
reactions will have the correct input copy number (Morrison et al., 1998; Saha et al., 2001). 
For example, a concentration of 1.5 x 103copies/ml corresponds to ~ 45 input copies in a 
30 µl volume. This small number becomes more variable due to stochastic effects when 
pipetting small template volumes. Moreover, variable RT efficiency reduces the number of 
initial targets for cDNA synthesis and further limits the sensitivity of RT-PCR (Hayward et 
al., 1998). Repeated experiments performed for the LUX assay using ES RNA dilutions 
from 4x102 to 4x106copies/ml showed good reproducibility of the assay (Table 2.2).  
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Reproducibility of the LUX assay was also analyzed using log10 transformed data (Figure 
2.12) and showed that overall variability (intra- and inter-assay variability) of the assay, 
except for a few outliers did not exceed 0.5 log10 copies. For quantitative assays, a 3-fold 
variation (0.5 log10 copies) is accounted for by intra-assay variability and biological 
variability, but clinically a 10-fold (1-log10) difference is regarded as clinically significant 
(Martin, 2000). The significance of 1-log10 variability in the assay is that it may lead to the 
clinical mismanagement of a patient on ARV treatment. Although the LUX assay shows an 
increased variability at lower quantitation levels and some variability between the 5.6 log10 
and 6.6 log10 range this is within acceptable ranges (< 0.5 log10). Thus, no clinically 
significant variability was found for the LUX assay. Preliminary evaluation of the 
quantitative performance of the LUX assay and an additional validation of an in-house 
quantitation standard (i.e. ES RNA) was conducted using the HIV-1 RNA Copy Controls 
from the VQA laboratory. As opposed to the FRET assay that failed to detect and 
quantitate the VQA samples, the LUX assay was successful in both real-time detection and 
quantitation. Similarly to the BBI panel tested with the FRET assay, the VQA samples 
showed that amplification efficiency of ES RNA is comparable to that of HIV-1 RNA, 
which is essential for quantitative PCR. Testing of the VQA copy control samples also 
demonstrated that the LUX assay quantified HIV-1 viral load in these samples in the same 
log10 range as the Ultra sensitive Roche Amplicor HIV-1 Monitor™ v1.5 test and with a 
maximum absolute log10 difference of 0.3 log10 (Table 2.3). Thus, preliminary evaluation 
showed that the LUX assay compares well to the in-country gold standard test.  
 
Preliminary clinical evaluation of the LUX assay was performed using a total number of 
458 clinical specimens collected from the South African population. The DNA IC was run 
in duplicate tests for 247 out of the 458 samples (due to costs), and confirmed there was no 
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PCR inhibition, while maintaining the good quantitative features of the LUX assay. 
However, future development and implementation of the LUX assay must aim to maintain 
good quantitative characteristics by spiking every sample with an RNA IC prior to 
extraction in order to provide full control for false negative results. 
 
To establish whether the assay would be applicable in individuals infected with non-C 
subtypes, a comparison of the primer sequences with all available sequences of HIV in the 
Los Alamos database (http://www.hiv.lanl.gov) was conducted. The primers bind in highly 
conserved regions of p24 of all isolates, with the exception of subtype G (single base 
mismatch at the 3’ end of the SKT150 primer). Since only a few subtype G, and G 
recombinants have been identified in South Africa (Bredell et al., 2002; Papathanasopoulos 
et al., 2002), the LUX assay is expected to work for the majority of HIV-1 infected 
individuals. Future evaluations of this assay will include degenerate SKT150 primer 
designs to ensure coverage of HIV-1 group M subtypes. The p24 region of HIV-1 gag has 
been well characterized as an amplification target in subtype C using the Roche Amplicor 
assay, versions 1.0 and 1.5 (Alaeus et al.,1999; Mechael et al., 1999; Parekh et al., 1999) 
and at the time of development of the in-house assay represented the best choice. However, 
recent literature suggests other conserved regions for amplification, e.g. LTR region of 
HIV-1 genome (Drosten et al., 2006). An ongoing molecular surveillance is necessary to 
identify sequences that are highly conserved in most non - B subtypes and in circulating 
recombinant forms (CRF). Determination of such a target in future studies may require 
some modifications to the current assay, which will ensure reliable quantitation of this 
highly divergent virus. 
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Good specificity of the LUX assay was shown using 50 HIV seronegative plasma 
specimens. Good quantitative performance of the assay was demonstrated using a random 
group of patients and a longitudinally followed-up cohort of patients receiving therapy. 
The analysis of a random group of patients (n = 142) revealed that both the described assay 
and the gold standard assay reflect overall similar distributions of viral load values 
(Figure.2 C). The differences in distribution at the highest values between the assays are 
largely due to an upper quantitation limit of the LUX assay being at 6.6 log10 (upper 
quantitation limit at 4 000 000 copies/ml) versus 5.8 log10 (upper quantitation limit at 750 
000 copies/ml) for the COBAS Amplicor test. The LUX assay shows higher distribution 
(frequencies) in 4 log10 (middle range of the LUX assay) when compared to the gold 
standard. This could be attributed to the different types of quantitation involved – real-time 
when using the LUX assay versus an end point quantitation when using the COBAS 
Amplicor. The agreement between the LUX assay and the COBAS Amplicor assay was 
studied using an intra class correlation (ICC) coefficient and the Bland – Altman method 
(Figure. 3). Good agreement appears to exist between the two assays since a high value for 
the ICC was found (0.85, 95% CI: 0.80 – 0.9). The Bland – Altman model revealed a mean 
bias of 0.03, which reflects good accuracy of quantitation using the LUX assay. In total, 
approximately 87% of the values showed less than absolute 1 log10 difference, which is not 
considered a clinically significant difference (Martin, 2000). Amongst values that showed 
higher variability (> absolute 1 log10), ~3.52% (5/142) were under-quantitated and ~9.15% 
(13/142) were over-quantitated by the LUX assay. Due to the lack of availability of 
retrospective samples it was not possible to perform DNA sequencing and thus exclude 
nucleotide mismatches in primers and/or probe binding sites as a likely reason for under 
quantitation observed in both assays. Some degree of viral RNA degradation in the stored, 
retrospective samples may contribute to the under- quantitation observed with the LUX 
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assay. Therefore, the Bland-Altman analysis shows good agreement between the LUX 
assay and the COBAS Amplicor assay for ~ 87% of the results. 
 
Clinical usefulness of the LUX assay in monitoring HIV-1 viral load was evaluated using 
the cohort of 55 patients on ARV treatment followed-up longitudinally. For this cohort of 
samples an automated MagNA Pure extraction system was used. The system utilizes 
magnetic glass particles for capture and detection of nucleic acid molecules and provides 
good efficiency using small volumes of plasma (Espy et al., 2001; Mohammadi et al., 
2003). For the baseline samples that were collected prior to treatment initiation both the 
standard COBAS Amplicor and the LUX assay showed median viral load values of 5.44 
log10 and 5.43 log10, respectively. A dramatic decrease in viral load values was observed in 
most patients 4 weeks after initiation of treatment indicating good response to the 
combination therapy used. This was reflected similarly by an ultra sensitive version of the 
COBAS Amplicor and the LUX assay that showed viral load values of 2.40 log10 and 2.60 
log10, respectively. HIV-1 viral load values below the detection limit of both assays were 
demonstrated in these patients during the subsequent visits (weeks 8, 12 and 24). During 
the course of therapy, 5 patients out of 55 showed an increase in HIV-1 viral load values. 
Both the ultra sensitive COBAS Amplicor and the LUX assay revealed viral rebound in 
these patients using the samples obtained on the same visit (Table 2.4). Even though the 
LUX assay in combination with the MagNA Pure extraction system uses 3.5 times less 
plasma than the ultra sensitive COBAS Amplicor assay, it provides sufficient sensitivity 
for early detection of viral rebound in patient’s on ARV treatment. Therefore, in the 
patients on HAART the LUX assay shows a similar downward trend in viral load values 
over time as the COBAS Amplicor assay (Figure 2.17). Most importantly, the “spikes” in 
HIV-1 viral load that occurred in five patients were all detected similarly by both the ultra 
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sensitive COBAS Amplicor assay and the LUX assay. This evaluation demonstrated good 
clinical performance of the LUX assay in monitoring the efficacy of ARV treatment in the 
patients during longitudinal follow-up.  
 
In conclusion, this study suggests that the LUX assay represents a more affordable 
alternative tool for monitoring HIV-1 viral load in South African patients on antiretroviral 
therapy. Preliminary cost estimation of the developed assay includes: cost for RNA 
extraction ~$5.7, RT-PCR reagents ~ $5.7, consumables ~ $ 3.4, cost for labor ~ $8.9. The 
total cost is ~ $ 23.7 per test, which is approximately 2 to 3 times less expensive than the 
commercial assays currently used in the public sector in South Africa (~$ 45 for EasyQ, 
Biomerieux; $ 75-80 COBAS Amplicor, Roche). Future development of the LUX assay 
will aim to further reduce the cost of the assay. It is also envisaged to transfer the assay 
onto the latest version of the LightCycler® system – version 480 and evaluate the LUX 
assay using fresh plasma samples. The LightCycler® 480 offers a significantly higher 
throughput (96 or 384 samples per run) than the approved commercial assay (Table A1, 
Appendix A). An ultimate goal of this study is to provide the high volume laboratories in 
South Africa with an affordable, high throughput assay with performance characteristics 
comparable to those of the commercial assays. The development and preliminary clinical 
evaluation of the LUX assay is the first step towards achieving this goal.  
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CHAPTER 3  
 
Evaluation of two commercially available, inexpensive 
alternative assays used for quantitation of human 
immunodeficiency virus type 1 (HIV-1) in plasma  
This chapter describes the evaluation of the heat-denatured (HD), signal-boosted p24 
antigen assay (the HiSens™ HIV-1 p24 Ag Ultra assay) and the reverse transcriptase (RT) 
enzyme activity assay (the ExaVir™ Load assay) using a total number of 117 plasma 
specimens. These specimens were obtained from a cohort of 20 HIV-1 positive patients (89 
samples) on HAART followed up longitudinally, and 28 treatment-naïve patients from 
South Africa. Performance of both alternative viral load assays was compared to the Roche 
Amplicor HIV-1 Monitor™ (version 1.5) assay. The main objectives of this component of 
the study were to:  
 Evaluate the performance of these surrogate viral load assays in HIV-1 subtype C, 
which is the predominant subtype in South Africa;  
 Evaluate the usefulness of these assays for monitoring HIV-1 viral load in patients 
on HAART;  
 Assess the technical complexity and ease of implementation of these assays in 
medium tier district laboratories in South Africa.  
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3.1 Introduction  
The South African National Antiretroviral Treatment Guidelines (National Department of 
Health, SA, 2004) recommend routine monitoring of HIV-1 viral load in patients on 
HAART. Approximately 10.3% of NHLS laboratories are classified as medium tier 
laboratories and do not have either the facilities or trained personnel for implementation of 
PCR or other NAT based viral load methods (see section 1.1). Thus, non-NAT based and 
technically less complex viral load assays represent a reasonable alternative for this group 
of laboratories and others in resource limited environments. Among such methods are the 
HiSens™ HIV-1 p24 Ag Ultra assay (Perkin Elmer) and the ExaVir™ Load assay 
(Cavidi).  
 
One of the commonly used alternative viral markers, the p24 protein, is the chief 
component of the nucleocapsid core proteins translated from the same RNA species as is 
enclosed in virus particles (Hammer, 1996). The test principle for p24 antigen detection 
and quantitation is based on formation of the antibody-antigen-antibody sandwich, which 
is detected in an ELISA plate format. In particular, p24 antigen present in plasma or serum 
is added to a microtiter plate coated with p24-specific, usually monoclonal, capture 
antibodies. After incubation, unbound reaction components are washed away and bound 
antigen is reacted with another p24-specific “tracer antibody”. The “tracer” antibodies are 
conjugated to an enzyme – horse radish peroxidase or alkaline phosphatase, which are 
capable of generating a colour signal when combined with a suitable substrate. The signal 
is detected as a change in the optical density of the reaction using a conventional ELISA 
plate reader (Schüpbach, 1999). The original version of the p24 quantitation assay was 
criticized for poor sensitivity and problems with generating false negative and false 
positive results (Lange et al., 1987). Insensitivity and/or false negative results of the p24 
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test were largely due to the immune complexes formed between of p24 antigen and anti-
p24 antibodies in the serum of the infected individuals. Another problem was caused by 
the immunoglobulin-specific (anti-Ig), rheumatoid-factor-like antibodies which may bridge 
the capture and the tracer antibody in the p24 test thus generating overdetection or false 
positive results. Professor Schüpbach and his colleagues managed to overcome these 
problems by including a heat denaturation step in the p24 test. During this step the diluted 
sample is boiled at 100ºC for 5 minutes. Thus interfering antibodies (i.e. anti-p24 anti-Ig) 
are eliminated by heat-mediated destruction of their 3 dimensional structure (Schüpbach 
and Bone, 1993). The heat denaturation step and the use of plasma instead of serum 
increased the sensitivity of the p24 test. Further improvement was achieved by boosting the 
signal using tyramide-based signal amplification with the NEN ELAST® reagents. This 
ELISA reaction allows p24 quantification across a range from 0.5 pg/ml to more than 6 
ng/ml (Schüpbach et al., 1996; Schüpbach et al., 2000). Further evaluation of the HD p24 
assay for diagnosis of pediatric HIV-1 infection demonstrated that the assay was as 
sensitive and specific as nucleic acid based HIV-1 diagnostic assays (Lyamuya et al., 1996; 
Schüpbach et al., 1994; Sherman et al., 2004; Sutthent et al., 2003). Recent work has 
suggested that a modified p24 antigen assay can also be used on dried whole-blood spots 
allowing accurate, reliable, inexpensive and early diagnosis of HIV-1 in infants (Patton et 
al., 2006). Good performance of the HD p24 assay for longitudinal monitoring of the 
efficacy of ARV therapy has been demonstrated using a cohort of 23 patients on HAART 
where p24 antigen was detected as sensitively as viral RNA. On average the changes in the 
p24 antigen concentrations and viral RNA copies/ml correlated excellently (Boni et al., 
1997). In a study reported by Ledergerber and colleagues, HD p24 quantitation results 
inversely correlated to CD4 counts and compared well to the concentrations of viral RNA 
showing that p24 is a marker of disease progression in adults (Ledergerber et al., 2000). 
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Moreover, the HD p24 test has been shown to have good specificity across different group 
M subtypes of HIV-1, including group O which is usually not detected by commercial 
RNA based assays (Burgisser et al., 2000). In three Swiss studies the improved HD signal-
boosted p24 assay showed good association with RNA levels in treated adults and children 
(Schüpbach, 2002).  
 
Another alternative viral load assay - ExaVir™ Load assay (Cavidi) uses a different 
marker of viral replication – HIV-1 reverse transcriptase (RT) enzyme activity. The 
ExaVir™ Load assay (RT assay) measures the activity of viral RT enzyme based on the 
quantity of product (DNA-RNA hybrid) synthesized by this enzyme. The earlier versions 
of this assay were hampered by the susceptibility of the RT enzyme to inhibitory 
antibodies and other interfering molecules (Burgisser et al., 2000). This problem was 
solved in the newer versions of the RT assay in which viral particles are first captured by a 
special gel and the remaining plasma containing the interfering substances is washed away. 
The assay procedure is divided into two parts: the plasma separation and the RT-assay. In 
the separation part of the assay plasma is treated to inactivate cellular enzymes and then 
incubated with a special liquid gel that binds the virion lipid membrane. Once viral 
particles are captured by the gel and the plasma containing disturbing products such as 
antibodies or anti-retroviral drugs is washed away. Captured virions are then lysed and the 
lysate containing RT enzyme is collected and used in the RT-assay step. The RT-assay is 
performed in 96-well plates coated with poly-A RNA molecules. The reaction mixture 
added to the plate contains primer, BrdUTP(s) (Bromo-deoxyuridine triphosphate) and 
viral lysates. In the presence of these entire reaction components active RT enzyme will 
synthesize DNA using an RNA template. The resulting DNA-RNA hybrid is detected in an 
ELISA set-up by the addition of anti-BrdU antibodies conjugated to alkaline phosphatase 
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(AP) and a colorimetric or fluorimetric AP substrate (Award et al., 1997; Braun et al., 
2003; Garcia et al., 1998). The RT activities found in plasma samples are expressed 
relative to a reference RT in femtograms per millilitre plasma (fg/ml). Studies conducted 
using the first generation of the ExaVir™ Load kit and a Stockholm cohort of patients, 
mostly subtype B, showed a strong correlation between RT activity and RNA genome 
copies present according to the Roche Amplicor™ assay (Malstein et al., 2002). The 
specificity of the viral load assays measuring viral genome or protein levels is dependent 
largely on the sequence of primers, probes and the antibodies used. The Cavidi ExaVir™ 
Load kit circumvents this problem by measuring the activity of the RT enzyme, which is 
essential for virus replication and well conserved across most subtypes (Award et al., 1997; 
Corrigan et al., 1998). Evaluation of the most recent, improved version of the ExaVir™ 
Load kit (version 2) showed sufficient sensitivity of the RT assay for longitudinal follow 
up of patients on ARV therapy. Good association of the RT assay with current 
amplification assays – the Roche Amplicor and the Bayer bDNA assays was demonstrated. 
Moreover, this study revealed no significant effect of efavirenz therapy on RT assay 
performance despite efavirenz binding to the RT enzyme (Greengrass et al., 2005).  
 
Evaluation of the ExaVir™ Load kit (version 2) as a tool for donor blood screening 
revealed 100% specificity of this assay. The fluorimetric version of the kit showed slightly 
better sensitivity than the colorimetric version. This study suggests that the detection of RT 
activity has a potential for use in blood screening in addition to other markers (Seyoum et 
al., 2005).  
 
The alternative methods described above use different surrogate markers for quantitation 
of HIV-1 viral load, therefore, extensive evaluation of these alternative assays is required 
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prior to implementation in routine diagnostics. Technical aspects of these alternatives 
should also be considered.  
 
3.2 Materials and Methods  
3.2.1 Sample population (Total n = 117)  
A total of 117 samples were collected from HIV positive individuals followed up at the 
Johannesburg hospital outpatient HIV clinic. All patients were from Johannesburg and 
surrounding areas and were all receiving HAART. Studies were conducted in full 
conformance with the local ethics committee approval (Appendix D). Clinical specimens 
were fresh and/or frozen plasma collected in vacutainer EDTA tubes. HIV Viral RNA was 
determined using the Amplicor HIV-1 Monitor™ assay version 1.5 (Roche Molecular 
Systems Inc., Branchburg, New Jersey, USA) as per manufacturer’s instructions. In 
patients who presented with a viral load values below the lower quantitation limit of the 
assay (<400 RNA copies/ml), the ultra-sensitive version of the assay was performed which 
has a detection limit of 50 RNA copies/ml. In addition, residual samples (n = 117) stored at 
–70 º C were evaluated using both the heat denatured p24 ultrasensitive assay as well as 
the ExaVir TM Load assay as per manufacturer’s instructions.  
 
Eighty-nine of the available plasma samples, representing 20 patients, were selected due to 
the availability of serial samples while patients were being monitored on HAART. The 
majority of patients returned for at least 4 sequential visits with a number of patients 
continuing onto the 6th visit. Blood samples for viral load determinations were scheduled at 
baseline and weeks 4, 8, 12, 16, 24 and then 8 weekly thereafter. The number of samples 
analyzed at each of the six visits was 20; 20; 20; 15; 9 and 5 respectively.  
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3.2.2 Heat-dissociated, boosted p24 antigen assay  
Measurements of the p24 antigen in plasma were performed using the HiSens HIV-1 p24 
Ag Ultra kit (Perkin Elmer Life and Analytical Sciences, Turku Finland) as per 
manufacturer’s instructions with some modifications. Briefly, 50 µl plasma was initially 
lyzed in 25 µl lysis buffer prior to being diluted 1:6 in 0.5% Triton X-100 (Schüpbach et 
al., 2003; Schüpbach et al., 2006). The lysis buffer (virus disruption buffer) used to 
conduct the assay was a new improved version kindly donated by Jorg Schüpbach 
(personal communication). The diluted sample was heat denatured for 5 minutes at 100ºC. 
Treated plasma samples (250 µl) were then transferred to wells of a microtiter plate coated 
with monoclonal antibody to HIV-1 p24 and incubated for two hours at room temperature 
on a micotiter plate shaker. Wells were washed with 1 x wash buffer, to which 100 µl of 
biotinylated detector antibody was then added and incubated for 1 hour at 37ºC. After 
washing, 100 µl of diluted S-HRP was added to all wells and incubated at 37ºC for 15 
minutes. Following washing 100 µl of biotinyl tyramide working solution was added to 
each well and incubated for 15 minutes at room temperature to allow for signal 
amplification. Next, the diluted S-HRP was added and incubated for a further 15 minutes at 
room temperature. Finally, o-phenylenedianine (OPD) substrate was added to all wells 
after washing and the plate was inserted into the kinetic ELISA plate reader (Bio-Tek 
Elx800 microtiter) Quanti-Kin Detection System Software, (DL3, Diagnostica Ligure, 
Genoa, Italy) was used to perform kinetic readings over a 30-minute period. A further 
incubation at room temperature for 10 minutes in the reader was stopped by the addition of 
100 µl stop solution and an end-point reading taken. The run was considered valid when 
the substrate blank had an OD < 0.05, the negative control OD < 0.10 and the 6103 fg/ml 
standard was OD > 0.15. The Quanti-Kin system incorporates programs for data reduction 
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and the results were obtained as printouts of calibration curves and concentrations for 
unknown samples. 
 
3.2.3 ExaVir TM Load Quantitative HIV-RT Load Kit  
HIV RT-activity was quantified using the ExaVir™ Load kit (Cavidi Tech AB, Uppsala, 
Sweden) according to manufacturer’s instructions. In the separation part 1ml of plasma 
was treated to inactivate interfering cellular enzymes. The viral particles were then 
captured and immobilized on a separation gel column and washed to remove other 
potential interfering factors. Isolated virions were lyzed with kit lysis buffer to recover the 
intraviral RT enzyme.  
 
During the RT-assay a reaction mix containing oligodT prime, BrdUTP and the lysates 
were added to the 96-well Poly A-coated plate. Two different amounts of lysates, 75μl and 
15μl were used in order to increase the detection range of the assay. Recombinant HIV-1 
RT supplied with the kit was used as a standard for quantitation. A serially diluted standard 
of a known concentration was also added to the plate in 75μl and 15μl volumes. In the 
presence of RT, DNA-RNA hybrids could be synthesized by RT during an overnight 
incubation at room temperature. After washing, this product was detected with α- BrdU 
antibodies conjugated with an AP. The product was quantified by addition of a 
colorimetric AP substrate. Colorimetric readings were taken on a Bio-Tek Elx800 
microtiter ELISA plate reader. The first reading was done immediately after the addition of 
the AP substrate to establish the baseline signal and then repeated two hours later. A final 
reading was taken after an overnight incubation. Viral RT activity was expressed as fg/ml. 
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These values were then converted to copies/ml equivalents by the software provided 
(Ledergerber et al., 2000).  
 
3.2.4 Plasma HIV RNA Assay  
The Amplicor HIV-1 MonitorTM version 1.5 assay (Roche Molecular Systems Inc., 
Branchburg, New Jersey, USA) was used as the gold standard assay. For the standard and 
the ultrasensitive version of the assay 200 µl and 500 µl of plasma were used, respectively. 
The assay was performed according to manufacturer’s instructions.  
 
3.2.5 Statistical analysis  
All statistical analyses were performed using 10log  transformed values for all the variables 
in the analyses, i.e. 10log p24, 10log RT ( 10log fg/ml) and 10log RNA ( 10log  copies/ml, 
Amplicor) except for CD4 counts. Schematic (box) plots of 10log p24, 10log RT and 
10log RNA over visits were constructed to evaluate the change in these values over time for 
all patients on treatment. Tests for trend of these values over visits were conducted using a 
mixed effects (repeated measures) model (Diggle et al., 1994) with orthogonal polynomial 
contrasts (Snedecor and W.G., 1989) for visits included in the model.  
 
To assess the association between 10log p24 and 10log RNA, 10log RT and 10log RNA, we 
used a mixed effects (repeated measures) model for each association with a heterogeneous 
first-order autoregressive-correlation structure for the values within a patient. This allows 
for lower correlations between values that are further apart than those that are adjacent 
within a patient, as well as adjusting for the heterogeneity of the outcome values within a 
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patient. The coefficient of determination (R2) as the square of the correlation between the 
observed and predicted values was calculated for each model. To show negative 
correlation between CD4 counts and all 3 viral load assays the Spearman test was applied. 
All statistical tests were two-sided and all statistical analyses were performed using the 
SAS V8.2 software.  
 
3.3 Results  
Four negative human plasma (NHP) samples of different lots supplied in the Roche 
Amplicor HIV-1 Monitor™ (version 1.5) kits were used as negative controls in each 
experiment and tested repeatedly negative for all assay methodologies used in this 
evaluation. RT enzyme activity and p24 antigen measurements were determined 
retrospectively on frozen plasma samples of all 117 samples once Amplicor HIV-1 RNA 
copy determinations were available. 
 
3.3.1 Description of data obtained for a cohort of 117 plasma samples using the 
gold standard viral load assay and CD4 counts  
Viral load values obtained for 117 samples using RNA assay ranged from 1.7 log10 (50 
copies/ml) to 5.9 log10 (750 000 copies/ml), which is within the lower and the upper limits 
of quantitation of the assay. Figure 3.1 A illustrates the distribution of the data within these 
log10 intervals. Approximately 40.5% of the samples tested by the RNA assay had viral 
load results less than 2.8 log10 (630 copies/ml), showing skewing of the results toward the 
group with lower log10 values. The box plot in Figure 3.1 B illustrates the range of CD4 
counts for 89 samples obtained from 20 patients over six visits. A line drawn through the 
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median shows an increase in a median CD4 count of 186 cells/µl at visit 1 to 304 cells/µl 
at visit 6.  
 
3.3.2 Comparison of the two alternative viral load assays to the RNA assay – 
statistical analysis  
 The data set obtained from these 117 samples with the two alternative methods and the 
gold standard HIV RNA assay were analysed using scatter plots. Figure 3.2 A illustrates a 
scatter plot for the p24 assay with the log10 p24 antigen concentration values indicated on 
the vertical axis and the corresponding log10 RNA concentrations on the horizontal axis.  
 
On this scatter plot approximately 39% of log10 RNA viral load values, which cover a 
range of 2.5 to 5 log10 (316 to 100 000 RNA copies/ml), were represented by no change in 
p24 antigen levels between visits. In the scatter plot of the log10 RT level versus the RNA 
log10 concentrations in Figure 3.2 B, the lowest RNA copy number detected by the RT 
assay is 3.5 log10. Due to this quantitation cut-off level, the change in the RNA load 
between 50 and 3000 copies/ml was not reflected by a change in the RT level. This was 
represented by approximately 52% of the results. The scatter plot for the RT assay also 
demonstrated the ability of the RT assay to measure viral load beyond the upper limit of 
the RNA assay (>750 000 copies/ml). Therefore, both alternative viral load assays when 
compared to the gold standard (i.e. RNA assay) revealed insufficient sensitivity of 
quantitation at the lower viral load range. The scatter plots also showed heteroscedasticity 
(increasing variance with increasing values of log10 RNA load), which was adjusted for in 
the statistical analysis.  
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B 
 
Figure 3.1: Distribution of log10 RNA results and range of CD4 counts (Adapted from 
Stevens et al., 2005a). A) Distribution of log10 RNA results: of the samples tested (n=117), 
40.5% of samples tested had viral loads <2.8log10 (630copies/ml) (n=117) B) Range of 
CD4 counts in 20 patients over 6 visits (n=89).  
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Figure 3.2: Scatterplots (Adapted from Stevens et al., 2005a). A) Scatterplots of log10 p24 
level versus log10 RNA; and B) scatterplots of log10 RT vs. log RNA (n=117 samples).  
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3.3.3 Analysis of patient viral load during ARV using all three monitoring 
assays  
The mixed effect model, performed on 89 samples from 20 patients, for 10log p24 (the 
regressor) and 10log RNA (the outcome variable) showed a significant association (having 
adjusted for heterogeneity, replication and the effect of time). The R-square for this model 
equals 0.686, thus 68.6% of the variation in 10log RNA was explained by the model. Also 
the slope parameter for 10log p24 equals 1.0386, which is very close to 1 thus indicating a 
fair amount of agreement between the two assays. Similarly, the mixed effect model for 
10log RT (the regressor) and 10log RNA (the outcome variable) showed a significant 
association (adjusting for heterogeneity, replication and the effect of time). The R-square 
for this model equals 0.8103, thus 81% of the variation in 10log RNA was explained by the 
model. Also the slope parameter for 10log RT equals 0.8663, which is also close to 1 but 
indicating less agreement between the two measures.  
 
The box plots in Figure 3.3A and B of 10log p24 and 10log RT vs. 10log RNA show the 
range of assay measurements on 20 patients followed over 6 visits. In 19 of the 20 patients 
the p24 antigen and RT serial results completely paralleled the RNA results.  The 
concentration of p24, RT and RNA exhibited a distinct decrease in all patients after 
therapy initiation, with the exception of 2 patients in whom p24 and RT remained 
undetectable.  All patients tested showed no significant viral rebound or lack of response 
and thus the performance of these assays in these scenarios could not be assessed. The 
repeated measures analyses with orthogonal polynomial contrasts have a significant linear 
decline in 10log p24 (P<0.0001) and a curvilinear decline (quadratic trend) in 10log RT 
(P<0.0001) and 10log RNA (P<0.0025).  
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Figure 3.3: Box plots showing trends in viral load values over time (Adapted from 
(Stevens et al., 2005a). A) Schematic box plots showing log10 p24 and log10 RNA levels 
(p24 values = darker boxes, RNA = lighter boxes); B) Schematic box plots showing log10 
RT and log10 RNA levels (RT values = darker boxes, RNA = lighter boxes). The secondary 
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axis versus the six visits over time was used (n = 89). A line has been drawn through the 
median of each visit.  
 
All three assays were inversely correlated with CD4 T-cell counts as shown by the 
Spearman test (CD4 vs. RNA r = -0.336, p = 0.001; CD4 vs. p24 r = -0.541, p < 0.0001; 
CD4 vs. RT r = - 0.358, p = 0.0006).  
 
3.4 Discussion  
The evaluation of the p24 antigen and RT enzyme assays using 48 HIV-1 positive patients 
(117 plasma specimens) from South Africa suggests that these assays may provide less 
expensive and simpler alternatives for monitoring the response to therapy in a 
predominantly HIV-1 subtype C infected population. The scatterplots in Figureure 3.2 
show heteroscadasticity (increasing variance with increasing log10 RNA loads) and 
insufficient sensitivity of both assays. Based on these results obtained for 117 samples, the 
quantitation limit for the p24 antigen assay is ~ 5 log10 and for the RT assay the sensitivity 
cut off is ~ 3.5 log10. The variability found for the alternative assays may be due to the fact 
that all three assays compared in this study measure completely different parameters of 
viral replication. The RT assay measures the activity of the virus-encoded enzyme, reverse 
transcriptase (RT), The HDp24Ag assay measures the p24 antigen either virion bound or 
relatively free circulating as immune complexes (Schüpbach et al., 1994) and the Roche 
RNA assay quantitates virion associated RNA in the blood plasma. Nevertheless, the 
mixed effects model shows a significant association between p24 antigen level, RT 
concentration and RNA viral load. Another evaluation of these alternative assays 
conducted in Burkina Faso, West Africa revealed good agreement between the RNA assay 
(Roche Amplicor) and RT activity quantitation, but poorer agreement with the p24 antigen 
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assay. This study also showed a similar pattern of HIV-1 viral load in the follow-up 
patients using the RNA and the RT activity assays (Lombart et al., 2005).Therefore, these 
alternative assays are more useful for the longitudinal monitoring of patients on ARV 
therapy rather than for a once off measurement of HIV-1 viral load. This study revealed 
that both assays under evaluation show a significant decline in viral load values over time 
in response to therapy (Figureure 3.3 A and B). In addition all 3 assays show the expected 
negative correlation with CD4 count (Holland et al., 2000), a conventional measure of the 
patient’s response to therapy (Johanson et al., 2001; Schüpbach et al., 2003). The 
specificity of both alternative viral load assays was not addressed in this study and requires 
additional exploration in future evaluations.  
 
Since this evaluation the HiSens™ HIV-1 p24 Ag Ultra assay and the reverse transcriptase 
(RT) enzyme activity assay have undergone further development and the new generations 
of these assays, especially the RT activity assay, have a ten-fold improved sensitivity. This 
improvement in sensitivity of the RT activity assay is achieved due to improved washing 
of the captured virions, an improved virion lysis procedure, doubling the amount of the 
template and prolonged time for RT assay (Malmsten et al., 2005; Sivapalasingam et al., 
2005). It was shown that the p24 antigen assay has good reproducibility and a sensitivity 
limit of 100% at ≥ 30 000 copies/ml when compared to the Versant bDNA assay (version 
2.0 or 3.0. Bayer Corp.) (Respess et al., 2005). The study was conducted comparing 
performance of the newer generation kits of both alternative assays to the Roche Amplicor 
assay (Jennings et al., 2005). Sensitivity limit of 400 copies/ml was demonstrated for the 
RT activity assay (the ExaVir™ Load assay, version 2), which is comparable to the Roche 
Amplicor standard assay. The RT activity assay showed excellent correlation with the 
Roche Amplicor assay. The same group of investigators demonstrated poorer sensitivity of 
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the p24 antigen assay with a limit of detection at approximately > 250 000 copies/ml (~ 5 
log10) and lower correlation with the RNA assay (Roche Amplicor) when compared to the 
RT activity assay. It was also suggested that more data is required to understand the utility 
of the p24 antigen assay for monitoring patients on ART, since the assay measures virion-
associated and non-virion-associated p24 antigen and the levels of both types of antigens 
may be influenced by therapy (Jennings et al., 2005).  
 
A major consideration when evaluating these alternative assays is to estimate not only the 
cost but also the complexity of conducting the investigations. In this study careful attention 
was paid to the technical aspects of the proposed viral load methodologies. The RNA assay 
is automated to a large degree allowing for easier implementation and standardization. 
However, the equipment is sophisticated and costly and requires an appropriate laboratory 
design to avoid cross contamination commonly seen with PCR technology. Both 
alternative assays can be implemented without a specialized laboratory set-up and use less 
expensive laboratory equipment such as an incubator, heating block, pipettes, ELISA plate 
reader and washer and a computer for quantitative data analysis. Most medium tier 
laboratories usually possess this type of equipment already. However, the disadvantages 
that remain for the RT assay include (i) time taken to complete the assay for only 32-30 
samples (2-3 days); (ii) the large sample volume required for analysis may pose problems 
in the pediatric treatment environment or in cases where a repeat test is required. Although 
the new generation RT assay has an improved sensitivity the technical procedure of the 
assay hasn’t changed. The p24 antigen assay has the advantage of facilitating a higher 
throughput than either the RT or RNA quantitation assays. The disadvantages of this assay 
include: (i) the variability of the p24 antigen results for a given RNA viral load (Figureure 
3.2 A) and (ii) the fact that the external virus disruption (lysis) buffer used to improve the 
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sensitivity of the assay is not currently commercially available. In fact, two studies 
conducted by different groups showed weak correlation between p24 antigen levels and 
viral RNA in patients on HAART when the HD p24 antigen assay was performed without 
the external virus disruption buffer - SNCR buffer (Bonard et al., 2003; Prado et al., 2004). 
By contrast, the study where the external lysis buffer was used reports on detectable levels 
of p24 antigen reflecting viral rebound and an inverse correlation with CD4+ T cell loss 
during structured treatment interruption (STI) (Schüpbach et al., 2005). Recent work 
demonstrated that the use of the external virus disruption buffer (SNCR buffer) 
significantly increases detection of particle associated HIV-1 p24, thus improving 
quantitation of p24 concentrations in samples with medium to high HIV-1 RNA 
(Schüpbach et al., 2006).A shortfall of both of the alternative assays is the lack of 
automation which may significantly increase the person-person variation and thus affect 
reproducibility of these assays. Based on our experience it will require a highly skilled and 
experienced technologist to obtain accurate and reproducible results using these alternative 
viral load assays.  
 
Full economic costing of each assay is required before implementation in any laboratory 
environment and should include: (i) the cost of reagents and consumables, (ii) labor, (iii) 
equipment and maintenance, (ix) transport of samples and fixed overheads. Preliminary 
estimation shows that the cost for reagents for the RT assay (per test) is approximately $10 
– 20 and for the p24 antigen assay ~ $10, which is significantly less expensive than the 
Roche Amplicor assay (~ $75). These costs may vary substantially in each geographical 
region and informed decision making thus needs to be facilitated to ensure the choice of an 
appropriate technology is based on costs, specimen volume and skill set available. Based 
on the data generated in this study, both alternative viral load assays represent viable 
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alternatives for further exploration in certain resource-constrained environments, such as 
the medium tier laboratories in SA.  
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CHAPTER 4  
 
Development and preliminary evaluation of a novel isothermal 
amplification technique for detection of human 
immunodeficiency virus type 1 RNA in plasma  
The most challenging and interesting component of this PhD project was the development 
of an innovative primer design named Loop Mediating Primer (LMP) that was applied to a 
novel isothermal amplification technique termed Reverse Transcription Loop Dependant 
Amplification (RT-LDA). This technique was specifically designed to amplify HIV-1 
RNA for a novel NAAT based point - of - care (POC) assay for early diagnosis of acute 
HIV-1 infection. This chapter describes a proof - of - concept study for two versions of the 
LMP design and two versions of the RT-LDA technique that were optimised and evaluated 
using in vitro transcribed RNA containing 128 bases of HIV-1 gag gene (ES RNA). 
According to the POC HIV-1 RNA assay design, detection of the amplification product is 
performed using nucleic acid lateral flow (NALF) and superparamagnetic particles as 
reporter molecules. Signal acquisition from these particles is achieved using the Magnetic 
Assay Reader (MAR™). Detection of RT-LDA amplification product was performed using 
FRET hybridization probes on the LightCycler® platform. This detection format is cost 
effective, sensitive and sequence specific and was chosen due to the unavailability of the 
MAR™ instrument in South Africa. Visual detection of amplicons using dipsticks was 
performed at the final stage of this proof - of - concept study to confirm compatibility of 
this novel amplification technique with the NALF detection format.  
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4.1 Background  
4.1.1 Assay Design  
The relevance of developing a NAT based POC assay for early diagnosis of acute HIV-1 
infection in the South African population was discussed in Chapter 1 of this thesis. The 
overall aim of this project was to develop an automated, POC assay for detection of HIV-1 
RNA in plasma. The proposed POC HIV-1 RNA assay design took into account the main 
requirements of POC testing. In general, POC tests are rapid, require minimal training, are 
easy to perform and do not require a laboratory set-up. A schematic representation of the 
assay design is shown in Figureure 4.1. Furthermore, it is envisaged that the entire process 
will be performed in one closed, automated system. According to the provisional design 
the POC HIV-1 RNA assay includes the following steps:  
 Separation of plasma from patient whole blood collected in an EDTA tube;  
 Filtration of plasma into a test tube containing lysis reagents for isolation of viral 
RNA;  
 An isothermal amplification of HIV-1 RNA using RT-LDA;  
 Addition of lyophilization buffer, detection probes, and other components required 
for NALF;  
 NALF using nitrocellulose dipsticks (NALF strips) for capture and detection of 
amplification product labelled with superparamagnetic beads ;  
 Final detection of the captured product using a magnetic assay reader (MAR™) – 
signal acquisition.  
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Figureure 4.1: Point - of - care RNA detection assay for diagnosis of HIV-1 – assay design.  
Main steps: 1) EDTA whole blood collected; 2) viral RNA isolated from plasma; 3) RNA 
is transferred to the next tube for an isothermal amplification using a novel RT-LDA 
method, NALF components are added to the same test tube; 4) after RT-LDA the 
amplification mix is applied to a dipstick for NALF; 5) after completion of lateral flow 
HIV specific product is captured on a dipstick and detected by the MAR™ instrument.  
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This assay design combines a few novel approaches to POC diagnosis of HIV infection. In 
particular, the use of the Magnetic Assay Reader (MAR™) for POC HIV diagnostics is 
novel and was given a priority due to its technical parameters. An innovative MAR™ 
technology is patented by Quantum Design Inc. (QD/MBS, San Diego, USA). The MAR™ 
platform provides quantitative results by the detection of superparamagnetic particles as 
reporter elements (i.e. labels) which are bound to the analyte (Figure 4.2 A, B and Figure 
4.3). The intensity of the magnetic signal (Figure 4.2 C) can be directly correlated to the 
amount of analyte in the sample. The platform offers sensitivity 10-1000 fold greater than 
visual assays. The MAR™ instrument can be miniaturized, which makes it easily 
adaptable for POC testing (Figure 4.2 D). MAR™ technology is compatible with well-
known assay formats such as lateral flow (Figure 4.2 A) and ELISA. The POC HIV RNA 
test under development employs a lateral flow detection format in combination with the 
MAR™ platform (Figure 4.1). An initial feasibility study for this project was conducted in 
collaboration with British Biocell International (BBI, Cardiff, UK; 
http://www.bbigold.com). BBI provide expertise in lateral flow and custom particle 
(superparamagnetic, latex, gold colloid, etc) conjugation technologies. BBI and 
MagnaBioSciences, LLC, a subsidiary of Quantum Design, Inc. (QD/MBS, San Diego, 
USA) have formed a strategic alliance to market a feasibility service to evaluate BBI’s 
proprietary conjugations and/or lateral flow in combination with QD/MBS MAR™ 
platform for a particular assay in a fast and cost-effective way. The first feasibility study 
aimed to evaluate probe design (Figure 4.3) proposed for the POC HIV-1 RNA test., 
optimise NALF conditions and estimate preliminary sensitivity of detection using the 
MAR™ instrument. This was performed using two structurally different synthetic single 
stranded DNA (ssDNA) targets (looped and linear ssDNA molecules that imitate real 
amplicons) containing HIV-1 sequence. Another feasibility study was initiated in parallel 
 124
and focused on developing a novel type of amplification technique suitable for the 
proposed POC HIV-1 RNA test.  
 
 
 
 
Figure 4.2: Magnetic Assay Reader (MAR™). A and B: Induction of a magnetic signal by 
exposing the superparamagnetic particles to a magnetic field and acquisition of the signal 
by the MAR™ instrument; C: A magnetic signal registered by the MAR™ from the 
labelled analyte captured on the NALF dipstick; D: A hand held version of the MAR™ 
instrument. (Images were adapted from: http://www.qdusa.com/index.html).  
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Figure 4.3: Detection of amplicons using lateral flow dipsticks and superparamagnetic 
conjugates. The detection probe labelled with biotin and the capture probe labelled with 
DNP bind to the partially looped ssDNA amplicons. Anti-DNP antibodies that are striped 
on the dipsticks capture the entire “amplicon/probes” hybridisation product. Anti-biotin 
antibodies labelled with the superparamagnetic conjugates bind to the biotin on the 
detection probe allowing visual and/or MAR™ based detection of the product captured on 
the dipsticks.  
 
4.1.2 Novel isothermal amplification technique for POC HIV-1 RNA test  
The term “isothermal’ indicates that the entire amplification process is performed under 
one constant temperature. Even though, many isothermal amplifications use an initial 
denaturation at high temperature or an initial reverse transcription (RT), ligation steps at a 
lower temperature, compared to PCR amplification, there is no temperature cycling. 
Therefore, an isothermal amplification does not require a thermocycler and it can be 
performed in a simple heating block. This feature makes an isothermal amplification 
approach adaptable to the POC testing format. There is a variety of published and 
commercially available methods for isothermal amplification of nucleic acids. Approved 
isothermal amplification techniques that are most commonly used for diagnostics may be 
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classified into two major groups: signal amplification and target amplification. Signal 
amplification methods include: branched DNA (b-DNA) amplification ( see Chapter 1, 
section 1.2), hybrid capture (Wick, 2000), cycling probe technology – CPT (Fong et al., 
2000; Modrusan et al., 2000), rolling circle amplification – RCA (Blab et al., 2004; 
Christlan et al., 2001; Zong et al., 2001), ramification amplification (Zong et al., 2001) and 
circle-to-circle amplification (Dahl et al., 2004). Among widely used target amplification 
methods are: NASBA (see Chapter 1, section 1.2), transcription mediated amplification - 
TMA (Emery et al., 2000), strand displacement amplification - SDA (Hellyer et al., 1999; 
Nadeau et al., 1999; Nycz et al., 1998; Pilcher et al., 2004a; Spargo et al., 1996; Walker, 
1993; Walker et al., 1995; Walker et al., 1992; Walker et al., 1996; Walker et al., 1994), 
loop-mediated isothermal amplification - LAMP (Notomi et al., 2000; Thai. et al., 2004) 
and Helicase - dependant isothermal DNA amplification - HDA (Vincent et al., 2004). The 
techniques listed above differ in their design and technical characteristics such as 
amplification efficiency and type of amplicons produced. Based on the proposed design for 
the POC HIV-1 RNA test (Figure 4.1), the amplification technique has to meet certain 
requirements. Firstly, it has to provide great power of amplification so that even low 
concentrations (3-4 log10 copies/ml) of virus can be amplified sufficiently in a short period 
of time. Secondly, an amplification method has to convert viral RNA into the short 
(maximum 200 bases), ssDNA or RNA amplicons in order to be readily compatible with 
the lateral flow detection format. To date, none of the available isothermal amplification 
methods fulfils both requirements at the same time. Signal amplification techniques are 
usually linear and take at least a few hours to provide sufficient sensitivity. Amplicons 
produced with these techniques are either long stretches of DNA (e.g. RCA) or complex, 
“branched” molecules (e.g. bDNA). Isothermal target amplification techniques which 
utilize the concept of strand displacement amplification (e.g. SDA, LAMP) show greater 
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efficiency than the techniques based on RNA transcription (e.g. NASBA, TMA). SDA and 
LAMP methods have good sensitivity, but in their existing format these methods cannot be 
used for the proposed POC HIV-1 RNA test since final amplification products are double 
stranded DNA (dsDNA) fragments and long stretches of dsDNA respectively. In addition, 
to accelerate the development process, the use of commercially available enzymes is 
desirable. SDA provides great power of amplification that would be suitable for the 
designed POC HIV-1 RNA test. During the exponential, cycling phase of SDA the typical 
target doubling time is 20-30 seconds and thus a 10 billion-fold amplification of specific 
targets can be achieved in less than 15 minutes (Spargo et al., 1996). Therefore, to achieve 
significant amplification it was decided to utilize the combination of enzymes used in SDA 
as well as the concept of including a nickable site in the primer sequences for a novel 
amplification. Figure 4.4 illustrates the mechanism of strand displacement amplification. 
SDA makes use of two enzymes – BsoBI restriction enzyme and Bst DNA polymerase that 
possesses the ability to synthesize new DNA strands and simultaneously displace the 
existing strand. In the case where RNA is used as a template the RT step is performed by 
the third enzyme – AMV (Avian Myeloblastosis Virus) reverse transcriptase (RT – SDA). 
Both SDA and RT-SDA consist of two phases (target generation and exponential target 
amplification) and employ four primers (a pair of bumping primers and a pair of primers 
containing a nickable site; see Figure 4.4). During the second, cycling phase of SDA 
dsDNA amplicons accumulate exponentially (Hellyer et al., 1999; Nadeau et al., 1999; 
Nycz et al., 1998; Spargo et al., 1996; Walker, 1993; Walker et al., 1995; Walker et al., 
1992; Walker et al., 1996; Walker et al., 1994).  
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Figure 4.4: Strand Displacement Amplification (SDA) (Adapted from Schweitzer and 
Kingsmore, 2001). In the target generation phase (top panel) of SDA, a dsDNA target (1) 
is denatured and hybridized with two primers (2). One primer (B1) is designated as a 
‘bumper’ primer, and the other primer (S1) contains a BsoBI restriction enzyme sequence 
5′ to the target binding region. The B1 (3) and S1 (4) primers are simultaneously extended 
by the thermostable enzyme Bst DNA polymerase in the presence of thiolated dCTP. 
Extension from the bumper primer displaces the S1 extended product, which can then 
hybridize to the opposite strand primers, B2 and S2 (5). Extension of both of these primers 
produces species 6, which is utilized in the exponential target amplification phase of the 
reaction (lower panel). The strand that has been extended from the S1 primer is nicked by 
BsoBI (7), but the complementary strand is refractory to cleavage owing to the presence of 
a thiolated dCTP within the restriction site. DNA polymerase binds to the nick and begins 
synthesis of a new strand while displacing the downstream strand (8—10). This recreates 
the double-stranded species 7, and the process repeats. The displaced strands bind to 
opposite strand primers, thus producing exponential amplification.  
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The design of a novel isothermal amplification technique - RT-LDA, envisages converting 
HIV-1 RNA into short, ssDNA molecules (Figure 4.5) with high efficiency. In summary 
the characteristic features of this technique and differences from SDA are described below:  
 RT is performed using only one HIV-1 sequence specific primer and a type of 
AMV enzyme that has both RT and RNase H activity (H+). No bumping primers 
are used for RT-LDA as opposed to conventional SDA. Instead, cDNA (anti-sense 
sequence) is released from the initial RNA/cDNA complex due to RNase H activity 
of AMV RT, which also makes the method different from SDA (Figures 4.6 and 
4.7);  
 RT-LDA is achieved mainly due to the innovative primer design - LMP. One of the 
primers has a 5’ overhang containing a sequence complementary to a sequence of a 
DNA strand extended from this primer (Figure 4.5). As a result of this primer 
modification the displaced amplicons assume a “loop” conformation at their 3’ end. 
This “looped” structure prevents the displaced amplicons from binding to a 
complementary primer and thus preserves their single stranded structure;  
 Due to LMP design this amplification technique (RT-LDA) does not have an 
exponential, cycling phase, which is characteristic for conventional SDA (Figure 
4.4);  
 Final amplification product generated with RT-LDA is represented by partially 
“looped”, ssDNA amplicons (Figure 4.5; 4.6 and 4.7) as opposed to dsDNA 
amplicons produced by SDA. A characteristic feature of this isothermal 
amplification is the generation of partially looped” ssDNA amplicons, which is 
reflected in the name of this technique – reverse transcription loop dependant 
amplification (RT-LDA).  
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Figure 4.5: Loop Mediating Primer (LMP) design for RT-LDA.  
1) Different parts of a primer that have different functions are colour coded. Red - a short 
artificial (i.e. non-target specific) sequence that serves to prevent a displaced amplicon 
from self-priming; blue - a sequence complementary to a strand extended from this primer 
(so called “loop” overhang); green - a short artificial sequence that forms a link between 
the “loop” overhang and a forward primer; black - HIV-1 sequence specific forward 
primer. 2) Forward primer with an overhang (parts indicated in red, blue and green) binds 
to the anti-sense cDNA strand and gets extended. Extension of a forward primer produces 
a dsDNA target. An overhang sequence also gets extended by Bst polymerase from the 3’ 
end of the cDNA strand. 3A) Anti-sense strand gets displaced from the nickable site 
(similarly to SDA, see Figure 4.4).The displaced anti-sense strand, which now can be 
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termed an anti-sense ssDNA amplicon contains a sequence complementary to an overhang 
of a forward primer. 3B) The two complementary sequences within one amplicon are in 
close proximity and the 3’ end of the anti-sense amplicon folds forward and hybridizes to 
its complementary sequence (indicated in blue). As a result a partially “looped” ssDNA 
amplicon is formed. The “loop” structure at the 3’ end of an amplicon prevents it from 
binding to another forward primer and from getting converted into a dsDNA target. Thus, 
most of the displaced anti-sense amplicon remains single stranded.  
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Figure 4.6: RT-LDA - design for linear amplification.  
HIV-1 RNA is an initial template for amplification. A reverse primer (R) comprises of 
three regions, starting from the 5’ end they are as follows: an artificial (random) sequence, 
sequence, recognition site (so called nickable site) for the restriction enzyme BsoBI 
(indicated as a box), and HIV-1 sequence specific (reverse) primer. Reverse primer (R) 
binds viral RNA and gets extended by the RT activity of AMV reverse transcriptase 
enzyme (RT). A double stranded RNA/cDNA hybrid is formed. The RNase H activity of 
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AMV digests viral RNA in the hybrid leaving only cDNA (anti-sense sequence). (AMV 
H+). A forward primer (F) (see Figure 4.4 for the detailed description) converts cDNA into 
dsDNA target (LDA 1). Due to the addition of chemically modified dCTPs (dCTP - αS) in 
the reaction mix the double stranded BsoBI recognition site is hemithiolated and only gets 
nicked by the restriction enzyme (see also Figure 4.3). Bst DNA polymerase, which also 
has strand displacement ability, extends the 3’-end of a newly formed nick and at the same 
time displaces the existing, anti-sense DNA strand (LDA 2). During this process of DNA 
strand extension/displacement the BsoBI nickable site gets regenerated and can be nicked 
over and over again, thus producing a large number of “looped” anti-sense ssDNA 
amplicons. The displaced amplicons assume a partially “looped” structure due to a 
carefully designed overhang of a forward primer, as described in Figure 4.4. Formation of 
partially “looped” amplicons prevents binding of the forward primer to the anti-sense 
amplicon and thus prevents the entire amplification process from cycling. The RT-LDA 
design illustrated in this figure provides for the accumulation of partially “looped” ssDNA 
anti-sense amplicons in a linear fashion.  
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Figure 4.7: Semi-cycling RT-LDA.  
Conversion of the initially designed linear amplification technique into semi-cycling was 
possible due to another novel design applied to the forward primer. Similarly to the 
original primer design (Figure 4.5) the new design includes an HIV-1 specific forward 
primer (black) with a 5’ overhang, but the structure of the overhang is different. From the 
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5’ end the primer overhang contains” an artificial” sequence (black), BsoBI recognition 
site (red box) and a sequence complementary to an amplicon (“loop” sequence) (blue) and 
a very short linking sequence (green). The RT step for the semi-cycling amplification is 
identical to the linear amplification (Figure 4.6). A modified forward primer that binds to 
cDNA (anti-sense) is extended by Bst polymerase and as a result a dsDNA target is formed 
(T1). The strands complementary to the BsoBI restriction site are generated during the 
primer/strand extension and thus contain modified dCTP - αS (thiolated), which prevents 
BsoBI from cutting dsDNA. Instead, only the unmodified nickable sites (in all targets - T1, 
T2 and T3) from the primers get nicked (single stranded nick) by the enzyme. T1 dsDNA 
has two nickable sites – one on a sense strand (forward primer; red box) and another one 
on an anti-sense strand (reverse primer; black box). Both nickable sites are recognized and 
nicked (cleaved) by BsoBI restriction enzyme. Next, the 3’- end of each nicked strand 
(sense and anti –sense) is extended by Bst DNA polymerase and the existing strands are 
displaced. The displaced sense strand forms a partially “looped” amplicon that has a 
sequence complementary to a reverse primer. The reverse primer binds this sense amplicon 
and converts it into dsDNA target (T2). T2 has only one BsoBI restriction site and a 
process on nicking and strand displacement/ polymerization occurs on the T2 target in a 
similar way as described above. A cascade of processes between formations of T1 and T2 
represents a linear phase of a RT-LDA. The displaced anti-sense amplicons have a 
sequence at their 3’- end which is complementary to the “loop” overhang of a forward 
primer. Thus, once displaced these amplicons assume a partially “looped” structure. The 
anti-sense strand, which is displaced from T1 possesses a 3’ sequence complementary to 
the entire forward primer and thus a forward primer binds to the anti-sense amplicon. 
Extension of a forward primer converts the anti-sense strand into dsDNA target (T3). 
Target T3 produces “looped” sense amplicons similarly to T1. These amplicons bind to the 
reverse primers which lead to the formation of dsDNA targets identical to T2. The cascade 
of processes, from formation of T1 to T3 and then to T2, represents a semi-cycling phase 
of this amplification technique. T2 generated during a semi-cycling phase also keeps 
producing “looped” ssDNA anti-sense amplicons. During this type of amplification both 
linear and semi-cycling phases of RT-LDA occur simultaneously and generate large 
amounts of the final amplification product - partially “looped” ssDNA anti-sense 
amplicons. The semi-cycling design provides for at least a 3-fold increase in magnitude of 
amplification.  
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Two versions of the RT-LDA design were made and evaluated: the initial design for linear 
amplification and the final design for the semi-cycling amplification technique. Figures 4.6 
and 4.7 provide a detailed description of the linear and semi-cycling RT-LDA designs, 
respectively. Both designs produce the same final product – partially “looped” ssDNA 
amplicons with anti-sense sequence, but the amount of final RT-LDA product is greater in 
the semi-cycling technique. The sole difference between linear and semi-cycling RT-LDA 
is in the design of a forward primer (Figure 4.7 A). This type of primer design leads to 
partial cycling of the reaction via formation of 3 types of dsDNA targets. Semi-cycling 
RT-LDA includes two simultaneously occurring phases: linear and semi-cycling phase 
(Figure 4.7 B). The second design for semi-cycling RT-LDA was made at the later stage of 
the assay development in an attempt to improve the power of amplification of this 
technique.  
 
The main challenge of this project was in obtaining experimental proof for the LMP 
design. The exact parameters (e.g. length of an overhang, etc) for a novel type of primer 
with a “loop” overhang had to be established experimentally. The “loop” structure must be 
sufficient to preserve the single stranded amplicons and at the same time it must not 
interfere with extension of the primer. Reaction conditions of RT-LDA suitable for 
maintaining four types of enzymatic activities also required optimization.  
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4.2 Materials and Methods  
4.2.1 Isothermal Amplification - RT-LDA  
4.2.1.1 Primers  
Primers were designed for a sequence of an in vitro transcribed RNA that represents an 
external quantitation standard (ES RNA) used for the LightCycler® viral load assays – the 
FRET assay and the LUX assay (see chapter 2). The ES RNA molecule includes a 128 bp 
region of HIV-1 gag gene (Figure 2.5). Primer names were assigned based on when the 
primer was designed during the development (e.g. forward primer named “Fw#1” was the 
initially designed primer; Fw #4A – represents the final primer design). Sequences of the 
primers used for RT-LDA reactions are as follows (HIV specific sequence of the primers is 
underlined):  
Forward #1  
5’ – AACAGCCTCC TCATTGATTG TATCTTTTAA CATGAAACAT 
CAAGCAGCCA TGCAAAT – 3’ (57 mer)  
 
Forward #1A  
5’– AGA ATT GAT TGT ATC TTT TAA CAT ACA TCA AGC AGC CAT GCA AAT – 
3’  
(45 mer) 
 
Forward #1B  
5’ – ACC TGT ATC TTT TAA CAT ACA TCA AGC AGC CAT GCA AAT - 3’ (39 mer)  
 
Forward #2  
5’ – GATATTCTGC AGGAAATACA   ATCAATGAGG AGGC T – 3’ (35 mer)  
 
Forward #3  
5’ – GAG GCA GCC TCC TCA TGC AAA TGT TAA AAG ATA CAA TCA AT- 3’  
(41 mer)  
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Forward #3 (a “new” version) - #3A  
5’- TCT CC TCC TCA T ACT TGT TAA AAG ATA CAA TCA AT- 3’ (35 mer)  
 
Forward #1C  
5’ – GGC C TTT TAA CAT AGA ACA TCA AGC AGC CAT GCA AAT - 3’ (37 mer)  
 
Forward # 4A (a version of #3A with the BsoBI nickable site (blue))  
5’- AAC CTA TCC GGA CAA CGA TAA CCC GGG CC TCC TCA T ACT TGT TAA 
AAG ATA CAA TCA AT- 3’ (59 mer)  
 
Reverse #R1 (blue – BsoBI nickable site)  
5’- GTCGACTTGC ATGCATGT CTC GGG TGTCAC TTCCCCTTGG TTCT CTCA – 
3’  
(48 mer)  
 
4.2.1.2 RT-LDA reaction conditions  
RT-LDA amplification reactions were performed in a total volume of 50 µl comprising of 
20 µl of template RNA and 30 µl of reaction mix. The reaction mix was assembled as 
follows: 35 mM Potassium phosphate buffer (K1PO4; Appendix B), 5% v/v dimethyl 
sulfoxide (DMSO; Sigma-Aldrich, USA), 4% v/v glycerol (Promega, Madison, WI, USA), 
5 µg acetylated bovine serum albumin (AcBSA; Promega, Madison, WI), 0.8 mM 2’-
deoxycytidine 5’-O- (1- thiotriphosphate) (dCTP - αS; Amersham Biosciences, 
Piscataway, NJ, USA), 0.6 mM dUTP, 0.2 mM each dATP and dGTP (Promega, Madison, 
WI, USA), 7.5 mM magnesium acetate (MgOAc2; Sigma-Aldrich, USA), 7.5 units AMV 
reverse transcriptase (USB Corp., Cleveland, Ohio, USA), 32 units BsoBI restriction 
enzyme (New England BioLabs Inc., USA), 20 units Bst DNA polymerase (New England 
BioLabs Inc., USA), 1µg T4gp32 ssDNA binding protein (USB Corp., Cleveland, Ohaio, 
USA), forward and reverse primers 0.75 µM each. All reaction components and RNA 
template were mixed and incubated at 53 ºC for 1 hour using a heating block (Labcon, 
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South Africa). Synthetic in vitro RNA (ES RNA) described in chapter 2, section 2.2.2, was 
used as a template for RT-LDA reactions.  
 
4.2.1.3 Detection of RT-LDA amplification product using FRET hybridization probes and 
Nucleic acid lateral flow (NALF)  
Detection of RT-LDA product using FRET hybridization probes and the melting curve 
analysis was performed using the LightCycler® platform, version 1.2 and the software 
version 4 (Roche Applied Science, Mannheim, Germany). This detection format was 
selected since it provides sequence specific detection and thus confirmation of the 
amplification product. The FRET probe format is also more rapid and allows better 
differentiation between dsDNA targets (e.g. T1-T3; Figure 4.7) and ssDNA amplicons than 
agarose or polyacrylamide gels. FRET hybridization probes were designed for the anti-
sense amplicons with the following sequences:  
Ampi/FRET 2032:  
5’ – TAG AAT ACA TCC AGI ICA TGC GG – Fluorescein – 3’  
Ampi/FRET 2033:  
5’- LCRed -640 – CCT IIT GCA CCA GGC CTA ATG AG – p – 3’ (I = Inosin)  
 
Probes were manufactured by Metabion International AG (Germany). Reconstituted 
probes, each at 100 µM concentration, were kept at -20 ºC until use. The post amplification 
detection using FRET probes was performed in a 30 µl volume using 27 µl of 
amplification reaction and 0.5 µM of each probe. The profile of the melting curve analysis 
was as follows: 95ºC for 5 s, 40ºC for 1 min and gradual heating up to 85-90ºC with 
0.1ºC/s ramping rate and continuous fluorescent signal acquisition. Melting curves were 
viewed using a combination of channels -640/Back530.  
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Reagents for nucleic acid lateral flow, including buffers, magnetic conjugate, nitrocellulose 
DNP striped half dipsticks, capture and detection probes were provided by British Biocell 
International (Cardiff, UK). Sequences of the LF probes are as follows:  
Ampi 2032 – Detection probe (two inosines):  
5’ Biotin TCTGC ACA TCC AGI ICA TGC GGG – 3’  
Ampi 2033 – DNP – capture probe (two inosines):  
5’ – GCC TII TGC ACC AGG CCT – DNP- 3’  
 
The positive control for NALF detection was also supplied by BBI. The positive control 
(ampi29) was made to imitate RT-LDA amplicons. Ampi29 represents a synthetic ssDNA 
molecule that has a partially looped “structure” and the sequence similar to the real 
amplification product. NALF detection was performed according to the protocol developed 
by BBI (proprietary) during the feasibility study for the POC HIV RNA assay.  
4.2.2 Conventional PCR for detection of RT - LDA product  
PCR was performed in a 50 µl volume using 25 µl of ReadyMix™ Taq PCR reaction with 
MgCl2 (Sigma, St. Louis, Missouri, USA), 0.5 µM forward and reverse primer, 15 µl of 
template (diluted RT-LDA product) and PCR grade water from the kit (Sigma). Different 
primers were used for different experiments and the exact combinations of forward and 
reverse primers used for particular experiments are described in section 4.3. 
PCR was performed using the MyCycler™ thermal cycler (BIO-RAD Laboratories, Inc., 
USA) according to the following profile: initial denaturation at 95ºC for 3 min and than 40 
cycles of amplification with denaturation at 95ºC for 30 s, annealing at 52ºC for 30 s, 
extension at 72ºC for 30s and final extension at 72ºC for 7 minutes.  
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Detection of PCR product was performed using high resolution MetaPhor® gels (Parry et 
al., 2001; Tatt et al., 2000) and conventional agarose gel electrophoresis. Fifteen 
microliters of amplification product were mixed with 5 µl of the gel loading dye 
(Fermentas UAB, Lithuania) and loaded onto the 1-2% MetaPhor® agarose (BioWhittaker 
Molecular Applications, Rockland, ME, USA) gel prepared with 1xTBE buffer (diluted 
from 10xTBE stock; Fermentas UAB, Lithuania) and 3 µl of ethidium bromide stock 
solution (10 mg/ml; Sigma –Aldrich., St. Louis, Missouri, USA) per 100 ml of gel. 
Agarose gel electrophoresis was performed at 100 V for 1-2 hours. Size verification of the 
product was performed by running 10 µl of the O’GeneRuler™ 50 bp DNA ladder 
(Fermentas, UAB, Lithuania) along side the sample. The gel was viewed under the UV 
light.  
 
4.2.3 Sequencing of RT - LDA product  
PCR product amplified using the RT-LDA reaction (see section 4.2.1.3) was used as a 
template for sequencing. Prior to sequencing the PCR product was excised from the 
MetaPhor® gel and purified using the MinElute™ Gel Extraction kit (Qiagen, GmbH 
Hilden, Germany) according to the manufacturer’s instructions. DNA was eluted in 10 µl 
of the elution buffer supplied in the kit.  
 
The sequencing reaction was performed with the Big Dye® Terminator version 3.1 cycle 
sequencing kit from Applied Biosystems (Foster City CA, USA) according to the 
manufacturer’s instructions, on the ABI Prism 3100-Avant Genetic Analyzer (Applied 
Biosystems). Primers used for sequencing are specified in the “Results” section (section 
4.3) when describing particular experiments. Sequence data analysis was performed using 
the Sequencing Analysis program, version 3.3 (Applied Biosystems) and assembled using 
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Sequencher program version 4.1.4 (Genecodes, Ann Arbor, MI). The edited sequence was 
aligned and compared with the DNA equivalent of the ES RNA sequence using the Clustal 
X program (http://bips.u-strasbg.fr/fr/Documentation/ClustalX).  
 
4.3 Results  
4.3.1 RT-LDA – optimisation and evaluation of a novel primer design for the 
linear type of amplification  
The initial experiments for optimisation of the RT-LDA reaction were performed using 
long incubation times and a two-step temperature profile with reverse transcription at 42ºC 
for 1 hour and amplification (strand displacement/polymerization) at 53ºC for 2 hours (3 
hours of RT-LDA in total). Template nucleic acid (i.e. ES RNA) was used at this stage of 
optimization only at high concentrations: ~ 4x107 and 4x108 copies/ml. Five forward 
primers (Fw#1, Fw#1A, Fw#1B, FW#2 and Fw#3) combined individually with the reverse 
primer (Rev#1) were first evaluated for the linear type of RT-LDA. Three out of five 
forward primers (Fw#1, Fw1A, Fw#1B) had the same HIV-1 specific sequence, but 
different lengths of the 5’ overhang. Forward primer Fw#2 is positioned more internally to 
Fw#1 and has the shortest “loop” overhang” with ~ 50% GC content. Primer Fw#3 is 
positioned between Fw#1 and Fw#2 and partially overlaps with primer Fw#2. Each of 
these primers was combined individually with the reverse primer Rev#1 in separate RT-
LDA reactions. Initial RT-LDA experiments revealed no amplification product for all five 
primer combinations using a 1% MetaPhor® gel and FRET probes for detection.  
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In order to exclude failure of amplification due to non-optimal RT-LDA conditions rather 
than a non-optimal primer design, the individual steps of the amplification reaction were 
assessed. To troubleshoot the RT step, ES RNA was reverse transcribed with the Rev#1 
primer using different concentrations of AMV enzyme. RT was performed for 1 hour at 
42ºC and 20 µl of undiluted RT reaction (cDNA) was than amplified by conventional PCR 
(see 4.2.2) using primers SKT145 and Rev#1. PCR product was confirmed using 1% 
MetaPhor® gel electrophoresis. Troubleshooting of the RT step revealed that 2.5 units of 
AMV enzyme used initially were insufficient and an optimal concentration of 7.5 units of 
AMV per reaction was established. Next, cDNA reverse transcribed with primer Rev#1 
under optimised RT conditions was PCR amplified using a set of primers SKT145/Rev#1. 
PCR product was incubated with BsoBI restriction enzyme at 53ºC for 3 hours. Digested 
and undigested PCR products were verified using 2% MetaPhor® gel electrophoresis 
(Figure 4.8). The presence of the digested product confirmed functional activity of BsoBI 
at 53ºC and the presence of a corresponding restriction site in the reverse primer Rev#1.  
 
Following this troubleshooting and optimisation of the RT step, RT-LDA reactions were 
performed using the combination of five forward primers described above and the Rev#1 
primer. Similarly to the first round of experiments no RT-LDA amplification product was 
detected for all primer combinations using MetaPhor® gel and FRET hybridization probes. 
Next, PCR was employed to confirm the presence/absence of RT-LDA product and to 
exclude insufficient sensitivity of the detection formats used. RT-LDA reactions were 
diluted 1:50 and 1:100 in molecular grade water and 15 µl of the diluted product was used 
for PCR as described in section 4.2.2. PCR was performed with the same primer 
combination that was originally used for each RT-LDA reaction (e.g. Fw#2/Rev#1, 
Fw#1A/Rev#1, etc.).
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Figure 4.8: MetaPhor® gel (2%) showing PCR products digested with BsoBI restriction. 
enzyme. Lane 1 – DNA ladder (50 bp); lanes 2, 3 – PCR product amplified from ES DNA 
(positive control), digested product (2) and undigested (3); lanes 4, 6 - digested PCR 
products amplified from the different cDNA templates; lanes 5, 7 – the corresponding 
undigested PCR products.  
 
For each primer combination the DNA equivalent of ES RNA (i.e. purified dsDNA 
amplification product obtained using ES RNA and a conventional RT-PCR) was used as a 
positive control and a corresponding RT-LDA no template control (NTC) sample was use 
as a negative control. PCR revealed the presence of RT-LDA product only in the reaction 
performed with the set of primers Fw#2 and Rev#1. Together with a specific amplification 
product the RT-LDA reaction and the blank sample revealed the presence of a non-specific 
product (data not shown). Since the non-specific product was found in a blank RT-LDA 
sample as well as in RT-LDA reaction it is likely to be due to the presence of partially 
complementary regions in primers Fw#2 and Rev#1 causing formation of this product 
under the low stringency isothermal amplification conditions. The specific RT-LDA 
product further amplified by PCR was excised from the gel, purified and used for 
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sequencing with a set of primers Fw#2 and Rev#1 (section 4.2.3). The nucleotide sequence 
of PCR amplified RT-LDA aligned with the ES DNA is shown in Figure 4.9.  These 
experiments demonstrated successful RT-LDA using a pair of primers Fw#2 and Rev#1. 
However, due to the presence of a non-specific amplification product the primer design 
required further improvement.  
 
In order to prevent formation of a non-specific product another two forward primers 
(Fw#3A and Fw#1C) were designed and evaluated in combination with the primer Rev#1. 
RT-LDA reactions were performed using a two step temperature profile and long 
amplification time as described above, and two combinations of primers: Fw#1C/Rev#1 
and Fw#3A/Rev#1. FRET hybridization probes revealed RT-LDA product amplified using 
both newly designed primers (Fw#1C and Fw#3A), but the fluorescent signals were weak 
(data not shown).  
 
The presence of RT-LDA product was confirmed with conventional PCR. RT-LDA 
samples amplified with primers Fw#1C/Rev#1and Fw#3A/Rev#1 and their corresponding 
blank samples were diluted 1:50 and 15 µl of each diluted sample was further PCR 
amplified with the corresponding RT-LDA primers. ES DNA was used as a positive PCR 
control for both combinations of primers. PCR product was detected in RT-LDA samples 
and in two positive control samples, but not in the RT-LDA blank samples (Figure 4.10). 
Non-specific product observed using initially designed primers was not present in any of 
these PCR samples. Significantly less amount of PCR product was generated using the set 
of primers Fw#1C/Rev#1 than using the set of primers Fw#3A/Rev#1, which reflects 
lower efficiency of  RT-LDA reactions performed with primers Fw#1C/Rev#1 (Figure 
4.10).  
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                  *        20         *        40         *        60       
ESDNA  : -----------------ACATCAAGCAGCCATGCAAATGTTAAAAGATACAATCAATGAG :  43 
RTLDA1 : ------------------------------------------------------------ :   - 
RTLDA2 : ---------------------TTCTCCTCCTCATACTTGTTAAAAGATACAATCAATGAG :  39 
RTLDA3 : TGGCCTTTTAACATAGAACATCAAGCAGCCATGCAAATGTTAAAAGATACAATCAATGAG :  60 
RTLDA4 : -------------------------------------TGTTAAAAGATACAATCAATGAG :  23 
                                                                            
                                                                            
                  *        80         *       100         *       120       
ESRNA  : GAGGCTGCAGAATGGGATAGAATACATCCAGTACATGCGGGGCCTATTGCACCAGGCCAA : 103 
RTLDA1 : ------GCAGAATGGGATAGAATACATCCAGTACATGCGGGGCCTATTGCACCAGGCCAA :  54 
RTLDA2 : GAGGCTGCAGAATGGGATAGAATACATCCAGTACATGCGGGGCCTATTGCACCAGGCCAA :  99 
RTLDA3 : GAGGCTGCAGAATGGGATAGAATACATCCAGTACATGCGGGGCCTATTGCACCAGGCCAA : 120 
RTLDA4 : GAGGCTGCAGAATGGGATAGAATACATCCAGTACATGCGGGGCCTATTGCACCAGGCCAA :  83 
                                                                            
                                                                   
                  *       140         *       160         *        
ESRNA  : ATGAGAGAACCAAGGGGAAGTGACA-------------------------- : 128 
RTLDA1 : ATGAGAGAACCAAGGGGAAGTGAGACCCGAGACATGCATGCAAGTCGACAA : 105 
RTLDA2 : ATGAGAGAACCAAGGGGAAGTGACACCCGAGACATGCATGCAAGTCGACA- : 149 
RTLDA3 : ATGAGAGAACCAAGGGGAAGTGACACCCGAGACATGCATGCAAGTCGACA- : 170 
RTLDA4 : ATGAGAGAACCAAGGGGAAGTGACACCCGAGACATGC-------------- : 120 
 
Figure 4.9: Sequence alignments. Nucleotide sequences obtained from four RT-LDA 
reactions performed using 4 different combinations of primers are aligned with the ES 
DNA sequence (i.e. DNA equivalent of ES RNA sequence; the ES RNA transcript that was 
used as a template in the RT-LDA reactions). The sequence of ES DNA (128 bp) is 
highlighted in green; test amplicon sequences (excluding primer binding sites) are 
highlighted in yellow. RT-LDA product n#1 (~ 105 bp) was amplified and sequenced 
using primers Fw#2/Rev#1; RT-LDA product n#2 - Fw#3A/Rev#1 (~ 149 bp); RT-LDA 
product n#3 - Fw#1C/Rev#1 (~ 170 bp); RT- LDA product n#4 was PCR amplified and 
sequenced using the primer set Fw#3A/Rev#1 (~ 120 bp). (Note: for the RT-LDA product 
n #4 primers Fw#3A was used instead of Fw#4a since it has a much shorter overhang to 
provide more optimal PCR and sequencing reactions).  
 
PCR products obtained with both sets of primers were gel purified and sequenced (see 
section 4.2.3). Sequencing revealed the presence of HIV-1 specific sequence in PCR 
products amplified using both sets of primers (Figure 4.9).  
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Figure 4.10: MetaPhor® gel (1%) showing PCR product amplified from the linear RT-
LDA reactions. Lane1- DNA ladder (50 bp); lane 2- ES DNA directly amplified by PCR 
using primers Fw#1C/Rev#1 (~ 170 bp; positive control for this primer set); lane 3 – PCR 
product amplified from RT-LDA using primers Fw#1C/Rev#1 (~ 170 bp specific product 
and ~ 90 bp non-specific product); lane 4 – corresponding RT-LDA blank sample 
containing only a non-specific product; lane 5 – ES DNA control directly amplified with 
primers Fw#3A/Rev#1 (~ 150 bp); lane 6 - PCR product amplified from RT-LDA using 
primers Fw#3A/Rev#1 (~ 150 bp); lane 7 – corresponding RT-LDA blank sample 
amplified by PCR (no product); lane 8 – PCR blank sample (no template control - NTC) 
showing no amplification product.  
 
4.3.2 RT-LDA – optimisation and evaluation of a novel primer design for the 
semi-cycling type of amplification  
The next phase in the development process involved a further modification that was 
applied to LMP forward primers and converted RT-LDA into a semi-cycling amplification 
method (Figure 4.7). Based on the results of preliminary optimisation and evaluation of the 
linear type of RT-LDA, the forward primer Fw#3A had the most optimal design. Thus, 
primer design for a semi-cycling RT-LDA incorporated the features of primer Fw#3A. In 
particular, primer Fw#4A includes the same HIV-1 specific sequence and the loop 
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overhang sequence as primer Fw#3A and in addition it has a nickable site for BsoBI and 
the random primer sequence (Figure 4.7). New forward primer Fw#4A designed for semi-
cycling RT-LDA was evaluated in combination with primer Rev#1 using high 
concentrations of ES RNA ~ 4x107 and 4x108 copies/ml and reaction conditions as 
described in section 4.3.1. Detection with FRET probes demonstrated the presence of 
amplification product in RT-LDA reactions performed with primer sets Fw#4A/Rev#1 and 
no product in the blank sample (Figure 4.11). The characteristic melting temperature (Tm) 
observed for RT-LDA amplicons using these FRET probes was ~ 68.8-71ºC. 
Unambiguous detection of RT-LDA amplicons with FRET probes was achieved and 
allowed further optimisation of this novel method. Thus, for optimization and preliminary 
evaluation of semi-cycling RT-LDA reactions only the post-amplification melting curve 
analysis with FRET hybridization probes was used for detection of product. RT-LDA 
reaction components such as DMSO and phosphate buffer affect the specificity and 
reproducibility of amplification. The concentration of DMSO was titrated from 4 to10% 
v/v and the concentration of phosphate buffer from 35mM to 50 mM. It was found that an 
increased concentration of DMSO requires higher concentrations of phosphate buffer to 
maintain sufficient amplification. Preliminary data obtained from the NALF/MAR™ 
feasibility study conducted by BBI demonstrated that higher concentrations of phosphate 
buffer decrease the intensity of magnetic signal detected with MAR™. Thus, high (8 -
10%) concentrations of DMSO that provide greater specificity of primer annealing 
required higher concentrations of phosphate buffer, which interferes with the MAR™ 
detection.  
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Figure 4.11: Melting curve analysis using FRET probes for detection of RT-LDA product.  
Melting curve profiles of both RT-LDA samples (blue and green lines) show the presence 
of the specific amplification product with a typical melting peak at ~ 69°C. No melting 
peak is observed in the RT-LDA blank sample (red line).  
 
Taking into account the desire for compatibility of RT-LDA with the MAR™ detection 
platform, the most optimal concentrations of both components were established at 35 mM 
for phosphate buffer and 5% for DMSO. Next, the concentrations of primers Fw#4A and 
Rev#1 were titrated in the range of 0.5 µM, 0.75 µM and 1 µM. Each concentration of 
primers was tested in duplicate using two ES RNA concentrations of 4x107 and 4x109 
copies/ml. A concentration of primers at 0.75 µM was found to be the most optimal for 
both concentrations of template ES RNA tested (data not shown). Further optimization of 
the RT-LDA aimed to reduce the total amplification time (< 3 hours) and to perform the 
amplification at only one constant temperature (53ºC). The initial experiment for time 
reduction was performed using two –step temperature profile as follows: RT step at 42ºC 
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for 30 min and amplification step at 53ºC for 1 hour. Total reaction time was halved from 3 
hours to 1.5 hours using this approach. For this experiment a wide range of ES RNA 
concentrations was used: 4x103, 4x104, 4x105, 4x106, 4x107, 4x108 copies/ml. RT-LDA 
amplicons were detected in all six samples using FRET probes and the melting curve 
analysis on the LightCycler® platform (Figure 4.12). Based on this successful experiment, 
further reduction in amplification time was attempted using only one constant temperature 
for both the RT and amplification steps. Two amplification profiles were tested for the RT-
LDA reactions: one at 53ºC with a total reaction time of 30 minutes and another profile 
was performed at 53ºC for 1 hour. Both amplification profiles were performed using a 
range of ES RNA concentrations: of 4x103, 4x104, 4x105, 4x106, 4x107, 4x108 copies/ml. 
RT-LDA product was detected using FRET probes in all samples (excluding a blank 
sample) amplified for 30 minutes and 1 hour respectively. Three RT-LDA samples were 
used for PCR to provide an additional confirmation of successful RT-LDA using the new 
times and temperature profiles. In particular, the RT-LDA samples containing ES RNA at 
a starting concentration of 4x107 and 4x106 copies/ml that were amplified for 1 hour and a 
sample containing 4x103 copies/ml of ES RNA amplified for 30 minutes were diluted 1:10 
and further amplified by PCR using primers Fw4A/Rev#1. PCR product for the RT-LDA 
sample of 4x107 copies/ml was clearly detected as a bright band on the 1% MetaPhor® gel; 
the other two samples revealed faint bands (data not shown).  
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Figure 4.12: Detection of RT-LDA product using FRET probes. After 90 minutes of RT-
LDA melting peaks (~ Tm at 68-69ºC) are observed in all samples from A1 to A6 with the 
corresponding concentrations: 4x103, 4x104, 4x105, 4x106, 4x107, 4x108 ES RNA 
copies/ml. These melting curve profiles reflect the presence of an HIV-specific 
amplification product detected with the FRET probes. The blank sample (blue line) shows 
a peak at ~ 84ºC, which is either due to the presence of a non-specific product or represents 
a detection artefact. This type of high melting peak was non-reproducible between the 
experiments.  
 
In order to confirm the presence of the specific product in these faint bands 18 µl of both 
(4x103 and 4x106 copies/ml) PCR reactions and 18 µl of the PCR product of the ES DNA 
control were used for FRET detection on the LightCycler®. The specific PCR product was 
detected using the melting curve analysis in all samples except the blank sample (Figure 
4.13).  
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Figure 4.13: Melting curve analysis using FRET probes for verification of PCR product.  
Melting peaks at ~ 53ºC indicate the presence of a specific amplification product in the 
samples: 1 – ES DNA control; 2 and 3 - RT –LDA samples with input template 
concentrations of 4x103 and 4x106  ES RNA copies/ml, respectively; 4 – PCR blank sample 
shows no detection of product. (Note: The temperature of melting peaks for PCR products 
is lower (~53ºC) than for RT-LDA products (68-69ºC) even though the same FRET probes 
are used for detection. This is due to different reaction mixes and salt compositions used in 
each type of amplification.  
 
RT-LDA product obtained with high ES RNA concentrations (4x107, 4x108 copies/ml) and 
primers Fw4A/Rev#1 was amplified again using conventional PCR and primers 
Fw3A/Rev#1. Primer Fw#3A has the same HIV-1 sequence specific region as the primer 
Fw#4A and was used due to the limited amounts of the primer Fw#4A available. PCR 
product (~ 150 bp) was gel purified and used for sequencing (Figure 4.14). The sequence 
obtained using primers Fw#4A and Rev#1 was aligned with the ES DNA (Figure 4.9).  
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Figure 4.14: MetaPhor® gel (1%) showing PCR product amplified from the semi-cycling 
RT-LDA reactions. Lane 1 – DNA ladder (50 bp); lane 2 – ES DNA used as a positive 
control for PCR shows the presence of a specific product (~ 150 bp); lanes 3 and 4 - PCR 
product obtained from further amplification of RT-LDA product (ES RNA input in the RT-
LDA reaction was 4x108 and 4x107 copies/ml respectively); lanes 5 and 6 – NTC (no 
template control) samples for RT-LDA and PCR, respectively shows the presence of 
primer dimers only.  
 
Since successful RT-LDA was demonstrated using 1 hour and even 30 minutes 
amplification time at 53ºC, initial evaluation of the method was performed to assess 
reproducibility of semi-cycling RT-LDA under the new conditions. Reproducibility of RT-
LDA was studied in five different experiments performed on five different days. Each 
experiment was performed using serial dilutions of a template ES RNA covering a range of 
concentrations: 4x103, 4x104, 4x105, 4x106, 4x107 and 4x108 copies/ml. RT-LDA reactions 
were performed at 53ºC for 1 hour. Post-amplification detection of amplicons was 
performed using melting curve analysis and FRET hybridization probes. RT-LDA product 
was detected using FRET probes in all samples in each of the five repeated runs. Thus, no 
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failed amplification was observed in any of the RT-LDA reactions performed on five 
different days using a concentration range of ES RNA covering six orders of magnitude. 
Figure 4.15 shows melting curve analysis for two out of five repeated RT-LDA 
experiments.  
 
Preliminary evaluation of semi-cycling RT-LDA also involved detection of the amplicons 
using anti-DNP striped dipsticks and NALF. RT-LDA reactions were performed using the 
short amplification profile described in section 4.2.1.2 and ES RNA template at 
concentrations of 4x108 and 4x107 copies/ml. Different dilutions (from 1:10 to 1:30) and 
input concentrations (from 1 µl to 30 µl) of the diluted RT-LDA product were used for 
NALF detection. The samples that gave positive detection in a visual detection range of 
NALF are shown in Figure 4.16. The most optimal detection was found in samples diluted 
1:10 and 10-30 µl of that dilution. Reproducibility of NALF detection of the RT-LDA 
amplicons was confirmed in a number of lateral flow experiments.  
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 B 
 
Figure 4.15: Melting curve analysis for repeated RT-LDA experiments.  
RT-LDA reproducibility experiments (2 out of 5) are illustrated in figure A and B, 
respectively. Specific RT-LDA amplification product is detected using FRET probes and 
melting curve analysis on the LightCycler® platform (Tm ~ 68.8 -71ºC) for the ES RNA 
concentration range of 4x103-4x108 copies/ml. No amplification product is detected in 
NTC samples.  
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Figure 4.16: Detection of RT-LDA amplicons (arrow) using NALF dipsticks. 
From left to right: RT-LDA blank sample (1); two positive controls containing an 
artificially synthesized looped amplicon (ampi29) (2, 3); the next 6 dipsticks show the 
detection of diluted RT-LDA amplification products obtained from the different 
experiments (4-9).  
 
 
 4.4 Discussion  
 Nucleic acid testing for diagnosis and monitoring of infectious diseases offers certain 
advantages, which makes it an attractive alternative for adaptation in rapid POC 
diagnostics. In particular, NAT provides significantly higher analytical sensitivity and 
accuracy of quantitation when compared to serologic or antigen-based assays. Nucleic acid 
amplification based assays usually comprise of three main steps: isolation of nucleic acids, 
target or/and signal amplification and detection of amplification product. Recently there 
has been an increasing interest in developing miniaturised instruments containing 
inexpensive, disposable test units (e.g. microfluidic cassettes) that allow performing 
amplification and detection steps of NAT in one closed system suitable for the near-patient 
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testing (Wang et al., 2006). Nucleic acid lateral flow represents a low cost, rapid detection 
system widely used for POC testing. Visual or instrument dependant detection of product 
on the NALF strips is achieved by using different reporter particles, for example, dye- 
encapsulating liposomes - biosensors (Edwards and Baeumner, 2006; Nugen et al., 2006). 
Dineva and colleagues (Dineva et al., 2005) report on the development of simultaneous 
visual detection of amplicons from HBV, HCV and HIV-1 using lateral flow dipsticks and 
antibodies conjugated to the colloidal gold particles. This inexpensive, rapid and 
instrument independent detection format showed good sensitivity allowing detection of 50, 
125 and 500 IU/ml for HBV DNA, HCV RNA and HIV-1 RNA respectively. Multiplex 
amplification of all three pathogens was performed using conventional RT-PCR. Although 
in its current format this assay (Dineva et al., 2005) represents a laboratory based assay, the 
study demonstrates a potential for adapting NAT for POC diagnostics.  
 
The feasibility study described in this chapter reports on the development of a novel 
method for isothermal amplification of RNA, termed RT-LDA. RT-LDA is designed to 
fulfil the criteria required for POC diagnostics: rapid and efficient amplification of ssDNA 
amplicons using viral RNA template. The RT-LDA technique combines an innovative 
primer design (LMP) and a known concept of strand displacement amplification using 
restriction enzyme BsoBI and Bst DNA polymerase. The RT-LDA reverse primer, 
similarly to primers used for strand displacement amplification, possesses a BsoBI 
recognition site that gets nicked and this ssDNA nick initiates a series of strand 
displacement/polymerisation driven by Bst polymerase (Hellyer et al., 1999; Nadeau et al., 
1999; Nycz et al., 1998; Spargo et al., 1996; Walker, 1993; Walker et al., 1995; Walker et 
al., 1992; Walker et al., 1996; Walker et al., 1994). The LMP design was applied to the 
RT-LDA forward primer - it possesses a 5’ overhang sequence, which is complementary to 
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the sequence of a sense strand extended from this primer. During the RT-LDA reaction 
dsDNA targets (T1, T2 and T3) are formed (Figure 4.7), and subsequent displacement of 
multiple anti-sense strands/amplicons begins. During strand polymerisation these 
strands/amplicons copy an overhang from the forward primer. Thus, the displaced anti-
sense amplicons have two regions at their 5’ end with complementary sequences, which 
hybridize to each other causing the partially “looped” structure of the ssDNA amplicons 
(Figure 4.5). Accumulation of partially “looped” ssDNA amplicons represents a key 
feature of RT-LDA. The “loop” structure closes the region complementary to the forward 
primer and thus, prevents conversion of anti-sense ssDNA amplicons into dsDNA 
amplicons. Another novelty applied to RT-LDA design is the absence of bumping primers 
that are normally used in the SDA technique. This is done to avoid production of multiple 
dsDNA species seen in SDA (Figure 4.4) and make RT-LDA less complex. Instead of 
bumping primers, RT-LDA makes use of AMV reverse transcriptase that has combined 
RNase H activity, which digests viral RNA in the RNA/cDNA hybrid leaving cDNA in a 
single stranded form. The functionality of the novel modifications applied to the RT-LDA 
design were proven experimentally.  
 
Two variations of the RT-LDA technique were designed and evaluated: linear and semi-
cycling (Figures 4.6 and 4.7). Originally the RT-LDA method with a linear type of 
amplification was designed. Semi-cycling RT-LDA was designed at the later stage, after 
preliminary evaluation of linear RT-LDA. Initial experiments were performed to set up a 
novel technique and find the most optimal design for a RT-LDA forward primer containing 
the “loop” overhangs. Theoretically, the “loop” overhang has to be complementary to the 
short sequence at the 3’end of the forward primer and to the longer sequence of the 
extended sense strand. The length of a complementary “loop” sequence has to be long 
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enough to preserve a single stranded structure of DNA amplicons, but not too long to 
interfere with the extension of a forward primer. The exact dimensions of the “loop” 
overhang in terms of the number of nucleotides and GC content were established 
experimentally. This was achieved by performing RT-LDA reactions using 7 forward 
primers with the 5’- “loop” overhangs of different length and sequence composition. 
According to the experimental data obtained for linear RT-LDA reactions, the most 
optimal design for RT-LDA forward primer suggests short sequence (9 bases) of a “loop” 
forming overhang with a high (~50%) GC% content. However, the amplicons produced 
with the linear RT-LDA method could not be sufficiently detected using FRET 
hybridization probes and the LightCycler® platform. RT-LDA product from linear 
amplification could only be seen by further amplification using conventional PCR and was 
confirmed additionally using DNA sequencing. This shortfall was attributed to the 
insufficient power of amplification provided by the linear RT-LDA.  
 
The new design for semi-cycling RT-LDA aimed to improve the magnitude of 
amplification of the technique making it more suitable for POC testing. The modification 
was achieved by the addition of the second BsoBI nickable site into the sequence of the 
forward loop mediating primer (Figure 4.7 A). This modification of the LMP does not 
interfere with displacement of ssDNA partially “looped” anti-sense amplicons. The 
modified forward LMP enhances amplification by at least 3- fold due to formation of three 
different types of dsDNA targets (T1, T2 andT3) as opposed to only one such target in the 
linear type of RT-LDA design (Figures 4.5 and 4.6). In particular, modification was 
applied to a forward primer Fw#3A, which was shown previously to produce the most 
optimal linear amplification. For ease of differentiating between primers a modified 
Fw#3A containing a BsoBI restriction site and a random sequence for “an anchoring 
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artificial” primer was termed Fw#4A (section 4.2.1.1). RT-LDA experiments performed 
with new primer Fw#4A and Rev#1 immediately showed an improved detection using 
melting curve analysis with the FRET hybridization probes. Optimisation of reaction 
conditions allowed further improvement of RT-LDA. Reduction in amplification time of 
RT-LDA that was performed using one constant temperature (53ºC) revealed good 
sensitivity of this method. In particular 4000 copies/ml of ES RNA template could be 
detected within only 30 minutes amplification. PCR product amplified from RT-LDA 
using a primer set Fw#4A/Rev#1, confirmed the presence of a specific product only. 
Sequence identity of each PCR product was confirmed by aligning the amplicon sequences 
with HIV-1 subtype C sequence (Figure 4.9). Preliminary evaluation of semi-cycling RT-
LDA was performed using a wide range of ES RNA concentrations from 4x103 to 4x108 
copies/ml, which were tested in five replicate RT-LDA experiments. Each RT-LDA run 
was performed at 53ºC for 1 hour. Repeated experiments showed that the newly designed 
RT-LDA technique is reproducible over six orders of magnitude. Preliminarily, the 
sensitivity of the one hour RT-LDA reaction combined with the FRET detection format 
can be set at 4000 copies/ml. According to the design of POC HIV-1 RNA test (Figure 4.1) 
NALF in combination with the MAR™ instrument represent a final detection format. 
Preliminary evaluation of RT-LDA also included NALF experiments in order to 
demonstrate compatibility of this new amplification technique with NALF detection. It was 
important to exclude possible interference between NALF reaction components and RT-
LDA reactions mix. Most importantly the detection of RT-LDA product using NALF 
dipsticks, without a prior denaturation step, provides experimental proof of the single 
stranded structure of the partially looped RT-LDA amplicons. Since the MAR™ 
instrument was not available in our setting during the initial assay development, NALF 
detection was performed in a visual range. Positive detection observed for RT-LDA 
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reactions showing that the newly developed amplification technique is fully compatible 
with NALF detection using anti-DNP striped dipsticks and anti-superparamagnetic 
conjugates.  
 
Overall, the newly developed isothermal amplification method – RT-LDA, offers a unique 
feature of converting RNA templates into ssDNA amplicons. A number of applications 
require ssDNA product of a defined length for further manipulation, for example, detection 
of nucleic acids by flow cytometry (Horejsh et al., 2005). Protocols have been developed 
that describe time consuming and cumbersome post-amplification treatment of dsDNA 
amplicons in order to convert them into ssDNA amplicons (Kuo, 2005; Nagamine et al., 
2002). The RT-LDA method generates ssDNA product and can be directly combined with 
detection systems like NALF, flow cytometry and microarrays. Further modifications can 
be made to the reaction conditions of RT-LDA to improve and simplify detection. For 
example, instead of using a capture and a detection probe format, single probe detection for 
NALF (Piepenburg et al., 2006) can be applied to RT-LDA. Addition of NALF probe at 
the beginning of RT-LDA may further reduce overall assay time.  
 
In conclusion, preliminary evaluation demonstrated that the novel RT-LDA technique 
(semi-cycling version) is reproducible over a wide range of template concentrations (4x103 
- 4x108 copies/ml) and provides good sensitivity using only one hour of amplification. RT-
LDA is fully compatible with NALF detection using dipsticks and thus, the new method 
can be used as an amplification front end for a novel POC HIV-1 RNA diagnostic test. It is 
envisaged that future optimisation and evaluation of RT-LDA using the MAR™ 
instrument and clinical specimens will allow for the implementation of this technology in a 
clinical setting, e.g. at VCT clinics, to detect acute HIV-1 infection.  
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CHAPTER 5  
 
General discussion and future development  
This thesis describes innovative approaches to developing more affordable HIV-1 
diagnostic and monitoring assays for resource limited settings (see diagram below). The 
study design takes into account the available laboratory infrastructure in South Africa 
represented by high tier, reference laboratories (~ 21%), medium tier laboratories (~ 
10.2%) and low tier laboratories at the primary health care clinics (68.8%). This type of 
infrastructure with different levels of laboratories unevenly distributed throughout the 
country eliminates a single solution for all laboratories. This mirrors the situation in 
numerous laboratory environments in other developing countries. Development of less 
expensive in-house assays as well as evaluation of more affordable commercial 
alternatives for monitoring HIV-1 viral load will facilitate the implementation of ARV 
treatment programs in South Africa (see Chapter 1).  
 
Commercial NAT for monitoring HIV-1 viral load is currently used in high volume 
laboratories in tertiary settings in South Africa. These assays include the NucliSens EasyQ 
(BioMérieux) and the COBAS Amplicor (Roche). The assays have good clinical 
performance, but are expensive to implement and maintain in a developing country 
environment with limited resources. Moreover, none of these assays provides sufficiently 
high throughput for the laboratories that need to process several hundred samples per day. 
Development of a less expensive in-house assay that has a potential for higher throughput 
will address this issue and was thus investigated in this project. 
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The successful development and preliminary clinical evaluation of an in-house viral load 
assay – the LUX assay is described in Chapter 2. The LUX assay makes use of real-time 
PCR technology and a LUX™ primer as a detection format. Real-time PCR technology 
offers a combined advantage of quick turnaround time, high throughput and performance 
of amplification and detection of PCR product in a closed system thus reducing 
contamination, an extremely valuable feature for a diagnostics laboratory. The 
LightCycler® is one of the most widely used real-time PCR platforms and it was selected 
based on its advanced technical characteristics and due to the availability of the Roche 
Diagnostics and Applied Sciences agency in South Africa. The agency provides a 
sufficient number of trained engineers and molecular research consultants who provide 
adequate support. All necessary reagents, consumables and technical assistance are readily 
available from the company within 1 day to a maximum of 10 working days. PCR reagents 
used in the LUX assay are obtained from Qiagen through the local Southern Cross 
Biotechnology agency. Qiagen is one of the leading international companies in 
manufacturing reagents for molecular research. Similarly to the Roche agency, technical 
assistance and reagents are available from the Southern Cross Biotechnology agency 
Affordable HIV-1 diagnostic 
and viral load approaches in 
South Africa 
High tier  
(reference) 
laboratories 
Medium tier 
laboratories 
Low tier laboratories 
 
 
Non-NAT, ELISA based 
alternative viral load 
assays 
(Quantitative p24 assay 
and RT activity assay) 
POC HIV-1 RNA 
assay for early 
diagnosis and 
monitoring of HIV-1 
           NAT  
(In-house real-time 
RT-PCR assay for 
monitoring HIV-1 
viral load) 
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within 1 – 14 working days. Supply of reagents and availability of the technical support are 
essential for successful implementation of a new technology in a diagnostics laboratory. 
Good clinical performance of the LUX assay was demonstrated using South African HIV-1 
subtype C stored specimens. The assay shows good specificity and analytical sensitivity of 
400 RNA copies/ml. The LUX assay shows good agreement with the COBAS Amplicor 
assay. Evaluation of the LUX assay on a longitudinal patient cohort on HAART showed 
that the newly developed assay reflects the expected decline in HIV-1 viral load over time. 
Viral rebounds in some patients were simultaneously detected by both the LUX and the 
COBAS Amplicor assays. Thus, the LUX assay represents a potential, more affordable 
alternative for high volume viral load monitoring in South Africa. Preliminary cost 
estimation shows that the LUX assay (cost of reagents and consumables) is 2-3 times less 
expensive than the NucliSens EasyQ and the COBAS Amplicor assays. Negotiations with 
the suppliers have been initiated and a further 10% discount on RT-PCR reagents is quite 
feasible. Future development of the LUX assay will aim to further reduce the cost of the 
assay. It is also envisaged to transfer the assay onto the latest, high throughput version of 
the LightCycler® system (version 480) and evaluate the LUX assay using fresh plasma 
samples. The LightCycler® 480 offers a significantly higher throughput (96 to 384 samples 
per run) than the most current commercial assay (Table A1, Appendix A). Although the 
new real-time PCR system is expensive we hope that the large number of tests will warrant 
discounts on the reagents and consumables used for the LUX assay.  
 
More affordable commercial alternatives for viral load monitoring were also evaluated in 
this study (Chapter 3). The HiSens™ HIV-1 p24 Ag Ultra assay (Perkin-Elmer) and the 
ExaVir® Load kit (Cavidi) for reverse transcriptase (RT) enzyme activity assay are non-
NAT, ELISA based assays, which represent a less complex option for implementation in 
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medium tier laboratories with a simplified set-up. The p24 antigen and the RT activity 
assays are significantly less expensive than the RNA based assays (NAT) with an 
approximate cost per test of $10 and $10- $20, respectively. Implementation of these 
assays and equipment maintenance is also less expensive when compared to NAT. 
Minimal training is sufficient to perform the assays. Technical assistance and training are 
available in South Africa through the local agencies. Evaluation of these assays using 
South African HIV-1 subtype C specimens obtained from the cohort of longitudinally 
followed-up patients on HAART demonstrated significant association between these 
assays and the Roche Amplicor assay. In this cohort of patients, similarly to the Roche 
Amplicor assay both the p24 antigen and the RT activity assays showed a downward trend 
in viral load values over time in response to therapy. These results suggest that both 
alternative assays hold a potential for use in clinical management of patients in resource 
limited settings. However, insufficient sensitivity of the p24 assay and low throughput of 
the RT enzyme activity assay are still of a major concern. More extensive evaluation of the 
newer, improved versions of these assays is required, especially in subtype C, before a 
final decision can be made about their implementation in diagnostics.  
 
Low tier laboratories, as mentioned above, represent the majority of NHLS laboratories in 
South Africa (~68.8%). These facilities are mostly located in the rural areas where patients 
often struggle to come back for their results on time. POC HIV-1 testing would be the most 
suitable approach for this type of scenario. A rapid and cost effective method for detection 
of viral RNA could provide a means for early diagnosis of acute HIV-1 infection in the 
window period. The development of a POC RNA assay is one of the most recent projects 
that has been initiated at WITS University and NHLS in collaboration with BBI (UK). The 
desired outcome for this project is to develop an instrument suitable for near-patient 
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testing, which could provide rapid and sensitive detection and possibly quantitation of 
HIV-1 RNA specific product. The POC type of instrument should ideally be easy to 
operate and it would allow performing main steps of the assay like RNA isolation, 
amplification and detection in a closed format using inexpensive (plastic or other material) 
disposable test cartridges and dipsticks. Possibilities of using lyophilized enzymes that can 
be stored at 4ºC have been provisionally discussed with BBI. Chapter 4 of this thesis 
describes the proof of concept study, which demonstrates the usefulness of a novel 
isothermal amplification method for the proposed POC HIV-1 RNA assay. The RT-LDA 
method was optimised and its performance characteristics were evaluated using a synthetic 
RNA transcript (ES RNA) containing 128 bases of HIV-1 gag sequence. A unique feature 
of RT-LDA is the ability to rapidly and efficiently convert RNA into short ssDNA 
amplicons under a constant temperature (53ºC). Partially looped ssDNA amplicons can be 
directly hybridized to the lateral flow probes without prior denaturation steps. Preliminary 
evaluation of the RT-LDA technique using ES RNA showed that the new method provides 
an efficient amplification of a wide range of template concentrations from 4x103 - 4x108 
RNA copies/ml in one hour. RT-LDA amplicons can be detected on the dipsticks with a 
signal from superparamagnetic particles detectable in a visual range (with no further signal 
amplification). Thus, full compatibility of this method with the NALF detection format 
was confirmed. Since the diluted reaction mixes were used for detection on the dipsticks it 
may be possible to reduce RT-LDA reaction time to less than one hour. Therefore, the 
encouraging preliminary results warrant further development of the RT-LDA technique. 
Future development and evaluation of RT-LDA will involve re-establishing the detection 
range and sensitivity of this method using superparamagnetic particles and more sensitive 
detection of amplicons with the MAR™ instrument. A method for isolation of viral RNA, 
which will be suitable for the proposed POC HIV-1 RNA assay, has to be investigated. 
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Future potential of converting this POC HIV RNA assay from a diagnostic into a 
monitoring assay is currently being considered.  
 
Overall, this project addresses the challenges faced by South Africa in providing 
government laboratories with an appropriate technology for more affordable diagnostics 
and monitoring of HIV-1 in our population. An advanced knowledge in the field of 
molecular diagnostics has been acquired through this study. In addition, a partnership 
between academia and an international commercial company has been established. The in 
depth evaluation of different technologies described in this thesis show that the 
development of more affordable and appropriate technologies for diagnostic and 
monitoring of HIV-1 in a resource poor setting is an achievable goal.  
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Appendix A: Comparison of NAT based HIV-1 viral load assays  
Table A1. Summary of the main characteristics of NAT based HIV-1 viral load assays. 
 
Company bioMerieux bioMerieux Bayer Roche Roche Abbott Abbott 
Assay Name  
NucliSens 
HIV-1QT 
 
 
NucliSens  
EasyQ 
Bayer Versant 
HIV-1 Quantiplex 
v 3.0 
COBAS Amplicor 
HIV-1 Monitor 
v1.5 
 
COBAS Taqman 
 
LcX HIV-1 
 
RealTime  
HIV-1 
Assay Type 
 
NASBA NASBA bDNA RT-PCR RT-PCR RT-PCR RT-PCR 
Dynamic Range (copies/ml) 50-8 000 000 50-3 000 000 75-500 000 50-750 000 40-10 000 000 50-1 000 000 40-10 000 000 
Specimen Type Plasma, 
serum, DBS 
Plasma, serum, 
DBS 
Plasma Plasma, DBS Plasma Plasma Plasma 
Specimen Volume (µl) 10-2000 10-2000 1000-2000 200-500 500 200-1000 1000 
Area of Genome Targeted gag gag pol gag gag pol pol 
Subtype Reactivity All All Group M (A-G) All All Group M and O Group M (B; C; 
F; B/F) 
Time to result (hrs) 3.5 3.5 22-24 6 2 5 2-4 
Tech Skill High High- Med, if 
automated 
High-Med, if 
automated 
High-Med, if 
automated 
High-Med, if 
automated 
High High-Med 
Lab Set up (PCR 
specifications required for 
all). Major Equipment 
Extractor 
Biohazard 
hoods 
Easy Q Reader 
 
Extractor 
Analyser 
Biohazard 
hoods 
 
Bayer system 340,  
Centrifuge 
Heating Block 
Waterbath 
Biohazard hoods 
 
 
COBAS Ampliprep 
Biohazard hoods 
Centrifuges 
Heating blocks 
Computer and 
printer 
Dead Air box 
COBAS Taqman 
system 
Waterbath 
Heating block 
Biohazard hoods 
Centrifuges 
 
 
Biohazard 
hoods 
Centrifuges 
Abbot LcX 
analyzer 
Thermalcycler 
Vacuum pump 
Heating block 
Biohazard hoods 
Centrifuges 
Abbot m2000sp 
and m2000rt 
Computer and 
printer 
Throughput (samples per 
run) 
50 40 12-168 9-48 9-48 21 48-96 
Cost/test, kit only (USD) 40-100 40-60 125 30-100 30-100 20-70 24-40 
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Appendix B: Polyacrylamide gel and buffers used for gel electrophoresis and 
DNA amplification  
 
15% Acrylamide/8 M Urea Gel:  
(For 15 ml, enough for a 13 cm x 15 cm x 0.75 mm thick gel):  
¾ 7.2 g urea, high quality.  
¾ 1.5 ml 10xTBE.  
¾ 5.7 ml 40% acrylamide (acrylamide: bis acrylamide = 19:1).  
¾ Adjust volume with dH2O up to 15 ml. 
¾ Stir at room temperature until urea has dissolved.  
Add:  
¾ 120 µl 10% ammonium persulfate in dH2O.  
¾ 16  µl TEMED  
¾ Mix briefly after adding the last two ingredients, which will catalyze 
polymerization, then pour gel immediately.  
 
50xTAE (Tris – Acetate EDTA, DNA electrophoresis buffer):  
¾ Dissolve 242 g Tris in 500 ml dH2O.  
¾ Add 100 ml 0.5 M Na2EDTA (pH 8.0) and 57.1 ml glacial acetic acid.  
¾ Adjust volume to 1 liter with H2O.  
¾ Store at room temperature.  
 
 
10xTBE Gel running buffer:  
¾ 0.89 M Tris (109 g Tris base)  
¾ 0.89 M Boric acid (55 g boric acid)  
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¾ 20 mM EDTA ( 40 ml 0.5 M EDTA, pH 8.0)  
¾ Mix and store at 4ºC until use.  
 
Potassium Phosphate buffer (pH 7.6):  
¾ 1M Mono-salt (KH2PO4): 13.6 g KH2PO4 dissolve in 50 ml H2O; adjust volume to 
100 ml with H2O.  
¾ 1 M Di-salt (K2HPO4): 17.4 g K2HPO4 dissolve in 50 ml H2O and then adjust to 
100m.l.  
¾ Mix 6.5 ml of 1 M mono- and 43.5 ml of 1 M di-salt solutions with 100 ml H2O. 
Check and adjust if necessary to pH 7.6. Make up final volume of the buffer to 200 
ml with H2O.  
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Appendix C: Composition of buffers and solutions used for cloning of DNA 
fragments  
 
IPTG stock solution (0.1 M):  
¾ 1.2 g IPTG (Promega cat # V3951)  
¾ Add H2O to 50 ml final volume. Filter-sterilize and store at 4ºC.  
 
X-Gal (2 ml):  
¾ 100 mg 5- bromo-4 chloro-3-indolyl-ß-D-galactoside (Promega Cat# V3941).  
¾ Dissolve in 2 ml of N, N’ – dimethyl- formamide. Cover with aluminum foil and 
store at - 20ºC.  
 
LB (Luria - Bertani) Medium (per 1 liter):  
¾ 10 g Bacto-tryptone  
¾ 5g Bacto - yeast  
¾ 5 g NaCl  
¾ Adjust pH to 7.0 with NaOH.  
¾ Autoclave.  
 
LB plates with ampicillin:  
¾ Add 15 g agar to 1 liter pf LB medium.  Autoclave. Allow the medium to cool to 
50ºC before adding ampicillin to a final concentration of 100µg/ml.  
¾ Supplement with 0.5 mM IPTG and 80 µg/ml X-Gal.  
¾ Pour 30-35 ml of medium into 85 mm Petri dishes. Let the agar harden and store at 
4ºC for up to 1 month or at room temperature for up to 1 week.  
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SOC Medium (100 ml):  
¾ 2.0 g Bacto – tryptone  
¾ 0.5 g Bacto-yeast extract  
¾ 1 ml 1 M NaCl  
¾ 0.25 ml 1 M KCl  
¾ 1 ml 2 M Mg2+ stock, filter-sterilized (as prepared below)  
¾ 1 ml 2 M glucose, filter-sterilized.  
¾  Add Bacto – tryptone, Bacto-yeast extract, NaCl and KCl to 97 ml of distilled 
water. Stir to dissolve. Autoclave and cool to room temperature. Add 2 M Mg2+ 
stock and 2 M glucose, each to a final concentration of20mM. Bring to 100 ml 
with sterile, distilled water. Filter the complete medium through a 0.2µm filter 
unit. The final pH should be 7.0.  
 
2 M Mg2+ stock:  
¾ 20.33 g MgCl·6 H2O  
¾ 24.65 g Mg SO4 7 H2O  
¾ Add distilled water to 100 ml. Filter sterilize.  
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Appendix D: Ethics Clearance  
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